<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD003463.pub2" GROUP_ID="VASC" ID="584401022214313143" MERGED_FROM="" MODIFIED="2014-05-16 13:58:12 +0100" MODIFIED_BY="Alma Adler" NOTES="&lt;p&gt;Please make changes for afiiliation as follows:&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;A) Dr. Marin Neto: Medical School of Ribeirao Preto, University of Sao Paulo, Brazil&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;B) Dra. Olga Cortes: Fundaci&amp;#243;n Cardioinfantil - Instituto de Cardiolog&amp;#237;a&lt;/p&gt;" NOTES_MODIFIED="2014-05-16 13:56:04 +0100" NOTES_MODIFIED_BY="Alma Adler" REVIEW_NO="9921" REVMAN_SUB_VERSION="5.2.5 " REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2014-05-16 13:56:04 +0100" MODIFIED_BY="Alma Adler">
<TITLE MODIFIED="2014-05-07 19:41:40 +0100" MODIFIED_BY="Anne Lawson">Trypanocidal drugs for chronic asymptomatic <I>Trypanosoma cruzi</I> infection</TITLE>
<CONTACT>
<PERSON ID="13962" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Juan Carlos</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Villar</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION>Professor</POSITION>
<EMAIL_1>jvillar@unab.edu.co</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>Universidad Autónoma de Bucaramanga (Colombia)</ORGANISATION>
<ADDRESS_1>Grupo de Cardiología Preventiva</ADDRESS_1>
<ADDRESS_2>UNAB Campus el Bosque Calle 157 No. 19-55</ADDRESS_2>
<CITY>Bucaramanga</CITY>
<ZIP/>
<REGION>Santander</REGION>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<PHONE_1>+577 643 6111 Ext 131</PHONE_1>
<PHONE_2/>
<FAX_1>+577 678 1080</FAX_1>
<FAX_2>+571 679 3505</FAX_2>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2014-05-16 13:53:33 +0100" MODIFIED_BY="Alma Adler">
<PERSON ID="13962" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Juan Carlos</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Villar</LAST_NAME>
<SUFFIX>MD, PhD</SUFFIX>
<POSITION>Professor</POSITION>
<EMAIL_1>jvillar@unab.edu.co</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Medicine</DEPARTMENT>
<ORGANISATION>Universidad Autónoma de Bucaramanga (Colombia)</ORGANISATION>
<ADDRESS_1>Grupo de Cardiología Preventiva</ADDRESS_1>
<ADDRESS_2>UNAB Campus el Bosque Calle 157 No. 19-55</ADDRESS_2>
<CITY>Bucaramanga</CITY>
<ZIP/>
<REGION>Santander</REGION>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<PHONE_1>+577 643 6111 Ext 131</PHONE_1>
<PHONE_2/>
<FAX_1>+577 678 1080</FAX_1>
<FAX_2>+571 679 3505</FAX_2>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1209251414288092318903010282484" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Juan Guillermo</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Perez</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>juguipe@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Fundación Cardioinfantil Instituto de Cardiología</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bogota</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1209251419012642425527307248348" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Olga Lucia</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Cortes</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>olgacortesf@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT/>
<ORGANISATION>Fundación Cardioinfantil Instituto de Cardiología</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Bogota</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="CO">Colombia</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1209251421383849230208502447274" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Adelina</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Riarte</LAST_NAME>
<SUFFIX/>
<POSITION>Chief of Department</POSITION>
<EMAIL_1>ariarte@yahoo.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>+54111558103434</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Departamento de Clínica, Patología y Tratamiento</DEPARTMENT>
<ORGANISATION>Instituto Nacional de Parasitología Dr M Fatala Chaben</ORGANISATION>
<ADDRESS_1>Av. Paseo Colon 568</ADDRESS_1>
<ADDRESS_2/>
<CITY>Buenos Aires</CITY>
<ZIP>1063</ZIP>
<REGION>Buenos Aires</REGION>
<COUNTRY CODE="AR">Argentina</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="z1209251424180309895918569861486" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Micah</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Pepper</LAST_NAME>
<SUFFIX/>
<POSITION/>
<EMAIL_1>micahpepper@gmail.com</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>School of Public Health</DEPARTMENT>
<ORGANISATION>Boston University</ORGANISATION>
<ADDRESS_1/>
<ADDRESS_2/>
<CITY>Boston</CITY>
<ZIP/>
<REGION/>
<COUNTRY CODE="US">USA</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="13894" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Jose Antonio</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Marin-Neto</LAST_NAME>
<SUFFIX/>
<POSITION>Head of Cardiology Division</POSITION>
<EMAIL_1>admin@fmrp.usp.br</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Medical School of Ribeirao Preto</DEPARTMENT>
<ORGANISATION>University of Sao Paulo</ORGANISATION>
<ADDRESS_1>Av. Bandeirantes, 3900</ADDRESS_1>
<ADDRESS_2/>
<CITY>Ribeirao Preto</CITY>
<ZIP>14025-640</ZIP>
<REGION>Sao Paulo</REGION>
<COUNTRY CODE="BR">Brazil</COUNTRY>
<PHONE_1>+11 55 166234715</PHONE_1>
<PHONE_2/>
<FAX_1>+11 55 54 16623-1144</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="B52F088682E26AA20130726F3E7AFF2D" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Gordon</FIRST_NAME>
<MIDDLE_INITIALS>H</MIDDLE_INITIALS>
<LAST_NAME>Guyatt</LAST_NAME>
<SUFFIX/>
<POSITION>Professor</POSITION>
<EMAIL_1>guyatt@mcmaster.ca</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE>905-541-1215</MOBILE_PHONE>
<ADDRESS>
<DEPARTMENT>Department of Clinical Epidemiology and Biostatistics</DEPARTMENT>
<ORGANISATION>McMaster University</ORGANISATION>
<ADDRESS_1>1200 Main Street West</ADDRESS_1>
<ADDRESS_2/>
<CITY>Hamilton</CITY>
<ZIP>L8N 3Z5</ZIP>
<REGION>Ontario</REGION>
<COUNTRY CODE="CA">Canada</COUNTRY>
<PHONE_1/>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2014-03-17 09:04:33 +0000" MODIFIED_BY="Nicole Martin">
<UP_TO_DATE>
<DATE DAY="10" MONTH="2" YEAR="2014"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="10" MONTH="2" YEAR="2014"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="10" MONTH="2" YEAR="2016"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2000"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2002"/>
<LAST_CITATION_ISSUE ISSUE="5" YEAR="2014"/>
</DATES>
<WHATS_NEW MODIFIED="2014-05-16 13:56:04 +0100" MODIFIED_BY="Nicole Martin">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2014-05-16 13:56:04 +0100" MODIFIED_BY="[Empty name]">
<DATE DAY="16" MONTH="5" YEAR="2014"/>
<DESCRIPTION>
<P>Searches re-run eight new studies included with conclusions not changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2014-03-17 13:27:44 +0000" MODIFIED_BY="Nicole Martin">
<DATE DAY="17" MONTH="3" YEAR="2014"/>
<DESCRIPTION>
<P>Searches were re-run in February 2014.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY/>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES/>
<EXTERNAL_SOURCES/>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2014-05-15 17:35:10 +0100" MODIFIED_BY="Anne Lawson">
<SUMMARY MODIFIED="2014-05-09 10:57:16 +0100" MODIFIED_BY="Anne Lawson">
<TITLE MODIFIED="2014-01-13 14:27:49 +0000" MODIFIED_BY="[Empty name]">Drugs against parasites for prevention of Chagas heart disease</TITLE>
<SUMMARY_BODY MODIFIED="2014-05-09 10:57:16 +0100" MODIFIED_BY="Anne Lawson">
<P>
<B>Background</B>
</P>
<P>Chagas disease is a form of heart disease that develops after decades of infection with a parasite called <I>Trypanosoma cruzi</I>. In addition to avoiding transmission of the parasites (through contact with insects in rural areas of many central and south American countries, blood transfusion, organ transplants from infected individuals or vertical transmission to newborns), one of the actions for prevention of Chagas disease is treating the estimated seven to 12 million infected individuals with medications against the parasites (trypanocidal therapy, or TT for short).</P>
<P>Despite the enthusiasm for using TT, there are limitations including uncertainty on its efficacy, poor tolerance and limited production of the conventional drugs. This review presents data from the studies evaluating the impact of TT on the tests looking at the presence of the parasites, the outcome of the infected individual and the tolerance to this short term (i.e. two to three months) treatment.</P>
<P>
<B>Study characteristics</B>
</P>
<P>We searched scientific databases for studies comparing TT versus a placebo (an inactive or pretend treatment) or no treatment in people with <I>Trypanosoma cruzi infection</I>. The search is current to February 2014.</P>
<P>
<B>Key results</B>
</P>
<P>We identified 13 studies comparing the outcomes of 4229 people after receiving TT or placebo. Five of these studies were from Argentina, five from Brazil, one from Venezuela, one from Chile and one from Bolivia.</P>
<P>Receiving TT was associated with a 50% to 90% smaller chance of having circulating antibodies or parasitic material, as compared with non-treated people. However, the results on progression towards Chagas disease or death indicate smaller benefits. Furthermore, the results were also statistically inconclusive, did not rule out potential harm and had substantial variation across studies conducted in different countries or testing different drugs. About one in five individuals treated abandoned the treatment and one in 40 treated individuals had a severe reaction (needing hospitalisation, additional treatments or interruption of this treatment).</P>
<P>We conclude that although TT may reduce the progression of Chagas disease, better quality studies are warranted before its use can be generally recommended for chronically infected individuals. New data should bring more certainty of the efficacy of TT and provide a precise evaluation of the balance between benefits and harms. Because of the variations across studies, these studies should include populations from more regions and test newer drugs.</P>
<P>
<B>Quality of the evidence</B>
</P>
<P>Only 25% of these data came from good-quality studies. Although most studies were published since 2000, all studies tested drugs developed in the 1960s.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2014-05-09 10:55:17 +0100" MODIFIED_BY="Anne Lawson">
<ABS_BACKGROUND MODIFIED="2014-05-09 10:51:23 +0100" MODIFIED_BY="Anne Lawson">
<P>Prevention of chronic chagasic cardiomyopathy (CCC) by treating infected populations with trypanocidal therapy (TT) remains a challenge. Despite a renewed enthusiasm for TT, uncertainty regarding its efficacy, concerns about its safety and limited availability remain barriers for a wider use of conventional drugs. We have updated a previous version of this review.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2012-08-29 20:00:42 +0100" MODIFIED_BY="[Empty name]">
<P>To systematically search, appraise, identify and extract data from eligible studies comparing the outcome of cohorts of seropositive individuals to <I>Trypanosoma cruzi </I>exposed to TT versus placebo or no treatment.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2014-05-07 19:47:26 +0100" MODIFIED_BY="Anne Lawson">
<P>We sought eligible studies in electronic databases (Cochrane Central Register of Controlled Trials (CENTRAL), Issue 1, 2014); MEDLINE (Ovid, 1946 to January week 5 2014); EMBASE (Ovid, 1980 to 2014 week 6) and LILACS (up to 6 May 2010)) by combining terms related with the disease and the treatment. The search also included a Google search, handsearch for references in review or selected articles, and search of expert files. We applied no language restrictions.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2014-05-07 19:50:25 +0100" MODIFIED_BY="Anne Lawson">
<P>Review authors screened the retrieved references for eligibility (those dealing with human participants treated with TT) and then assessed the pre-selected studies in full for inclusion. We included randomised controlled trials (RCTs) and observational studies that provided data on either mortality or clinical progression of CCC after at least four years of follow-up.<BR/>
</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2014-05-09 10:50:45 +0100" MODIFIED_BY="Anne Lawson">
<P>Teams of two review authors independently carried out the study selection, data extraction and risk of bias assessment, with a referee resolving disagreement within the pairs. Data collection included study design, characteristics of the population and interventions or exposures and outcome measures. We defined categories of outcome data as parasite-related (positive serology, xenodiagnosis or polymerase chain reaction (PCR) after TT) and participant-related (including efficacy outcomes such as progression towards CCC, all-cause mortality and side effects of TT). We reported pooled outcome data as Mantel-Haenszel odds ratios (OR) or standardised mean differences (SMD) along with 95% confidence intervals (CI), using a random-effects model. I<SUP>2</SUP> statistics provided an estimate of heterogeneity across studies. We conducted an exploratory meta-regression analysis of the relationship between positive-serology and progression of CCC or mortality.<BR/>
</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2014-05-09 10:55:17 +0100" MODIFIED_BY="Anne Lawson">
<P>We included 13 studies involving 4229 participants (six RCTs, n = 1096, five RCTs of intermediate risk of bias, one RCT of high risk of bias; four non-randomised experiments, n = 1639 and three observational studies, n = 1494). Ten studies tested nitroderivative drugs nifurtimox or benznidazole (three exposed participants to allopurinol, one to itraconazole). Five studies were conducted in Brazil, five in Argentina, one in Bolivia, one in Chile and one in Venezuela.</P>
<P>TT was associated with substantial, but heterogeneous reductions on parasite-related outcomes such as positive serology (9 studies, OR 0.21, 95% CI 0.10 to 0.44, I<SUP>2</SUP> = 76%), positive PCR (2 studies, OR 0.50, 95% CI 0.27 to 0.92, I<SUP>2</SUP> = 0%), positive xenodiagnosis after treatment (6 studies, OR 0.35, 95% CI 0.14 to 0.86, I<SUP>2</SUP> = 79%), or reduction on antibody titres (3 studies, SMD -0.56, 95% CI -0.89 to -0.23, I<SUP>2</SUP> = 28%). Efficacy data on patient-related outcomes was largely from non-RCTs. TT with nitroderivatives was associated with potentially important, but imprecise and inconsistent reductions in progression of CCC (4 studies, 106 events, OR 0.74, 95% CI 0.32 to 1.73, I<SUP>2</SUP> = 66%) and mortality after TT (6 studies, 99 events, OR 0.55, 95% CI 0.26 to 1.14, I<SUP>2</SUP> = 48%). The overall median incidence of any severe side effects among 1475 individuals from five studies exposed to TT was 2.7%, and the overall discontinuation of this two-month therapy in RCTs (5 studies, 134 events) was 20.5% (versus 4.3% among controls) and 10.4% in other five studies (125 events).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2014-05-08 15:09:10 +0100" MODIFIED_BY="Anne Lawson">
<P>Despite the evidence that TT reduced parasite-related outcomes, the low quality and inconsistency of the data for patient-important outcomes must be treated with caution. More geographically diverse RCTs testing newer forms of TT are warranted in order to 1. estimate efficacy more precisely, 2. explore factors potentially responsible for the heterogeneity of results and 3. increase knowledge on the efficacy/tolerance balance of conventional TT.<BR/>
</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2014-05-15 17:35:10 +0100" MODIFIED_BY="Anne Lawson">
<BACKGROUND MODIFIED="2014-05-09 12:14:11 +0100" MODIFIED_BY="Anne Lawson">
<P>This review updates a previously published version (<LINK REF="REF-Villar-2002" TYPE="REFERENCE">Villar 2002</LINK>). Chagas disease, a condition described more than one hundred years ago (<LINK REF="REF-Chagas-1909" TYPE="REFERENCE">Chagas 1909</LINK>), is the result of human infection by <I>Trypanosoma cruzi</I>. Most commonly, humans acquire this parasite through contact with insects of the <I>reduviidae</I> species living close to wild mammals and domestic animals around or inside poorly built houses in rural areas of Latin America (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>). Chagas disease remains a public health threat for 21 Latin American countries, where seven to 12 million people are estimated to be infected and 28 million people remain at high risk (<LINK REF="REF-Grupo-de-trabajo-cient_x00ed_fico-OMS-2007" TYPE="REFERENCE">Grupo de trabajo científico OMS 2007</LINK>). The region carries most of the burden of Chagas disease (99.8%), accounting for at least 662,000 disability-adjusted life years lost (<LINK REF="REF-Hotez-2008" TYPE="REFERENCE">Hotez 2008</LINK>).</P>
<P>Migration from rural areas to large urban centres within Latin America and more recently to more developed nations has spread this public health threat. The number of infected individuals living in the USA has been estimated as 300,000 (<LINK REF="REF-Bern-2009" TYPE="REFERENCE">Bern 2009</LINK>), with 80,000 additional cases in Europe (about two-thirds in Spain) (<LINK REF="REF-WHO-2010" TYPE="REFERENCE">WHO 2010</LINK>). This population migratory dynamics, along with the risk of infection to receptors of blood or solid-organ donations, or from infected pregnant women to their children, is increasingly making Chagas disease a global problem (<LINK REF="REF-Coura-2010" TYPE="REFERENCE">Coura 2010</LINK>).</P>
<CONDITION MODIFIED="2014-05-09 10:23:17 +0100" MODIFIED_BY="Anne Lawson">
<P>Primary acute <I>T. cruzi</I> infection is seldom clinically evident. Serology, and increasingly polymerase chain reactions (PCR), confirm the diagnosis of chronic infection. For the most part, the burden of Chagas disease comes from the 10% to 30% of individuals who develop, after decades of silent infection, chronic chagasic cardiomyopathy (CCC). Clinical suspicion of CCC arises in <I>T. cruzi</I> chronically infected individuals with cardiac rhythm or conduction abnormalities, symptoms of heart failure or embolism originating in dilated hearts (<LINK REF="REF-Laranja-1956" TYPE="REFERENCE">Laranja 1956</LINK>; <LINK REF="REF-Hagar-1991" TYPE="REFERENCE">Hagar 1991</LINK>; <LINK REF="REF-Coura-2005" TYPE="REFERENCE">Coura 2005</LINK>). Once clinically evident, CCC conveys a much worse prognosis than other forms of dilated cardiomyopathy (<LINK REF="REF-Freitas-2005" TYPE="REFERENCE">Freitas 2005</LINK>). This review focuses on prevention of CCC, rather than other complications of <I>T. cruzi</I> infection (e.g. those in the central nervous system or the gastrointestinal (GI) tract).</P>
<P>Prevention of CCC among infected individuals (i.e. host-based control) was for many years considered a difficult goal to achieve. Based on that perspective, efforts from public health authorities focused on preventing infection among individuals at risk (i.e. vector-based control). This policy led to the interruption of the transmission of <I>T. cruzi</I> infection by <I>Triatoma infestans</I>, the most important vector in southern South America in the early 1990s (<LINK REF="REF-Moncayo-2003" TYPE="REFERENCE">Moncayo 2003</LINK>). However, sustaining and extending this achievement to the Andean and Central American countries was limited by logistical, political and biological barriers (<LINK REF="REF-Guhl-2005" TYPE="REFERENCE">Guhl 2005</LINK>; <LINK REF="REF-Dias-2009" TYPE="REFERENCE">Dias 2009</LINK>). As a result, it has been recognised that dissemination, emergence and re-emergence all hinder elimination of <I>T. cruzi </I>infection, now seen as a more elusive goal (<LINK REF="REF-WHO-2009" TYPE="REFERENCE">WHO 2009</LINK>).</P>
</CONDITION>
<INTERVENTION MODIFIED="2014-05-09 10:58:55 +0100" MODIFIED_BY="Anne Lawson">
<P>The difficulties found for vector-based control paralleled a renewed enthusiasm for improving the host-based control. The first and more logical intervention of this control strategy is treating chronically infected individuals with trypanocidal therapy (TT). Before the 1990s, scepticism was associated with the idea of offering TT to people at risk of CCC for a number of reasons: uncertainty on the pathogenic role of parasitism; low sensitivity and responsiveness of tools to evaluate change in parasite-related outcomes (i.e. xenodiagnosis and conventional serology) and the need for very large person-years of follow-up to record patient-important outcomes. Finally, use of conventional TT drugs (developed in the 1960s with no substantial innovations afterwards) was associated with uncertain efficacy and a relatively high incidence of side effects.</P>
<P>Since the 2000s, there has been a growing interest in TT. On the one hand, it was argued that focusing on vector-based control left the risk of CCC in the population already infected uncovered (<LINK REF="REF-Villar-2001" TYPE="REFERENCE">Villar 2001</LINK>). On the other hand, scientific findings began to overcome the logistic or methodological barriers regarding the use of TT. First, studies incorporating deoxyribonucleic acid (DNA) hybridisation techniques showed that circulating parasitic load and parasitic DNA/antigens in tissues correlated well with the degree of inflammation, and that no organ damage occurred in the absence of these lesions (<LINK REF="REF-Jones-1993" TYPE="REFERENCE">Jones 1993</LINK>; <LINK REF="REF-Marinho-1999" TYPE="REFERENCE">Marinho 1999</LINK>; <LINK REF="REF-Higuchi-2003" TYPE="REFERENCE">Higuchi 2003</LINK>). In addition, several investigators showed in experimental models of T. cruzi infection that reduction of parasite load with TT led to significantly less myocardial damage (<LINK REF="REF-Andrade-1991" TYPE="REFERENCE">Andrade 1991;</LINK> <LINK REF="REF-Garc_x00ed_a-2005" TYPE="REFERENCE">García 2005;</LINK> <LINK REF="REF-Bahia-2012" TYPE="REFERENCE">Bahia 2012</LINK>). Finally, investigators evaluated the impact of TT on clinically relevant outcomes among individuals with chronic infection through comparison with untreated controls (<LINK REF="STD-Andrade-1996" TYPE="STUDY">Andrade 1996</LINK>; <LINK REF="STD-Sosa_x002d_Estani-1998" TYPE="STUDY">Sosa-Estani 1998</LINK>; <LINK REF="STD-Viotti-2006_x002a_" TYPE="STUDY">Viotti 2006*</LINK>).</P>
<P>There is consensus that all patients with primary acute Chagas disease or reactivation of chronic infection (e.g. after immunosuppression, human immunodeficiency virus (HIV) co-infection or following organ transplantation) should receive TT with nitroderivatives. The recommended dose is usually 5 to 7 mg/kg/day, divided in two or three times daily, for 30 to 90 days. However, no consensus has been achieved regarding TT for chronically infected people. The more frequently reported side effects are skin reactions and neuropathy, which occasionally forces interruption of treatment.</P>
<P>The first randomised, placebo-controlled trials addressing the issue included children (i.e. more responsive individuals) and recorded more sensitive or responsive diagnostic methods than previously (e.g. antitrypsin enzyme-linked immunosorbent assay (AT ELISA) and, more recently, PCR-based detection of circulating parasite materials). Investigators tested not only the conventional TT nitroderivative drugs available since the 1970s (i.e. nifurtimox (NFTMX) and benznidazole (BZD)) but also clinically approved drugs with possible trypanocidal activity such as allopurinol (ALLOP) or itraconazole (ITRA) (<LINK REF="STD-Gianella-1994" TYPE="STUDY">Gianella 1994</LINK>; <LINK REF="REF-Apt-1998" TYPE="REFERENCE">Apt 1998</LINK>; <LINK REF="REF-Gallerano-2001" TYPE="REFERENCE">Gallerano 2001</LINK>).</P>
</INTERVENTION>
<IMPORTANCE MODIFIED="2014-05-09 12:14:11 +0100" MODIFIED_BY="Anne Lawson">
<P>This scientific progress finally translated into a recommendation for treating children with recent chronic infection (<LINK REF="REF-Sosa-1999" TYPE="REFERENCE">Sosa 1999</LINK>; <LINK REF="REF-Grupo-de-trabajo-cient_x00ed_fico-OMS-2007" TYPE="REFERENCE">Grupo de trabajo científico OMS 2007</LINK>). However, apart from this indication, the use of TT is still controversial for people in the chronic phase of Chagas disease. Systematic reviews have highlighted the remaining uncertainty regarding the efficacy of TT on chronically infected populations (<LINK REF="REF-Villar-2002" TYPE="REFERENCE">Villar 2002</LINK>; <LINK REF="REF-Reyes-2005" TYPE="REFERENCE">Reyes 2005</LINK>; <LINK REF="REF-Bern-2009" TYPE="REFERENCE">Bern 2009</LINK>; <LINK REF="REF-Perez_x002d_Molina-2009" TYPE="REFERENCE">Perez-Molina 2009</LINK>). In fact, the First Latin American Guidelines for the Diagnosis and Treatment of Chronic Chagas Cardiomyopathy also did not make any recommendations for TT in people with the indeterminate or the clinically overt CCC. In an attempt to overcome those limitations, new, large randomised trials testing the impact of TT in this population are underway (<LINK REF="STD-Prado-2008" TYPE="STUDY">Prado 2008</LINK>; <LINK REF="REF-L_x00f3_pez-2009" TYPE="REFERENCE">López 2009</LINK>; <LINK REF="STD-Marin_x002d_Neto-2009" TYPE="STUDY">Marin-Neto 2009</LINK>). New observational studies (<LINK REF="STD-Fabbro-2000_x002a__x002a_" TYPE="STUDY">Fabbro 2000**</LINK>; <LINK REF="REF-Lauria_x002d_Pires-2000" TYPE="REFERENCE">Lauria-Pires 2000</LINK>), and new reports from previous studies (<LINK REF="REF-Galvao-2003" TYPE="REFERENCE">Galvao 2003</LINK>; <LINK REF="STD-Andrade-2004" TYPE="STUDY">Andrade 2004</LINK>; <LINK REF="STD-Viotti-2006_x002a_" TYPE="STUDY">Viotti 2006*</LINK>), have also emerged since the publication of the first version of this review in 2002. Therefore, we are updating this work.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2014-05-09 10:45:43 +0100" MODIFIED_BY="Anne Lawson">
<P>To systematically search, appraise, identify and extract data from eligible studies comparing the outcome of cohorts of seropositive individuals to <I>T. cruzi</I> exposed to TT versus placebo or no treatment.</P>
</OBJECTIVES>
<METHODS MODIFIED="2014-05-15 17:23:52 +0100" MODIFIED_BY="Anne Lawson">
<SELECTION_CRITERIA MODIFIED="2014-05-15 17:23:01 +0100" MODIFIED_BY="Anne Lawson">
<CRIT_STUDIES MODIFIED="2014-05-09 10:05:24 +0100" MODIFIED_BY="Anne Lawson">
<P>We included data from reports of studies on the topic of interest of two types:</P>
<UL>
<LI>randomised controlled trials (RCTs) allocating participants to one or more forms of TT with an experimental arm receiving placebo or no treatment;</LI>
<LI>observational studies comparing the outcomes of people who received TT versus other people derived from the same population setting with no exposure to TT, as long as they reported the incidence of patient-important outcomes (see <LINK TAG="CRIT_OUTCOMES_PRIMARY" TYPE="SECTION">Primary outcomes</LINK>; <LINK TAG="CRIT_OUTCOMES_SECONDARY" TYPE="SECTION">Secondary outcomes</LINK>) after at least four years of follow-up to both study groups.</LI>
</UL>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2014-05-08 16:42:36 +0100" MODIFIED_BY="Anne Lawson">
<P>People with chronic <I>T. cruzi</I> infection, as diagnosed with positive serology by at least two of the following techniques: ELISA, indirect haemaglutination (IHA) or indirect immunofluorescence (IIF) without clinically evident (i.e. symptomatic) CCC. For studies without clear distinction of the clinical status of the infected population included, we planned to interpret the information from the description of the population (outpatients not receiving any supportive treatment), or clarify this issue with the authors, aiming at including studies with at least 80% of the population free of symptomatic CCC.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2014-05-09 10:51:34 +0100" MODIFIED_BY="Anne Lawson">
<P>We considered TT as any oral treatment offered for at least 30 days to study participants because of their <I>T. cruzi</I> serology status, intended to reduce or suppress the parasitic load, as stated by the authors, and compared against a placebo or a control group. </P>
<P>We divided the TT offered to study participants into:</P>
<UL>
<LI>nitroimidazolic derivatives, such as NFTMX and BZD;</LI>
<LI>non-nitroimidazolic derivatives, including ALLOP, ITRA and other drugs meeting the criteria for our definition of TT.</LI>
</UL>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2014-05-15 17:23:01 +0100" MODIFIED_BY="Anne Lawson">
<P>We included studies when reporting data on outcomes of two types:</P>
<UL>
<LI>parasite-related outcomes: they included positive serology (dichotomous); mean reduction of antibodies titres (continuous), positive xenodiagnosis (dichotomous), or positive PCR (dichotomous) after receiving treatment;</LI>
<LI>patient-related outcomes: they were divided into:</LI>
</UL>
<UL>
<UL>
<LI>
<U>efficacy outcomes</U>, such as all-cause mortality, or significant progression of CCC. We recorded data on sudden death; mortality or hospitalisation due to cardiovascular causes as long as the study source described a treatment-blinded outcome adjudication process. We defined "significant progression of CCC" was defined as the emergence of substantial changes in the diagnostic tests or clinical status (requiring hospitalisation, implantation of cardiac devices or causing death), or both diagnostic tests and clinical status. For participants with normal electrocardiogram (ECG) at baseline, progression was defined as developing two new ECG abnormalities, or a single ECG abnormality that normally requires medical treatment (e.g. ventricular tachycardia, atrial fibrillation or flutter, complete A-V block). For studies following Kuschnir's classification criteria (<LINK REF="REF-Kuschnir-1985" TYPE="REFERENCE">Kuschnir 1985</LINK>), we recorded as progression a change of at least two stages during the follow-up period. That is, infected individuals with a normal ECG at baseline (stage 0) who developed either cardiomegaly (as documented through any imaging method) or symptoms of heart failure (stage II), and infected asymptomatic individuals with abnormal ECGs at baseline (stage I) who develop symptoms of heart failure (stage III). All deaths during follow-up were also recorded as significant progression of CCC.</LI>
<LI>
<U>Safety-related outcomes</U>, defined as any symptom potentially related with TT that authors decided to record in treated groups. These outcomes were categorised as mild-to-moderate (e.g. headache, nausea, dyspepsia, pruritus) or severe, including conditions that authors included in this category, described as requiring discontinuation of therapy or hospitalisation (e.g. seizures, fever, Stevens-Johnson syndrome or severe dermatitis, leukopenia or toxic hepatitis).</LI>
</UL>
</UL>
<P>We recorded any safety-related outcome of interest in placebo-controlled RCTs. In contrast, such outcome data from other studies in this review included only severe safety-related outcomes (as stated by the authors, related with hospitalisation, or causing treatment withdrawal).</P>
<P>Xenodiagnosis is a test for parasite infection, in which the natural vector of <I>T. cruzi</I> infection is used as a growth medium for seeking parasites in the human individuals tested. In the typical procedure, nymphs of laboratory-bred insects of reduviiduae species (not carrying any parasites) are covered in a Petri's box and attached to the forearm of the individual being tested. These nymphs are allowed to feed on the individual's blood for 48 hours, before removal of the Petri's box. One month later, the insects have grown to an adult stage. They are sacrificed in order to look for parasites in their intestinal contents. If parasites are found in the adult reduviidae insects, the patient is deemed to have a "positive xenodiagnosis".</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2014-05-08 16:50:36 +0100" MODIFIED_BY="Anne Lawson">
<OL>
<LI>Any patient-related outcomes regarding efficacy.</LI>
</OL>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2014-05-09 11:00:17 +0100" MODIFIED_BY="Anne Lawson">
<OL>
<LI>All parasite-related outcomes from RCTs.</LI>
<LI>Patient-related outcomes regarding safety considered severe.</LI>
<LI>Patient-related outcomes regarding safety of mild-to-moderate relevance (from RCTs).</LI>
<LI>All parasite-related outcomes recorded in non-RCTs.</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2014-05-09 08:50:24 +0100" MODIFIED_BY="Anne Lawson">
<ELECTRONIC_SEARCHES MODIFIED="2014-05-09 08:50:24 +0100" MODIFIED_BY="Anne Lawson">
<P>Searches were originally run for this review in 2000 (<LINK REF="REF-Villar-2002" TYPE="REFERENCE">Villar 2002</LINK>). They were updated in May 2010 (without an RCT filter, <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>) and again in February 2014 (with an RCT filter, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>). We searched:</P>
<UL>
<LI>Cochrane Central Register of Controlled Trials (CENTRAL) (Issue 1, 2014);</LI>
<LI>MEDLINE (Ovid, 1950 to April week 4 2010);</LI>
<LI>EMBASE (Ovid, 1980 to 2010 week 17);</LI>
<LI>LILACS (1982 to 6 May 2012).</LI>
</UL>
<P>In the 2014 search, the RCT filter for MEDLINE was the Cochrane sensitivity-maximising RCT filter, and for EMBASE, terms as recommended in the <I>Cochrane Handbook for Systematic Reviews of Interventions</I> have been applied (<LINK REF="REF-Lefebvre-2011" TYPE="REFERENCE">Lefebvre 2011</LINK>).</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2014-05-08 16:55:00 +0100" MODIFIED_BY="Anne Lawson">
<P>Additional searches for relevant material included a Google search (the first 100 hits, in order of relevance, when typing 'Chagas treatment'); handsearching of references of the narrative and systematic reviews retrieved with the electronic search, and questions to experts in the field. </P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2014-05-15 17:23:52 +0100" MODIFIED_BY="Anne Lawson">
<P>The process for identifying relevant material followed a two-step process. </P>
<P>Step one consisted of a pre-selection after screening titles and abstracts (or full papers when the abstract was not available) of all retrieved citations in the electronic search. A reference was pre-selected material when it referred to:</P>
<OL>
<LI>human participants (rather than animal studies);</LI>
<LI>therapy (rather than diagnosis, pathophysiology, etc.) of Chagas disease;</LI>
<LI>use of TT (rather than other forms of treatment).  </LI>
</OL>
<P>Two review authors (MRP and JGP) attempted step one in parallel. A reference was pre-selected when at least one of the review authors considered it potentially relevant for inclusion. </P>
<P>Step two consisted of a further examination of all pre-selected material by having both review authors assessing full-text material and deciding on inclusion. We resolved discrepancies by consensus, or called a referee, when needed. We computed the Kappa statistics for agreement on inclusion with the Epi Info 6.04 software package (Centers for Disease Control and Prevention (CDC), USA).</P>
<P>We designed a form in order to collect information from included studies. It covered general characteristics of the studies, information on demographics, disease, intervention, follow-up, outcomes and study quality features. Three review authors (MRP, JGP and OLC) independently extracted the information from each study, resolving any differences by discussion with the leading review author until reaching consensus.</P>
<P>Assessment of risk of bias of included studies applied different criteria for RCTs than the non-RCTs. We followed a pre-defined, itemised checklist of risk of bias, that three review authors independently judged as present or absent (see <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>). For RCTs, review authors checked the report of methods of randomisation, blinding, loss to follow-up, the rate of participants completing the planned follow-up period (considering acceptable if over 90%), and the presence of intention-to-treat analysis. We categorised the risk of bias of RCTs as low if zero to two features were present, intermediate if three or four features were present or high when all five features were present.</P>
<P>For non-RCTs, our extraction form considered a description of seven items: the sampling/selection of participants as well as the eligibility criteria, blinding status of outcome assessors, comparisons of baseline characteristics of the participants, report of any methods to deal with confounding, report of adjusted results and description of the proportion of participants completing the scheduled follow-up period (considering acceptable if over 80%). Based on that form, we considered quality as low if zero to two features were present, intermediate if three to five features were present or high if six or seven features were present.</P>
<P>The data synthesis comprised a description of characteristics of included studies, the items included in the Cochrane quality assessment tool as well as a quantitative synthesis of their outcome data. For the included RCTs, we extracted all outcome data reported. For non-RCT studies, we considered only patient-important outcomes. Data on parasite-related outcomes from non-RCTs served for exploratory analysis only. Extraction of dichotomous outcomes followed the intention-to-treat principle, where denominators were the number of participants originally allocated to TT. Participants with uncertain outcome (i.e. people lost during follow-up) were considered as having no events. The numbers for continuous outcomes were the numbers of participants with available information.</P>
<P>Summary measures consisted of generating, when appropriate, pooled effect estimates and their 95% confidence intervals (CI) of the outcomes of interest. For dichotomous outcomes (e.g. positive serology after treatment), we computed Mantel-Haenszel odds ratios (OR). When available and appropriate, we conducted separate analysis for different outcomes according to categories of interest, including type of studies (RCT data versus other studies), populations (e.g. children or adults) and interventions (i.e. nitroderivative or other drugs). For continuous outcomes, we computed pooled standardised mean differences (SMDs) with their 95% CIs between treatment groups. Differences within studies resulted from subtracting the mean antibody titres after treatment from the antibody titres at baseline. Variance of the mean differences within studies was inferred using the methodology suggested by <LINK REF="REF-Follmann-1992" TYPE="REFERENCE">Follmann 1992</LINK>.</P>
<P>We used Review Manager 5 software package to generate pooled effect estimates, using a random-effects model (<LINK REF="REF-RevMan-2012" TYPE="REFERENCE">RevMan 2012</LINK>). All those estimates included a general statistics for the main effects as well as for the heterogeneity of the data across studies. We considered a statistically significant effect when the P value for the overall Z statistics was less than 0.05. We judged heterogeneity across studies using the I<SUP>2</SUP> statistic, expressed as percentage.</P>
<P>We ran a meta-regression analysis to explore the relationship between trypanocidal effect and clinical efficacy (in terms of parasite-related and patient-related outcomes, respectively). We computed the slope along with their 95% CI using the Stata software package (version 11.2).</P>
<P>We carried out no subgroup or sensitivity analysis due to the small number of RCTs available.</P>
<P>Finally, we used the GRADE profiler software package (V 3.6), in order to assign a level of evidence around the data extracted and to generate pooled estimates and CIs (see <LINK REF="SOF-01" TYPE="SOF">Summary of findings table 1</LINK>; <LINK REF="SOF-02" TYPE="SOF">Summary of findings table 2</LINK>).</P>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2014-05-15 17:35:10 +0100" MODIFIED_BY="Anne Lawson">
<STUDY_DESCRIPTION MODIFIED="2014-05-09 11:51:50 +0100" MODIFIED_BY="Anne Lawson">
<SEARCH_RESULTS MODIFIED="2014-05-09 11:51:50 +0100" MODIFIED_BY="Anne Lawson">
<P>The search for the first edition of this review (MEDLINE, EMBASE, the World Health Organization (WHO) database for the Tropical Disease Research Programme) identified 1306 potentially relevant titles or abstracts. After screening, we assessed 43 of these studies in full for inclusion, and five met the inclusion criteria (Kappa = 0.77 for inclusion).</P>
<P>The updated search identified 1279 references for screening in May 2010. We considered 101 studies (97 retrieved from databases and four through reference lists or contact with study authors) to be potentially relevant and 30 underwent a more detailed assessment (with the full-length report) for inclusion. We included eight study reports presented in 10 articles (Kappa = 0.84 for inclusion) and identified one ongoing study (<LINK REF="STD-Marin_x002d_Neto-2009" TYPE="STUDY">Marin-Neto 2009</LINK>).</P>
<P>One final updated search in February 2014 identified 282 references for screening and none of these were eligible for inclusion (<LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
<P>Therefore, our review included data from 13 studies described in 15 reports (see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table). The reasons for exclusion of studies are described in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2014-05-09 11:51:50 +0100" MODIFIED_BY="Anne Lawson">
<P>This review included six RCTs (<LINK REF="STD-Gianella-1994" TYPE="STUDY">Gianella 1994</LINK>; <LINK REF="STD-Coura-1997" TYPE="STUDY">Coura 1997</LINK>; <LINK REF="STD-Sosa_x002d_Estani-1998" TYPE="STUDY">Sosa-Estani 1998</LINK>; <LINK REF="STD-Andrade-2004" TYPE="STUDY">Andrade 2004</LINK>; <LINK REF="STD-Rassi-2007" TYPE="STUDY">Rassi 2007</LINK>; <LINK REF="STD-Prado-2008" TYPE="STUDY">Prado 2008</LINK>); four non-randomised experiments (<LINK REF="REF-Apt-1998" TYPE="REFERENCE">Apt 1998</LINK>; <LINK REF="STD-Silveira-2000_x002a_" TYPE="STUDY">Silveira 2000*</LINK>; <LINK REF="STD-Catalioti-2001_x002a_" TYPE="STUDY">Catalioti 2001*</LINK>; <LINK REF="STD-Viotti-2006_x002a_" TYPE="STUDY">Viotti 2006*</LINK>), and three observational studies (<LINK REF="STD-Fabbro-2000_x002a__x002a_" TYPE="STUDY">Fabbro 2000**</LINK>; <LINK REF="STD-Gallerano-2000_x002a__x002a_" TYPE="STUDY">Gallerano 2000**</LINK>; <LINK REF="REF-Lauria_x002d_Pires-2000" TYPE="REFERENCE">Lauria-Pires 2000</LINK>). Studies were conducted in a variety of South American countries, five of them from Brazil, five from Argentina, one from Chile, one from Bolivia and one from Venezuela.</P>
<P>Altogether, these studies included 4229 participants, 1883 people receiving different forms of TT (BZD 1082 people, NFTMX 210 people, ALLOP 456 people and itraconazole 135 people) and 2346 people in control groups (779 receiving placebos and 1567 receiving no treatment with TT). Data from RCTs accounted for 26% of the participants in the included studies. The <B>appended </B>
<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK> summarises the main features of the included studies.</P>
</INCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2014-05-09 11:52:24 +0100" MODIFIED_BY="Anne Lawson">
<P>We judged none of the six RCTs as low risk of bias. However, five of these studies had intermediate risk of bias and the remaining study was of high risk of bias. Study authors did not report on the method of randomisation, although all studies reported their outcome assessors (largely parasite-related) as blinded (<B>appended </B>
<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>). Only one of the other seven studies (four non-randomised experiments and three observational studies) filled criteria to be low risk of bias (<LINK REF="STD-Viotti-2006_x002a_" TYPE="STUDY">Viotti 2006*</LINK>). The remaining studies were of intermediate risk of bias. As shown in the <B>appended </B>
<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>, there was little consistency in the presence/absence of these markers of validity, except for the absence of reporting adjusted results in six out of these seven studies. Risk of bias is shown in <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK> and <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2014-05-15 17:35:10 +0100" MODIFIED_BY="Anne Lawson">
<SUBSECTION>
<HEADING LEVEL="3">Parasite-related outcomes</HEADING>
<P>RCT data on positive serology after treatment (four studies, two testing BZD in children, and the other two testing TT in adults, one testing both nitroderivatives, and the other testing ALLOP) differed substantially (I<SUP>2</SUP> = 76%). We were not able to estimate the effect in the two studies of adults (no changes in any of the 112 participants included), whereas the studies in children (both using the AT ELISA technique) showed a substantial and significant reduction of the risk of persistence of positive serology (OR 0.12, 95% CI 0.03 to 0.42). The one RCT providing data on conventional serology, AT ELISA and ELISA against the F29 antigen showed substantial variation among serology techniques, with significantly better results with the ELISA technique (P value &lt; 0.001 for comparison with either of the other techniques). Data on positive serology recorded in five non-RCTs (all with conventional serology) showed an effect of nitroderivatives in a similar direction and magnitude of the effect (OR 0.34, 95% CI 0.16 to 0.73), with borderline heterogeneity (I<SUP>2</SUP> = 47%). <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> summarises these data.</P>
<P>Data on positive PCR after treatment (one RCT recording 57 events) suggest that nitroderivatives reduced this risk by half (<LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK>), with borderline statistical significance (P value = 0.06). Results from one non-RCT also testing nitroderivative drugs showed similar results (I<SUP>2</SUP> = 0% between both studies). If considered together, the effect size (OR 0.50, 95% CI 0.27 to 0.92) reached statistical significance.</P>
<P>Xenodiagnosis is the most frequently recorded of these outcomes (<LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK>). Data from RCTs testing nitroderivatives also showed a sizeable and significant effect (OR 0.09, 95% CI 0.04 to 0.18) with homogeneous results (I<SUP>2</SUP> = 0%). The two RCTs testing ALLOP showed a reduction that was both non-significant and homogeneous. Information on the impact of itraconazole comes from a single study (a quasi-randomised experiment) that showed a non-significant reduction (OR 0.42, 95% CI 0.17 to 1.03).</P>
<P>Data from the two RCTs testing BZD in children also showed a significant and homogeneous reduction of the antibody titres. This effect was not observed in the one RCT testing ALLOP in adults that provided similar outcome data (<LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK>).</P>
<P>Taking together, all available sources of information, TT reduced parasite-related outcomes, with substantial heterogeneity, both clinically and statistically. Higher levels of certainty are associated with trials of children receiving BZD, whereas results from other drugs/populations await for more extensive evaluation.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Patient-related outcomes</HEADING>
<SUBSECTION>
<HEADING LEVEL="4">Efficacy outcomes (Analysis 2.1, Analysis 2.2)</HEADING>
<P>The only RCT data available in patient-related outcomes showed a non-significant reduction in the appearance of ECG abnormalities, with seven events out of 235 randomised (two events for BZD-treated children and five events for children receiving placebo), as shown in <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>.</P>
<P>Four non-RCTs provided data on progression of CCC (<LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>), all testing nitroderivatives in adults from Brazil and Argentina. The pooled effect size estimate (analysis based on 106 events, 45 among individuals receiving TT) suggested a non-significant and heterogeneous reduction in the progress of CCC (OR 0.74, 95% CI 0.32 to 1.73, I<SUP>2</SUP> = 66%). Two of these studies show a non-significant excess of progression of CCC in TT-treated participants, whereas a single study (21 events, 25% of the weight) showed a significant reduction of this outcome. This study accounted for the heterogeneity of results (I<SUP>2</SUP> = 0% after removal of that study).</P>
<P>The six non-RCT studies reported all-cause mortality data (total of 126 events), with a non-significant reduction (OR 0.55, 95% CI 0.26 to 1.14) with borderline heterogeneity (I<SUP>2</SUP> = 48%), as shown in <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>. Evaluation of nitroderivatives, which accounts for 80% of the weight (84 events) show similar results (OR 0.66, 95% CI 0.28 to 1.56, I<SUP>2</SUP> = 49%). Four out of the seven results pooled showed an increased risk of mortality (<LINK REF="STD-Fabbro-2000_x002a__x002a_" TYPE="STUDY">Fabbro 2000**;</LINK> <LINK REF="REF-Lauria_x002d_Pires-2000" TYPE="REFERENCE">Lauria-Pires 2000</LINK>; <LINK REF="STD-Silveira-2000_x002a_" TYPE="STUDY">Silveira 2000*</LINK>; <LINK REF="STD-Catalioti-2001_x002a_" TYPE="STUDY">Catalioti 2001*</LINK>), all of them testing nitroderivatives. Two of the studies showing reductions of mortality tested nitroderivatives (<LINK REF="STD-Gallerano-2000_x002a__x002a_" TYPE="STUDY">Gallerano 2000**</LINK>; <LINK REF="STD-Viotti-2006_x002a_" TYPE="STUDY">Viotti 2006*</LINK>), and the remaining result favoured ALLOP over no treatment in terms of mortality (42 events, 20% of the weight, OR 0.28, 95% CI 0.11 to 0.72).</P>
<P>Overall, data on these patient-related outcomes came from non-RCTs, did not show a significant effect or consistency across studies. Other than intrinsic biases, variations across populations in these studies may explain the heterogeneity. For mortality, most studies (four out of six) showed a relative increase of the risk. For progression of CCC, two of the four studies showed increased risk. Results for populations from Brazil and Venezuela showed increased risk of these events, whereas results from Argentinian studies showed better results.  </P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="4">Safety outcomes (Analysis 3.1 to Analysis 3.9)</HEADING>
<P>Authors of the included studies reported a number of severe side effects such as toxic hepatitis (6 out of 482), arthritis (10 out of 352), peripheral neuropathy (11 out of 482), lymphadenopathy (9 out of 352), oedema (19 out of 352), fever (17 out of 635), severe skin reactions (54 out of 424) and severe GI intolerance (6 out of 424) among participants treated with BZD. The median proportion of any severe side effects was 2.7%. For ALLOP-treated participants, authors reported severe skin reactions, fever and severe GI intolerance, with a median proportion of 2.4%. For NFTMX, the median proportion of severe side effects (including polyneuritis, toxic hepatitis, malaise and severe skin reactions) was 6.3%. The overall median proportion including all recorded data was 2.7%.</P>
<P>Mild-to-moderate side effects recorded from RCTs reaching statistical significance (P value &lt; 0.001 in all cases) came from the TRAENA trial (352 participants treated with BZD and 357 participants treated with placebo) and consisted of skin reactions, such as pruritus (23.9% with BZD versus 7.6% with placebo), mild rash (36.4% with BZD versus 7.0% with placebo) and moderate rash where physician prescribed antihistamines (21.3% with BZD versus 3.4% with placebo).</P>
<P>Finally, five RCTs provided data on drug discontinuation, 547 individuals treated with TT (from which 96% were included in studies testing nitroderivatives) and 509 treated with placebo. The pooled rates were 20.5% and 4.3% for TT and placebo, respectively (pooled OR 2.65, 95% CI 0.4 to 17.7), with substantial heterogeneity (I<SUP>2</SUP> = 90%) indicating significantly lower discontinuation rates for children in comparison with adults. The only study showing significant results was the TRAENA trial, where 25.3% of the 352 participants receiving BZD abandoned this treatment, compared with 2.0% of participants receiving placebo. Data from the remaining studies indicated an overall discontinuation of TT in 10.6% of the treated individuals, with substantial variations, ranging from 11.4% to 31.1% among individuals receiving nitroderivatives and ranging from 0.7% to 3.9% for individuals receiving other forms of TT.</P>
</SUBSECTION>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Relationship between parasite-related and patient-related outcomes</HEADING>
<P>
<B>Appended </B>
<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>
<B> and </B>
<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK> show our meta-regression analysis of odds of having positive serology after TT and patient-related efficacy outcomes. We did not identify a relationship between our dependent variables (effect of TT on progression of CCC or mortality) and the effect of TT on serology in the studies providing such information (regression slope non-significantly different from 1 in either case).</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2014-05-09 11:41:48 +0100" MODIFIED_BY="Anne Lawson">
<P>This review included considerably more information than our previous version, allowing validation of NFTMX and BZD as standard forms of TT. However, the substantial growth of the data available is largely from observational studies. Thus, the studies are at substantial risk of bias and convincing results (i.e. those needed to support the notion that TT is generally beneficial for <I>T. cruzi</I>-infected individuals) would require methodologically robust studies yielding a large and precise effect size and consistent results. This is not the case for the data summarised in this review, as data on clinical efficacy of TT remains imprecise and highly inconsistent.</P>
<SUMMARY_OF_RESULTS MODIFIED="2014-05-09 11:41:48 +0100" MODIFIED_BY="Anne Lawson">
<P>This updated systematic review provides three major findings: first, a substantial growth in the information produced on this topic since 2000. Second, more results favouring the efficacy of TT, although hampered by methodological flaws, imprecision and inconsistency. Third, a more reliable estimate of the side effects of conventional drugs.</P>
<P>The first version of this review presented data from five RCTs including 756 participants reporting predominantly parasite-related outcomes. Now, some of those RCTs (i.e. <LINK REF="STD-Andrade-2004" TYPE="STUDY">Andrade 2004</LINK>) have reported extended follow-up periods and provide data regarding a new parasite-related outcome, <I>T. cruzi</I> circulating materials detected by PCR techniques. This review also adds safety data from a relatively large, blinded RCT of TT with BZD in adults (the TRAENA trial, still ongoing, with results on efficacy pending). Further, inclusion of non-RCTs allowed extraction of additional patient-related outcome data from over 3000 individuals. This growth in the amount of information reflects the renewed interest for TT and for resolving the uncertainty around its efficacy.</P>
<P>This data-enhanced review confirms the validity (i.e. proof of concept) of TT as a treatment reducing parasite-related outcomes (including now a positive PCR after treatment). It also suggests that TT reduces both mortality and progress of the associated CCC. However, this potential reduction in outcomes such as ECG abnormalities, progression of CCC and mortality is associated with a number of limitations.</P>
<P>First, our patient-related outcome data on efficacy originate from studies other than RCTs. In seeking this type of information, we accepted the inclusion of studies in which allocation to TT was both non-randomised and open-label. We tried to reduce bias by extracting outcome data that were less prone to influence from assessors (i.e. 'hard' outcomes). Examples included extracting data on severe, rather than mild side effects, and defining progress of CCC as a composite change, rather than an isolated finding, or after at least four years of follow-up. Since the only patient-related efficacy outcome data generated from RCTs were seven cases of new ECG abnormalities in two studies, definitive interpretation of clinical efficacy of TT was not possible on the basis of the currently available data.</P>
<P>Second, in addition to our concerns on validity, there is imprecision and statistical heterogeneity of the combined effect size estimates. For example, mortality data for nitroderivatives (the best-known drugs as valid TT in terms of reducing parasite-related outcomes) still appears to include a risk excess of 56% among individuals receiving active treatment. Furthermore, heterogeneity for mortality or progression of CCC for adults treated with nitroderivatives remains substantial (I<SUP>2</SUP> statistics of 49% for mortality and 66% for progression).</P>
<P>Third, as shown by meta-regression analysis, efficacy data on patient-related outcomes have no relationship to results on serology. In addition, the efficacy of ALLOP was greater than that of nitroderivatives in terms of progress of CCC and mortality, but was smaller in terms of parasite-related outcomes. In summary, no patient-related efficacy outcome data summarised in this review replicate findings from at least one RCT in terms of both statistical significance and homogeneity.</P>
<P>An additional aspect of our findings derived from having access, for the first time, to data from the TRAENA trial (the first report of an RCT testing BZD in more than 600 adults). This study identified reliably the mild side effects and, along with other studies, provided data on severe side effects. While rash was the mild side effect more strongly associated with BZD (20% of treated individuals developed moderate rash, a seven-fold greater incidence than controls), participants had several severe side effects.</P>
<P>Treatment with BZD in TRAENA was associated with fever, lymphadenopathy, arthritis and polyneuritis (around 2.5% versus no participants in the control groups). Combined data showed that TT with both BZD and NFTMX was also associated with hepatitis, at least in the short term. This finding had approximately the same frequency of the other side effects (17 of 578, or 2.9% of individuals exposed to TT). TRAENA investigators stopped TT with BZD in 16% of their participants based on pre-established medical criteria. Overall, 25% of the BZD-allocated participants interrupted their treatment, as compared with 2% in the placebo group. In fact, adherence to TT, a treatment lasting usually eight weeks, was overall 80%. Clinicians recommending TT should expect that one in four to five patients abandon their treatment and at least one severe side effect occurring in every 40 treated patients.</P>
<SUBSECTION>
<HEADING LEVEL="2">Agreements and disagreements with other studies or reviews</HEADING>
<P>As compared with other reviews in the field, this work has some differences and coincidences. Among different reviews, two publications have appeared as systematic reviews in the field since 2007. The first work focused on the effect of BZD (<LINK REF="REF-Perez_x002d_Molina-2009" TYPE="REFERENCE">Perez-Molina 2009</LINK>), whereas the second review (<LINK REF="REF-Bern-2007" TYPE="REFERENCE">Bern 2007</LINK>) aimed at guiding the medical community of the USA to deal with <I>T. cruzi-</I>infected individuals (as a response to the new epidemiological challenges discussed in the <LINK TAG="BACKGROUND" TYPE="SECTION">Background</LINK> section of this review).</P>
<P>The review by Perez-Molina also included both RCTs (three studies) and non-RCTs (six studies) testing BZD. These authors included two non-RCTs excluded from this review (<LINK REF="STD-Streiger-2004" TYPE="STUDY">Streiger 2004</LINK>; <LINK REF="STD-De-Castro-2006" TYPE="STUDY">De Castro 2006</LINK>), because authors did not record any patient-related outcome or had a follow-up period below four years, or both. In contrast, our review includes two studies testing BZD that these authors did not include (one from Venezuela and one from Brazil), providing data on mortality.</P>
<P>The accompanying meta-analyses on that review showed different results compared with our review for a number of reasons. First, those authors recorded and combined data on parasite-related outcomes (i.e. xenodiagnoses and serology status) that we analysed separately. Second, for consistency across outcomes, we treated any "positive effect" as a risk reduction (i.e. reduction of the risk of remaining seropositive), whereas these authors reported outcomes in the inverse way (i.e. BZD increased the rate of negative seroconversion). More importantly, our review treated patient-related outcomes as reported by authors, whereas we recorded outcome data based on our standard definition of "clinical progression". Despite reaching a similar conclusion, numerical results of the review by Pérez-Molina and colleagues would have been different, had they included the two studies that we did include (both with results not favouring BZD).</P>
<P>The review by Bern and colleagues aimed at guiding practice in the USA has a broader scope, covering aspects such as diagnosis, classification and treatment, focusing on nitroderivatives, the drugs available through the CDC. The authors did not present a quantitative synthesis of their data. They stated "benznidazole and nifurtimox are the only drugs with proven efficacy against Chagas disease", citing a book chapter and an expert, narrative review as supporting references. This review offered guidance with levels of evidence for different clinical situations.</P>
<P>Our work adds to this literature in a number of ways: extracting data from all relevant studies, both RCTs and non-RCTs; comparing cohorts after at least four years of follow-up; and recording data on clinical progress using a uniform, explicit definition. We treated similarly all drugs tested as hypothetical TT. We presented a quantitative synthesis of these data, dividing the information by type of study design. Finally, we reported all data extracted from RCTs, and only those from the non-RTCs with lower risk of ascertainment biases.</P>
</SUBSECTION>
</SUMMARY_OF_RESULTS>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2014-05-09 10:51:51 +0100" MODIFIED_BY="Anne Lawson">
<IMPLICATIONS_PRACTICE MODIFIED="2014-05-09 08:17:32 +0100" MODIFIED_BY="Anne Lawson">
<P>The data summarised in this review should make patients, doctors and public health authorities confident that nitroderivatives are a proven form of trypanocidal therapy (TT). For individuals treated with nifurtimox (NFTMX) or benznidazole (BZD), data originated from randomised controlled trials (RCTs) showed substantial reductions in at least two response variables (specialised serology, xenodiagnosis or polymerase chain reaction (PCR)), that were replicated in at least two studies. In contrast, data for individuals treated with the several other drugs tested in the included studies did not meet such criteria.</P>
<P>In contrast, clear inferences on clinical efficacy of TT (depending upon reductions on patient-related outcomes) remain elusive. Clinical care of individuals with chronic <I>Trypanosoma cruzi</I> infection but free of chronic chagasic cardiomyopathy (CCC) is a complex scenario, where lack of definitive evidence for the efficacy of TT compounds to other uncertainties. The imprecision and inconsistency of the efficacy data speaks of a treatment that is probably efficacious, but to an as yet unknown extent, include risk of moderate or severe side effects in exposed individuals. When advising on TT for this population, clinicians should also consider that one in five of their patients will not complete this treatment, and one of every 10 of these patients will discontinue because of severe side effects. Finally, as few of the studies were deemed to be of low risk of bias, all results should be currently viewed with caution. Given the above reasons, TT with NFTMX or BZD should be offered to patients after individualised discussion of the persisting uncertainties and a medical appraisal of the risk-benefit ratio.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2014-05-09 10:51:51 +0100" MODIFIED_BY="Anne Lawson">
<P>Data summarised in this review call for additional research in a number of directions. First, newer, safer forms of TT need formal testing. Clinical investigators can use BZD or NFTMX as comparators for newly proposed drugs with trypanocidal activity. Second, the clinical and statistical heterogeneity across studies testing TT needs further exploration. Assuming that efficacies of different drugs were the same, such variability should come from differences in patients, parasites or both. For example, results from studies included in this review testing BZD showed clearly different results on mortality in Argentina in comparison to Venezuela. A great variability in seroconversion was also seen in a series of more than 2500 BZD-treated children in Honduras, Guatemala and Bolivia (<LINK REF="REF-Escriba-2009" TYPE="REFERENCE">Escriba 2009</LINK>). The third and more important need is to resolve the clinical efficacy question of TT. It is fortunate that two relatively large trials comparing the outcome of individuals treated with BZD or placebo are now ongoing. One is TRAENA, a study of 600 participants in Argentina, and the other is the BENEFIT study, an international trial designed to recruit 3000 participants (<LINK REF="STD-Prado-2008" TYPE="STUDY">Prado 2008</LINK>; <LINK REF="STD-Marin_x002d_Neto-2009" TYPE="STUDY">Marin-Neto 2009</LINK>). Enormous progress in knowledge about clinical efficacy of TT is expected from these studies, given the differences in the baseline risk and the geographical diversity of their participants.</P>
<P>In conclusion, the well-documented efficacy of TT on parasite-related outcomes still requires confirmation in terms of patient-related outcomes. More geographically diverse RCTs, testing newer forms of TT are needed in order to 1. generate more precise efficacy estimates, 2. explore the heterogeneity of results and 3. allow a better efficacy/tolerance balance of conventional TT options.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2014-05-09 08:22:07 +0100" MODIFIED_BY="Anne Lawson">
<P>We thank Drs. A. Gianella, S. Sosa-Estani, C. Silveira and D. Fabbro for providing additional information (on serology titres with antitrypsin enzyme-linked immunosorbent assay (AT ELISA) or conventional serology, or progression to chronic chagasic cardiomyopathy) from their studies.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2013-10-21 22:42:18 +0100" MODIFIED_BY="[Empty name]">
<P>Dr. Riarte is the principal investigator of TRAENA, one of the studies included in this review. Dr. Marin-Neto is one of the co-principal investigators of the BENEFIT trial. All other authors declare having no conflict of interest.</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2014-05-09 08:22:38 +0100" MODIFIED_BY="Anne Lawson">
<P>JC Villar designed the protocol, reviewed the data extracted and drafted this review.</P>
<P>OL Cortés, JG Pérez and MR Pepper classified the references, assessed studies for inclusion and extracted data.</P>
<P>All other authors had access to the data recorded and critically reviewed the protocol and manuscript.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2014-05-09 12:20:02 +0100" MODIFIED_BY="Anne Lawson">
<STUDIES MODIFIED="2014-05-09 12:10:35 +0100" MODIFIED_BY="Anne Lawson">
<INCLUDED_STUDIES MODIFIED="2014-05-09 11:48:55 +0100" MODIFIED_BY="Anne Lawson">
<STUDY DATA_SOURCE="PUB" ID="STD-Andrade-1996" MODIFIED="2014-05-07 20:10:20 +0100" MODIFIED_BY="Anne Lawson" NAME="Andrade 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-05-07 20:10:20 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Andrade ALS, De Oliveira RM, Almeida e Silva S, Luquetti A, Travassos LR, Almeida IC, et al</AU>
<TI>Randomised trial of efficacy of benznidazole in treatment of early <I>Trypanosoma cruzi</I> infection</TI>
<SO>Lancet</SO>
<YR>1996</YR>
<VL>348</VL>
<PG>1407-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andrade-2004" MODIFIED="2014-05-07 20:16:59 +0100" MODIFIED_BY="Anne Lawson" NAME="Andrade 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-05-07 20:16:59 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrade AL, Martelli C, Oliveira R, Silva S, Aires A, Soussumi L, et al</AU>
<TI>Short report: benznidazole efficacy among <I>Trypanosoma cruzi</I>-infected adolescents after a six-year follow-up</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2004</YR>
<VL>71</VL>
<NO>5</NO>
<PG>594-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apt-1998_x002a_" MODIFIED="2014-05-07 20:17:29 +0100" MODIFIED_BY="Anne Lawson" NAME="Apt 1998*" YEAR="1998">
<REFERENCE MODIFIED="2014-05-07 20:17:29 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apt W, Aguilera X, Arribada A, Pérez C, Miranda C, Sánchez G, et al</AU>
<TI>Treatment of chronic Chagas' disease with itraconazole and allopurinol</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1998</YR>
<VL>59</VL>
<PG>133-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Britto-2001_x002a_" MODIFIED="2014-03-17 10:44:30 +0000" MODIFIED_BY="Nicole Martin" NAME="Britto 2001*" YEAR="2001">
<REFERENCE MODIFIED="2014-03-17 10:44:30 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Britto C, Silveira C, Cardoso MA, Marques P, Luquetti A, Macêdo V, et al</AU>
<TI>Parasite persistence in treated chagasic patients revealed by xenodiagnosis and polymerase chain reaction</TI>
<SO>Memorias do Instituto Oswaldo Cruz</SO>
<YR>2001</YR>
<VL>96</VL>
<PG>1-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Catalioti-2001_x002a_" MODIFIED="2014-05-07 20:22:07 +0100" MODIFIED_BY="Anne Lawson" NAME="Catalioti 2001*" YEAR="2001">
<REFERENCE MODIFIED="2014-05-07 20:22:07 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Catalioti F, Acquatella H</AU>
<TI>Mortality comparison of 5 years follow up in subjects with chronic Chagas disease with and without benznidazol treatment</TI>
<TO>Comparación de mortalidad durante seguimiento por 5 años en sujetos con enfermedad de Chagas crónica con y sin tratamiento de benznidazol</TO>
<SO>Revista de Biología Tropical</SO>
<YR>1998</YR>
<VL>27</VL>
<NO>Suppl</NO>
<PG>29-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coura-1997" MODIFIED="2014-03-17 10:49:13 +0000" MODIFIED_BY="Nicole Martin" NAME="Coura 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-03-17 10:49:13 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coura Rodrigues J, De Abreu LL, Faraco Wilcox HP, Petana W</AU>
<TI>Comparative controlled study using benznidazole, nifutimox and placebo in chronic Chagas' disease in field areas with interrupted transmission. I. Preliminary Evaluation</TI>
<TO>Estudo comparativo controlado com emprego de Benznidazole, nifurtimox e placebo, na forma cronica da doenca de Chagas, em uma area de campo com transmissao interrompida. I. Avialação Preliminar</TO>
<SO>Revista da Sociedade Brasileira de Medicina Tropical</SO>
<YR>1997</YR>
<VL>30</VL>
<PG>139-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fabbro-2000_x002a__x002a_" MODIFIED="2014-05-07 20:23:22 +0100" MODIFIED_BY="Anne Lawson" NAME="Fabbro 2000**" YEAR="2000">
<REFERENCE MODIFIED="2014-05-07 20:23:22 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fabbro de Suasnábar D, Arias E, Streiger M, Piacenza M, Ingaramo M, Del Barco M, et al</AU>
<TI>Evolutive behavior towards cardiomyopathy of treated (nifurtimox or benznidazole) and untreated chronic chagasic patients</TI>
<SO>Revista de Instituto de Medicina Tropical de Sao Paulo</SO>
<YR>2000</YR>
<VL>42</VL>
<NO>2</NO>
<PG>99-109</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallerano-2000_x002a__x002a_" MODIFIED="2014-05-09 11:48:55 +0100" MODIFIED_BY="Anne Lawson" NAME="Gallerano 2000**" YEAR="2000">
<REFERENCE MODIFIED="2014-05-09 11:48:55 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallerano R, Sosa R</AU>
<TI>Intervention study on the natural evolution of Chagas disease: evaluation of specific antiparasitic treatment</TI>
<TO>Estudio de intervencion en la evolucion natural de la enfermedad de Chagas: evaluacion del tratamiento antiparasitario especifico</TO>
<SO>Revista de la Facultad de Ciencias Médicas (Córdoba, Argentina)</SO>
<YR>2000</YR>
<VL>57</VL>
<NO>2</NO>
<PG>135-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galv_x00e3_o-_x0028_Andrade-substudy_x0029_" MODIFIED="2014-05-09 09:43:51 +0100" MODIFIED_BY="Anne Lawson" NAME="Galvão (Andrade substudy)" YEAR="2003">
<REFERENCE MODIFIED="2014-05-07 20:25:10 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galvão L, Chiari E, Macedo A, Luquetti A, Silva S, Andrade AL</AU>
<TI>PCR assay for monitoring <I>Trypanosoma cruzi</I> parasitemia in childhood after specific chemotherapy</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>2003</YR>
<VL>41</VL>
<NO>11</NO>
<PG>5066-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gianella-1994" MODIFIED="2014-05-08 21:48:06 +0100" MODIFIED_BY="Anne Lawson" NAME="Gianella 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-05-08 21:48:06 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gianella A, Holzman A, Lihoshi N, et al</AU>
<TI>Efficacy of allopurinol in chronic Chagas disease. Results of a randomized controlled trial in Santa Cruz, Bolivia</TI>
<TO>Eficacia del alopurinol en la enfermedad de Chagas crónica. Resultados del estudio realizado en Santa Cruz, Bolivia</TO>
<SO>Boletín científico del CENETROP</SO>
<YR>1997</YR>
<VL>16</VL>
<PG>25-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lauria_x002d_Pires-2000_x002a__x002a_" MODIFIED="2014-05-09 10:46:04 +0100" MODIFIED_BY="Anne Lawson" NAME="Lauria-Pires 2000**" YEAR="2000">
<REFERENCE MODIFIED="2014-05-09 10:46:04 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lauria-Pires L, Braga M, Vexenat A, Nitz N, Simões-Barbosa A, Tinoco D, et al</AU>
<TI>Progressive chronic chagas heart disease ten years after treatment with anti-<I>Trypanosoma cruzi</I> nitroderivatives</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2000</YR>
<VL>63</VL>
<NO>3,4</NO>
<PG>111-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Prado-2008" MODIFIED="2014-05-08 21:15:38 +0100" MODIFIED_BY="Anne Lawson" NAME="Prado 2008" YEAR="2008">
<REFERENCE MODIFIED="2014-05-08 21:15:38 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Prado N, Hernández Y, De Rissio AM, Esteve M, Riarte A</AU>
<TI>Security in a randomized control trial (RCT) - TRAENA Study - in adult patients with Chagas disease</TI>
<TO>La seguridad en un ensayo clínico aleatorizado (ECA) - Estudio TRAENA - en pacientes adultos con Enfermedad de Chagas</TO>
<SO>Instituto Nacional de Parasitología Dr M Fatala Chaben, ANLIS GCG Malbrán, Ministerio de Salud</SO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rassi-2007" MODIFIED="2014-05-08 21:16:15 +0100" MODIFIED_BY="Anne Lawson" NAME="Rassi 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-05-08 21:16:15 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rassi A, Luquetti AO, Rassi A Jr, Rassi GG, Rassi SG, Da Silva IG, et al</AU>
<TI>Short report: specific treatment for <I>Trypanosoma cruzi</I>: lack of efficacy of allopurinol in the human chronic phase of Chagas disease</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2007</YR>
<VL>76</VL>
<NO>1</NO>
<PG>58-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Silveira-2000_x002a_" MODIFIED="2014-05-08 21:18:30 +0100" MODIFIED_BY="Anne Lawson" NAME="Silveira 2000*" YEAR="2000">
<REFERENCE MODIFIED="2014-05-08 21:18:30 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="BOOK">
<AU>Silveira CAN</AU>
<SO>Avaliação a longo prazo do tratamento específico da doença de chagas [PhD thesis]</SO>
<YR>2000</YR>
<PG>123pp</PG>
<PB>Faculdade de Medicina, Universidade de Brasília</PB>
<CY>Distrito Federal, Brazil</CY>
<IDENTIFIERS MODIFIED="2012-08-30 15:16:12 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2011-01-17 21:17:15 +0000" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sosa_x002d_Estani-1998" MODIFIED="2014-05-08 21:20:45 +0100" MODIFIED_BY="Anne Lawson" NAME="Sosa-Estani 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-05-08 21:20:45 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sosa-Estani S, Segura EL, Ruiz AM, Velazquez E, Porcel BM, Yampotis C</AU>
<TI>Efficacy of chemotherapy with benznidazole in children in the intermediate phase of Chagas' disease</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1998</YR>
<VL>59</VL>
<PG>526-9</PG>
<IDENTIFIERS MODIFIED="2010-11-02 17:26:37 +0000" MODIFIED_BY="Micah R Pepper"/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Viotti-2006_x002a_" MODIFIED="2014-05-08 21:21:17 +0100" MODIFIED_BY="Anne Lawson" NAME="Viotti 2006*" YEAR="2006">
<REFERENCE MODIFIED="2014-05-08 21:21:17 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Viotti R, Vigliano C, Bertocchi G, Petti M, Alvarez MG, Postan M, et al</AU>
<TI>Long-term cardiac outcomes of treating chronic Chagas disease with benznidazole versus no treatment: a nonrandomized trial</TI>
<SO>Annals of Internal Medicine</SO>
<YR>2006</YR>
<VL>144</VL>
<NO>10</NO>
<PG>724-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2014-05-09 12:10:35 +0100" MODIFIED_BY="Anne Lawson">
<STUDY DATA_SOURCE="PUB" ID="STD-Abitbol-1981" MODIFIED="2014-03-17 11:02:08 +0000" MODIFIED_BY="Nicole Martin" NAME="Abitbol 1981" YEAR="1981">
<REFERENCE MODIFIED="2014-03-17 11:02:08 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Abitbol H</AU>
<TI>Treatment of Chagas disease</TI>
<TO>Tratamiento de la enfermedad de Chagas</TO>
<SO>Anales de la Real Academia Nacional de Medicine (Madr)</SO>
<YR>1981</YR>
<VL>98</VL>
<PG>755-8</PG>
<IDENTIFIERS MODIFIED="2012-07-17 03:59:23 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2012-07-17 03:57:14 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Aguilera-1987" MODIFIED="2014-05-08 21:27:20 +0100" MODIFIED_BY="Anne Lawson" NAME="Aguilera 1987" YEAR="1987">
<REFERENCE MODIFIED="2014-05-08 21:27:20 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aguilera X, Apt W, Arribada A</AU>
<TO>Evaluación del allopurinolen la enfermedad de Chagas crónica humana en Chile</TO>
<SO>Parasitol Dia</SO>
<YR>1987</YR>
<VL>11</VL>
<PG>132-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amato-1980" MODIFIED="2014-05-08 21:29:43 +0100" MODIFIED_BY="Anne Lawson" NAME="Amato 1980" YEAR="1980">
<REFERENCE MODIFIED="2014-05-08 21:29:43 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amato NV</AU>
<TI>Specific treatment of Chagas' disease</TI>
<TO>Tratamento específico da doença de Chagas</TO>
<SO>Revista do Hospital das Clínicas</SO>
<YR>1980</YR>
<VL>35</VL>
<PG>27-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Amato-1998" MODIFIED="2014-05-08 21:31:17 +0100" MODIFIED_BY="Anne Lawson" NAME="Amato 1998" YEAR="1998">
<REFERENCE MODIFIED="2014-05-08 21:31:17 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Amato NV</AU>
<TI>Therapeutics of the chronic form of Chagas' disease. Specific treatment of <I>Trypanosoma cruzi </I>infection</TI>
<TO>Terapêutica da forma crônica da doençade Chagas</TO>
<SO>Arquivos Brasileiros de Cardiologia</SO>
<YR>1998</YR>
<VL>70</VL>
<PG>63-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andrade-1973" MODIFIED="2014-05-09 11:13:15 +0100" MODIFIED_BY="Anne Lawson" NAME="Andrade 1973" YEAR="1973">
<REFERENCE MODIFIED="2014-05-09 11:13:15 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrade SG, Macedo V</AU>
<TI>Combined treatment of Chagas' disease with Bayer 2502 and corticoid (experimental and clinical study)</TI>
<TO>Tratamento combinado dadoença de Chagas com Bayer 2502 e corticóide (Estudo experimental e clínico)</TO>
<SO>Revista do Instituto de Medicina Tropical de Sao Paulo</SO>
<YR>1973</YR>
<VL>15</VL>
<PG>421-30</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Andrade-1992" MODIFIED="2014-05-08 21:32:24 +0100" MODIFIED_BY="Anne Lawson" NAME="Andrade 1992" YEAR="">
<REFERENCE MODIFIED="2014-05-08 21:32:24 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Andrade SG, Rassi A, Magalhaes JB, Ferriolli FF, Luquetti AO</AU>
<TI>Specific chemotherapy of Chagas disease: a comparison between the response in patients and experimental animals inoculated with the same strains</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1992</YR>
<VL>86</VL>
<PG>624-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apt-1985" MODIFIED="2014-05-08 21:32:46 +0100" MODIFIED_BY="Anne Lawson" NAME="Apt 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-05-08 21:32:46 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apt W</AU>
<TI>Treatment of Chagas' disease</TI>
<TO>Tratamiento de la enfermedad de Chagas</TO>
<SO>Revista Medica de Chile</SO>
<YR>1985</YR>
<VL>113</VL>
<PG>162-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apt-1994" MODIFIED="2014-05-08 21:33:32 +0100" MODIFIED_BY="Anne Lawson" NAME="Apt 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-05-08 21:33:32 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apt W, Aguilera X, Arribada A, Perez C, Miranda C, Zulantay I, et al</AU>
<TI>Treatment of chronic human Chagas disease with itraconazole and allopurinol. Preliminary report</TI>
<TO>Tratamiento de la enfermedad de Chagashumana con Itraconazol y alopurinol. Informe preliminar</TO>
<SO>Revista Medica de Chile</SO>
<YR>1994</YR>
<VL>122</VL>
<PG>420-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apt-2003" MODIFIED="2014-03-17 11:10:10 +0000" MODIFIED_BY="Nicole Martin" NAME="Apt 2003" YEAR="2003">
<REFERENCE MODIFIED="2014-03-17 11:10:10 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apt W, Arribada A, Zulantay I, Sanchez G, Vargas SL, Rodriguez J</AU>
<TI>Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the regression and prevention of electrocardiographic abnormalities during 9 years of follow-up</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2003</YR>
<VL>97</VL>
<NO>1</NO>
<PG>23-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Apt-2005" MODIFIED="2014-03-17 11:10:47 +0000" MODIFIED_BY="Nicole Martin" NAME="Apt 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-03-17 11:10:47 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Apt W, Arribada A, Zulantay I, Solari A, Sanchez G, Mundaca K, et al</AU>
<TI>Itraconazole or allopurinol in the treatment of chronic American trypanosomiasis: the results of clinical and parasitological examinations 11 years post-treatment</TI>
<SO>Annals of Tropical Medicine and Parasitology</SO>
<YR>2005</YR>
<VL>99</VL>
<NO>8</NO>
<PG>733-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bestetti-1997" MODIFIED="2014-05-08 20:26:28 +0100" MODIFIED_BY="Anne Lawson" NAME="Bestetti 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-05-08 20:26:28 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bestetti RB</AU>
<TI>Should benznidazole be used in chronic Chagas' disease?</TI>
<SO>Lancet</SO>
<YR>1997</YR>
<VL>349</VL>
<PG>653</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bocca-Tourres-1969" MODIFIED="2014-05-08 20:26:13 +0100" MODIFIED_BY="Anne Lawson" NAME="Bocca Tourres 1969" YEAR="1969">
<REFERENCE MODIFIED="2014-05-08 20:26:13 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bocca Tourres CL</AU>
<TI>Acute period of Chagas' disease and its treatment with Bay 2502</TI>
<TO>La enfermedad de Chagas en periodo agudo y su tratamiento con el Bay 2502</TO>
<SO>Boletin Chilenocde Parasitologia</SO>
<YR>1969</YR>
<VL>24</VL>
<PG>24-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Braga-2000" MODIFIED="2014-05-09 10:46:23 +0100" MODIFIED_BY="Anne Lawson" NAME="Braga 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-05-09 10:46:23 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braga S, Lauria-Pires L, Argañaraz E, Nascimento R, Teixeira A</AU>
<TI>Persistent infections in chronic Chagas' disease patients treated with anti-<I>Trypanosoma cruzi</I> nitroderivatives</TI>
<SO>Revista do Instituto de Medicina Tropical de Sao Paulo</SO>
<YR>2000</YR>
<VL>42</VL>
<NO>3</NO>
<PG>157-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Braga-2006" MODIFIED="2014-03-17 11:14:43 +0000" MODIFIED_BY="Nicole Martin" NAME="Braga 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-03-17 11:14:43 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Braga JCV, Reis F, Aras R, Costa ND, Bastos C, Silva R, et al</AU>
<TI>Clinical and therapeutic aspects of heart failure due to Chagas disease</TI>
<SO>Arquivos Brasileiros de Cardiologia</SO>
<YR>2006</YR>
<VL>86</VL>
<NO>4</NO>
<PG>296-301</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brener-1975" MODIFIED="2014-05-08 21:35:18 +0100" MODIFIED_BY="Anne Lawson" NAME="Brener 1975" YEAR="1975">
<REFERENCE MODIFIED="2014-05-08 21:35:18 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brener Z</AU>
<TI>Chemotherapy of <I>Trypanosoma cruzi</I> infections</TI>
<SO>Advances in Pharmacological Chemotherapy</SO>
<YR>1975</YR>
<VL>13</VL>
<PG>1-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Can_x00e7_ado-2002" MODIFIED="2014-05-09 09:50:28 +0100" MODIFIED_BY="Anne Lawson" NAME="Cançado 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-05-08 21:35:59 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cançado JR</AU>
<TI>Long term evaluation of etiological treatment of Chagas disease with benznidazole</TI>
<SO>Revista do Instituto de Medicina Tropical de Sao Paulo</SO>
<YR>2002</YR>
<VL>44</VL>
<NO>1</NO>
<PG>29-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carpintero-1993" MODIFIED="2014-05-08 21:38:02 +0100" MODIFIED_BY="Anne Lawson" NAME="Carpintero 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-05-08 21:38:02 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carpintero DJ</AU>
<TO>Quimioterapia antiparasitaria en la tripanosomiasis americana (Enfermedad de Chagas). Relatode 15 años de experiencia</TO>
<SO>CM Publicación Médica</SO>
<YR>1993</YR>
<VL>6</VL>
<PG>117-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chippaux-2010" MODIFIED="2014-05-09 09:51:01 +0100" MODIFIED_BY="Anne Lawson" NAME="Chippaux 2010" YEAR="2010">
<REFERENCE MODIFIED="2014-05-09 09:51:01 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chippaux JP, Salas Clavijo A, Santalla J, Postigo J, Schneider D, Brutus L</AU>
<TI>Antibody drop in newborns congenitally infected by <I>Trypanosoma cruzi</I> treated with benznidazole</TI>
<SO>Tropical Medicine and International Health</SO>
<YR>2010</YR>
<VL>15</VL>
<NO>1</NO>
<PG>87-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Coura-1996" MODIFIED="2014-05-08 21:39:47 +0100" MODIFIED_BY="Anne Lawson" NAME="Coura 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-05-08 21:39:47 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Coura JR</AU>
<TI>Current prospects of specific treatment of Chagas' disease</TI>
<TO>Perspectivas actuales en el tratamiento específico de la enfermedad de Chagas</TO>
<SO>Boletin Chileno de Parasitologia</SO>
<YR>1996</YR>
<VL>51</VL>
<PG>69-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Cutrullis-2007" MODIFIED="2014-05-08 21:41:19 +0100" MODIFIED_BY="Anne Lawson" NAME="Cutrullis 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-05-08 21:41:19 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Cutrullis R, Ballering G, Altcheh J, Moscatelli G, Corral R, Petray P, et al</AU>
<TI>Anti-M2 muscarinic receptor autoantibodies in <I>Trypanosoma cruzi</I>-infected pediatric patients treated with benznidazole</TI>
<SO>Revista de Patologia Tropical</SO>
<YR>2007</YR>
<VL>36</VL>
<NO>2</NO>
<PG>141-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Araujo-Malta-1993" MODIFIED="2014-03-17 11:18:36 +0000" MODIFIED_BY="Nicole Martin" NAME="De Araujo Malta 1993" YEAR="1993">
<REFERENCE MODIFIED="2014-03-17 11:18:36 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Araujo Malta J</AU>
<TO>Terapêutica etiológica da doença de Chagas. Consensos e divergências</TO>
<SO>Arquivos Brasileiros de Cardiologia</SO>
<YR>1993</YR>
<VL>61</VL>
<PG>201-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Castro-2006" MODIFIED="2014-05-08 21:41:52 +0100" MODIFIED_BY="Anne Lawson" NAME="De Castro 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-05-08 21:41:52 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Castro AM, Luquetti AO, Rassi A, Chiari E, Galvão LM</AU>
<TI>Detection of parasitemia profiles by blood culture after treatment of human chronic <I>Trypanosoma cruzi</I> infection</TI>
<SO>Parasitology Research</SO>
<YR>2006</YR>
<VL>99</VL>
<PG>379-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Lana-2009" MODIFIED="2014-03-17 11:20:45 +0000" MODIFIED_BY="Nicole Martin" NAME="De Lana 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-03-17 11:20:45 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Lana M, Lopes L, Martins H, Bahia M, Machado-de-Assis G, Wendling A, et al</AU>
<TI>Clinical and laboratory status of patients with chronic Chagas disease living in a vector-controlled area in Minas Gerais, Brazil, before and nine years after aetiological treatment</TI>
<SO>Memorias do Instituto Oswaldo Cruz</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>8</NO>
<PG>1139-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Oliveira-1967" MODIFIED="2014-03-17 11:21:11 +0000" MODIFIED_BY="Nicole Martin" NAME="De Oliveira 1967" YEAR="1967">
<REFERENCE MODIFIED="2014-03-17 11:21:11 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Oliveira H</AU>
<TO>Tratamento da doença de Chagas (Fase aguda) com Bayer 2502</TO>
<SO>Revista do Instituto de Medicina Tropical Sao Paulo</SO>
<YR>1967</YR>
<VL>9</VL>
<PG>343-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Oliveira-1990" MODIFIED="2014-03-17 11:22:07 +0000" MODIFIED_BY="Nicole Martin" NAME="De Oliveira 1990" YEAR="1990">
<REFERENCE MODIFIED="2014-03-17 11:22:07 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Oliveira H</AU>
<TO>Tratamento da forma indeterminada da doença de Chagas com Nifurtimox e Benznidazol</TO>
<SO>Revista da Sociedade Brasileira de Medicina Tropical</SO>
<YR>1990</YR>
<VL>23</VL>
<PG>209-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fabbro-2007" MODIFIED="2014-03-17 11:22:33 +0000" MODIFIED_BY="Nicole Martin" NAME="Fabbro 2007" YEAR="2007">
<REFERENCE MODIFIED="2014-03-17 11:22:33 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fabbro D, Streiger M, Arias E, Bizai M, Barco M, Amicone N</AU>
<TI>Trypanocide treatment among adults with chronic Chagas disease living in Santa Fe City (Argentina), over a mean follow-up of 21 years: parasitological, serological and clinical evolution</TI>
<TO>Tratamiento tripanocida em adultos chagasicos cronicos, residentes na cidade de Santa Fe (Argentina), com sequimento de 21 anos em media: evolucao parasitologica, sorolgica e clinica</TO>
<SO>Revista da Sociedade Brasileira de Medicina Tropical</SO>
<YR>2007</YR>
<VL>40</VL>
<NO>1</NO>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandes-2009" MODIFIED="2014-05-09 11:23:12 +0100" MODIFIED_BY="Anne Lawson" NAME="Fernandes 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-03-17 11:23:48 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandes C, Teicher F, Balbinot M, Liarte D, Scholl D, Steindel M, et al</AU>
<TI>Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up</TI>
<SO>Memorias do Instituto Oswaldo Cruz</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>1</NO>
<PG>27-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fernandez-1969" MODIFIED="2014-05-08 21:42:57 +0100" MODIFIED_BY="Anne Lawson" NAME="Fernandez 1969" YEAR="1969">
<REFERENCE MODIFIED="2014-05-08 21:42:57 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fernandez JJ, Cedillos RA, Godoy GA</AU>
<TI>Treatment of acute Chagas' disease with Bay 2502</TI>
<TO>Tratamiento de la enfermedad de Chagas crónica con Bay 2502</TO>
<SO>Boletin Chileno de Parasitologia</SO>
<YR>1969</YR>
<VL>24</VL>
<PG>51-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fragata-Filho-1995" MODIFIED="2014-05-08 21:43:38 +0100" MODIFIED_BY="Anne Lawson" NAME="Fragata Filho 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-05-08 21:43:38 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fragata Filho AA, da Silva MA, Boainain E</AU>
<TI>Ethiologic treatment of acute and chronic Chagas' disease</TI>
<SO>Revista Paulista de Medicina</SO>
<YR>1995</YR>
<VL>113</VL>
<PG>867-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Fragata_x002d_Filho-1995" MODIFIED="2014-01-13 22:36:35 +0000" MODIFIED_BY="[Empty name]" NAME="Fragata-Filho 1995" YEAR="1995">
<REFERENCE MODIFIED="2014-01-13 22:27:28 +0000" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Fragata-Filho AA, Boainaim E, Dias da Silva MA</AU>
<TI>Validade do tratamento etiológico na fase crônica da doença de Chagas com benznidazol</TI>
<SO>Arquivos Brasileiros de Cardiologia</SO>
<YR>1995</YR>
<VL>65</VL>
<NO>Suppl I</NO>
<PG>71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallerano-1990a" MODIFIED="2014-05-09 09:52:26 +0100" MODIFIED_BY="Anne Lawson" NAME="Gallerano 1990a" YEAR="1990">
<REFERENCE MODIFIED="2014-05-08 21:48:46 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallerano RH, Marr JJ, Sosa RR</AU>
<TI>Therapeutic efficacy of allopurinol in patients with chronic Chagas' disease</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1990</YR>
<VL>43</VL>
<PG>159-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gallerano-1990b" MODIFIED="2014-05-09 09:52:33 +0100" MODIFIED_BY="Anne Lawson" NAME="Gallerano 1990b" YEAR="1990">
<REFERENCE MODIFIED="2014-05-08 21:47:34 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gallerano RH, Sosa RR</AU>
<TO>Allopurinol vs testigo en la parasitemia de la enfermedad de Chagas crónica asintomática valorada por xenodiagnósticos seriados</TO>
<SO>Boletín Científico del CENETROP</SO>
<YR>1990</YR>
<VL>14</VL>
<PG>38-43</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gonnert-1972" MODIFIED="2014-05-08 21:49:01 +0100" MODIFIED_BY="Anne Lawson" NAME="Gonnert 1972" YEAR="1972">
<REFERENCE MODIFIED="2014-05-08 21:49:01 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gonnert R</AU>
<TI>Nifurtimox: causal treatment of Chagas' disease</TI>
<SO>Arzneimittelforschung</SO>
<YR>1972</YR>
<VL>22</VL>
<PG>1563</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gutteridge-1976" MODIFIED="2014-05-08 21:49:38 +0100" MODIFIED_BY="Anne Lawson" NAME="Gutteridge 1976" YEAR="1976">
<REFERENCE MODIFIED="2014-05-08 21:49:38 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gutteridge WE</AU>
<TI>Chemotherapy of Chagas' disease</TI>
<SO>Transactions of the Royal Society of Tropical Medicine and Hygiene</SO>
<YR>1976</YR>
<VL>70</VL>
<PG>123-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ivanovic-1994" MODIFIED="2014-03-17 11:32:13 +0000" MODIFIED_BY="Nicole Martin" NAME="Ivanovic 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-03-17 11:32:13 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ivanovic D</AU>
<TO>Actualizacion sobre el tratamiento de la enfermedad de la enfermedad de Chagas</TO>
<SO>Revista Chilena de Infectologia</SO>
<YR>1994</YR>
<VL>11</VL>
<PG>131-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lacunza-2006" MODIFIED="2014-05-08 21:50:12 +0100" MODIFIED_BY="Anne Lawson" NAME="Lacunza 2006" YEAR="2006">
<REFERENCE MODIFIED="2014-05-08 21:50:12 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lacunza C, Negrete O, Mora M, Uncos A, Segura M, Castillo N, et al</AU>
<TI>Use of the polymerase chain reaction (PCR) for early evaluation of etiological treatment in young adults, chronically infected with <I>Trypanosoma cruzi</I>
</TI>
<SO>Revista de Patologia Tropical</SO>
<YR>2006</YR>
<VL>35</VL>
<NO>3</NO>
<PG>227-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levi-1971" MODIFIED="2014-05-08 21:51:37 +0100" MODIFIED_BY="Anne Lawson" NAME="Levi 1971" YEAR="1971">
<REFERENCE MODIFIED="2014-05-08 21:51:37 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levi GC, Amato NV</AU>
<TI>Treatment of patients with chronic Chagas' disease by means of the nitrofuran compound Bayer 2502 or Lampit</TI>
<TO>Observaçoes sôbre o tratamento de pacientes com a forma crônica da doença de Chagas mediante emprêgo do composto nitrofurânico "Bayer 2502" o "lampit"</TO>
<SO>Revista do Instituto de Medicina Tropical de Sao Paulo</SO>
<YR>1971</YR>
<VL>13</VL>
<PG>369-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Levi-1996" MODIFIED="2014-05-08 21:55:38 +0100" MODIFIED_BY="Anne Lawson" NAME="Levi 1996" YEAR="1996">
<REFERENCE MODIFIED="2014-05-08 21:55:38 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Levi GC, Lobo IM, Kallas EG, Amato Neto V</AU>
<TI>Etiological drug treatment of human infection by <I>Trypanosoma cruzi</I>
</TI>
<SO>Revista do Instituto de Medicina Tropical de Sao Paulo</SO>
<YR>1996</YR>
<VL>38</VL>
<PG>35-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-L_x00f3_pez_x002d_Antu_x00f1_a_x00f1_o-1997" MODIFIED="2014-05-08 21:57:18 +0100" MODIFIED_BY="Anne Lawson" NAME="López-Antuñaño 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-05-08 21:57:18 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>López-Antuñaño FJ</AU>
<TO>Quimioterapia de las infecciones producidas por <I>Trypanosoma cruzi</I>
</TO>
<SO>Salud Pública de México</SO>
<YR>1997</YR>
<VL>39</VL>
<PG>463-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Maldonado-1997" MODIFIED="2014-05-08 22:00:16 +0100" MODIFIED_BY="Anne Lawson" NAME="Maldonado 1997" YEAR="1997">
<REFERENCE MODIFIED="2014-05-08 22:00:16 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Maldonado M, Vera de Bilbao N, Samudio M, Schinini A, Acosta N, López E, et al</AU>
<TO>Tratamiento con benznidazol en niños de seis a doce años infectados con <I>T. cruzi</I>
</TO>
<SO>EFACIM-EDUNA</SO>
<YR>1997</YR>
<PG>154-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Marr-1986" MODIFIED="2014-05-08 22:01:17 +0100" MODIFIED_BY="Anne Lawson" NAME="Marr 1986" YEAR="1986">
<REFERENCE MODIFIED="2014-05-08 22:01:17 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marr JJ, Docampo R</AU>
<TI>Chemotherapy for Chagas' disease: a perspective of current therapy and considerations for future research</TI>
<SO>Reviews of Infectious Diseases</SO>
<YR>1986</YR>
<VL>8</VL>
<PG>884-903</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martins_x002d_Filho-2002" MODIFIED="2014-05-08 22:01:44 +0100" MODIFIED_BY="Anne Lawson" NAME="Martins-Filho 2002" YEAR="2002">
<REFERENCE MODIFIED="2014-05-08 22:01:44 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martins-Filho O, Eloi-Santos S, Carvalho A, Oliveira R, Rassi A, Luquetti O, et al</AU>
<TI>Double-blind study to evaluate flow cytometry analysis of anti-live Trypomastigote antibodies for monitoring treatment efficacy in cases of human Chagas' disease</TI>
<SO>Clinical and Diagnostic Laboratory Immunology</SO>
<YR>2002</YR>
<VL>9</VL>
<NO>5</NO>
<PG>1107-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Meirovich-1985" MODIFIED="2014-05-08 22:02:15 +0100" MODIFIED_BY="Anne Lawson" NAME="Meirovich 1985" YEAR="1985">
<REFERENCE MODIFIED="2014-05-08 22:02:15 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Meirovich CI, Montrull HL, Gallerano RH, Sosa RR</AU>
<TI>Allopurinol in the treatment of chronic Chagas' disease</TI>
<TO>Allopurinol en el tratamiento de la enfermedad de Chagas crónica</TO>
<SO>Arquivos Brasileiros de Cardiologia</SO>
<YR>1985</YR>
<VL>45</VL>
<PG>217-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mendoza-1992" MODIFIED="2014-05-09 11:25:40 +0100" MODIFIED_BY="Anne Lawson" NAME="Mendoza 1992" YEAR="1992">
<REFERENCE MODIFIED="2014-05-09 11:25:40 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mendoza I, Guiniger A, Velazco V, Marques J, Moleiro F, Sgammini H</AU>
<TI>Opinion of the USCAS Electrophysiology Committee on the treatment of ventricular arrhythmias in Chagas disease</TI>
<TO>Opinión del Comité de Electrofisiología de USCAS sobre el tratamiento de las arritmias ventricularesen la enfermedad de Chagas</TO>
<SO>Rev Urug Cardiol</SO>
<YR>1992</YR>
<VL>7</VL>
<PG>25-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-P_x00e9_rez_x002d_Molina-2009" MODIFIED="2014-05-09 09:53:54 +0100" MODIFIED_BY="Anne Lawson" NAME="Pérez-Molina 2009" YEAR="2009">
<REFERENCE MODIFIED="2014-03-17 11:38:18 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pérez-Molina J, Pérez-Ayala A, Morena S, Fernández-González C, Zamora J, López-Velez R</AU>
<TI>Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2009</YR>
<VL>64</VL>
<PG>1139-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prata-1978" MODIFIED="2014-05-08 22:10:59 +0100" MODIFIED_BY="Anne Lawson" NAME="Prata 1978" YEAR="1978">
<REFERENCE MODIFIED="2014-05-08 22:10:59 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prata A</AU>
<TI>Possibility of treatment in Chagas' disease</TI>
<TO>Possibilidade de tratamento na doença de Chagas</TO>
<SO>Revista da Associacao Medica Brasileira (1992)</SO>
<YR>1978</YR>
<VL>24</VL>
<PG>140-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rassi-1982" MODIFIED="2014-05-08 22:11:13 +0100" MODIFIED_BY="Anne Lawson" NAME="Rassi 1982" YEAR="1982">
<REFERENCE MODIFIED="2014-05-08 22:11:13 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rassi A</AU>
<TI>Etiological treatment of Chagas' disease</TI>
<TO>Tratamento etiológico da doença de Chagas</TO>
<SO>Arquivos Brasileiros de Cardiologia</SO>
<YR>1982</YR>
<VL>38</VL>
<PG>277-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Romeu-Can_x00e7_ado-1976" MODIFIED="2014-05-08 22:11:50 +0100" MODIFIED_BY="Anne Lawson" NAME="Romeu Cançado 1976" YEAR="1976">
<REFERENCE MODIFIED="2014-05-08 22:11:50 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="OTHER">
<AU>Romeu Cançado J, Salgado A, Cardoso dos Santos JF, Batista SM, Chiair CC</AU>
<TI>Clinical trials in Chagas' disease</TI>
<SO>New Approaches in American Trypanosomiasis Research. 1. Washington, DC: PAHO</SO>
<YR>1976</YR>
<PG>266-72</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubio-1969" MODIFIED="2014-05-08 22:12:07 +0100" MODIFIED_BY="Anne Lawson" NAME="Rubio 1969" YEAR="1969">
<REFERENCE MODIFIED="2014-05-08 22:12:07 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubio M, Donoso F</AU>
<TI>Chagas' disease in children and its treatment with Bay 2502</TI>
<TO>Enfermeda de Chagas en niños y tratamiento con Bay 2502</TO>
<SO>Boletin Chileno de Parasitologia</SO>
<YR>1969</YR>
<VL>24</VL>
<PG>43-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Santana-1969" MODIFIED="2012-07-17 15:22:52 +0100" MODIFIED_BY="[Empty name]" NAME="Santana 1969" YEAR="1969">
<REFERENCE MODIFIED="2012-07-17 15:22:52 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Santana ET, Magalhaes J Jr, Nagashiro E, Nagashiro A, Sadae G, Delfino SA</AU>
<TO>Doença de Chagas crônica. Situaçao actual de seu tratamento</TO>
<SO>O Hospital</SO>
<YR>1969</YR>
<VL>76</VL>
<PG>67-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Silveira-2000" MODIFIED="2014-05-09 10:46:51 +0100" MODIFIED_BY="Anne Lawson" NAME="Silveira 2000" YEAR="2000">
<REFERENCE MODIFIED="2014-05-09 10:46:51 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Silveira C, Castillo E, Castro C</AU>
<TI>Specific treatment evaluation for <I>Trypanosoma cruzi</I> in children in the evolution of the indeterminate phase</TI>
<TO>Avaliacão do tratamento específico para o <I>Trypanosoma cruzi</I> em criancas, naevolucão da fase indeterminada</TO>
<SO>Revista da Sociedade Brasileira de Medicina Tropical</SO>
<YR>2000</YR>
<VL>33</VL>
<NO>2</NO>
<PG>191-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Sosa_x002d_Estani-2004" MODIFIED="2014-05-09 11:26:59 +0100" MODIFIED_BY="Anne Lawson" NAME="Sosa-Estani 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-05-09 11:26:59 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sosa-Estani S, Armenti A, Araujo G, Viotti R, Lococo B, Ruiz Vera B, et al</AU>
<TI>Treatment of Chagas disease with benznidazole and thioctic acid</TI>
<TO>Tratamiento de la enfermedad de Chagas con benznidazol y acido tioctico</TO>
<SO>MEDICINA (Buenos Aires)</SO>
<YR>2004</YR>
<VL>64</VL>
<PG>1-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Streiger-2004" MODIFIED="2014-03-17 11:41:54 +0000" MODIFIED_BY="Nicole Martin" NAME="Streiger 2004" YEAR="2004">
<REFERENCE MODIFIED="2014-03-17 11:41:54 +0000" MODIFIED_BY="Nicole Martin" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Streiger M, Del Barco M, Fabbro D, Arias E, Amicone N</AU>
<TI>Longitudinal study and specific chemotherapy in children with chronic Chagas' disease, residing in a low endemicity area of Argentina</TI>
<TO>Estudo longitudinal e quimioterapia específica em criancas, com doenca de Chagas cronica, residentes em area de baixa endemicidade da republica Argentina</TO>
<SO>Revista da Sociedade Brasieira de Medicina Tropical</SO>
<YR>2004</YR>
<VL>37</VL>
<NO>5</NO>
<PG>365-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Viotti-1994" MODIFIED="2014-05-09 12:10:21 +0100" MODIFIED_BY="Anne Lawson" NAME="Viotti 1994" YEAR="1994">
<REFERENCE MODIFIED="2014-05-09 12:10:21 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Viotti R, Vigliano C, Armenti H, Segura E</AU>
<TI>Treatment of chronic Chagas' disease with benznidazole: clinical and serologic evolution of patients with long-term follow-up</TI>
<SO>American Heart Journal</SO>
<YR>1994</YR>
<VL>127</VL>
<PG>151-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wegner-1972a" MODIFIED="2014-05-09 12:10:28 +0100" MODIFIED_BY="Anne Lawson" NAME="Wegner 1972a" YEAR="1972">
<REFERENCE MODIFIED="2014-05-09 12:10:28 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wegner DH, Rohwedder RW</AU>
<TI>The effect of nifurtimox in acute Chagas' infection</TI>
<SO>Arzneimittelforschung</SO>
<YR>1972</YR>
<VL>22</VL>
<PG>1624-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wegner-1972b" MODIFIED="2014-05-09 12:10:35 +0100" MODIFIED_BY="Anne Lawson" NAME="Wegner 1972b" YEAR="1972">
<REFERENCE MODIFIED="2014-05-09 12:10:35 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wegner DH, Rohwedder RW</AU>
<TI>Experience with nifurtimox in chronic Chagas' infection. Preliminary report</TI>
<SO>Arzneimittelforschung</SO>
<YR>1972</YR>
<VL>22</VL>
<PG>1635-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zulantay-2005" MODIFIED="2014-05-09 10:47:02 +0100" MODIFIED_BY="Anne Lawson" NAME="Zulantay 2005" YEAR="2005">
<REFERENCE MODIFIED="2014-05-09 10:47:02 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zulantay I, Arribada A, Honores P, Sánchez G, Solari A, Ortiz S, et al</AU>
<TI>No association between persistence of the parasite and electrocardiographic evolution in treated patients with Chagas disease</TI>
<TO>La mejoría electrocardiográfica con el tratamiento de la enfermedad de Chagas crónica, es independiente de la persistencia de <I>Trypanosoma cruzi</I>
</TO>
<SO>Revista Medica de Chile</SO>
<YR>2005</YR>
<VL>113</VL>
<PG>1153-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES MODIFIED="2014-05-08 22:22:52 +0100" MODIFIED_BY="Anne Lawson">
<STUDY DATA_SOURCE="PUB" ID="STD-Marin_x002d_Neto-2009" MODIFIED="2014-05-08 22:22:52 +0100" MODIFIED_BY="Anne Lawson" NAME="Marin-Neto 2009" YEAR="2009 Jul">
<REFERENCE MODIFIED="2014-05-08 22:22:52 +0100" MODIFIED_BY="Anne Lawson" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Marin-Neto JA, Rassi A Jr, Avezum A Jr, Mattos AC, Rassi A, Morillo CA, et al</AU>
<TI>The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease</TI>
<SO>Memoria do Instituto Oswaldo Cruz</SO>
<YR>2009</YR>
<VL>104 Suppl 1</VL>
<PG>319-24</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="OTHER" VALUE=""/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2014-05-09 12:20:02 +0100" MODIFIED_BY="Anne Lawson">
<ADDITIONAL_REFERENCES MODIFIED="2014-05-09 12:20:02 +0100" MODIFIED_BY="Anne Lawson">
<REFERENCE ID="REF-Andrade-1991" MODIFIED="2014-05-08 22:23:41 +0100" MODIFIED_BY="Anne Lawson" NAME="Andrade 1991" TYPE="JOURNAL_ARTICLE">
<AU>Andrade SG, Freitas LAR, Peyrol S, Pimentel AR, Sadigursky M</AU>
<TI>Experimental chemotherapy of <I>Trypanosoma cruzi </I>infection: persistence of parasite antigens and positive serology in parasitologically cured mice</TI>
<SO>WHO Bulletin OMS</SO>
<YR>1991</YR>
<VL>69</VL>
<PG>191-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Apt-1998" MODIFIED="2014-03-17 11:45:53 +0000" MODIFIED_BY="Nicole Martin" NAME="Apt 1998" TYPE="JOURNAL_ARTICLE">
<AU>Apt W, Aguilera X, Arribada A, Perez C, Miranda C, Sanchez G, et al</AU>
<TI>Treatment of chronic Chagas' disease with itraconazole and allopurinol</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1998</YR>
<VL>59</VL>
<NO>1</NO>
<PG>133-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bahia-2012" MODIFIED="2014-05-08 22:24:33 +0100" MODIFIED_BY="Anne Lawson" NAME="Bahia 2012" TYPE="JOURNAL_ARTICLE">
<AU>Bahia MT, de Andrade IM, Martins TA, do Nascimento ÁF, Diniz L de F, Caldas IS, et al</AU>
<TI>Fexinidazole: a potential new drug candidate for Chagas disease</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2012</YR>
<VL>6</VL>
<NO>11</NO>
<PG>1-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bern-2007" MODIFIED="2014-05-08 22:25:11 +0100" MODIFIED_BY="Anne Lawson" NAME="Bern 2007" TYPE="JOURNAL_ARTICLE">
<AU>Bern C, Montgomery SP, Herwaldt BL, Rassi A Jr, Marin-Neto JA, Dantas RO, et al</AU>
<TI>Evaluation and treatment of Chagas disease in the United States: a systematic review</TI>
<SO>JAMA</SO>
<YR>2007</YR>
<VL>298</VL>
<PG>2171-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bern-2009" MODIFIED="2014-05-08 22:25:51 +0100" MODIFIED_BY="Anne Lawson" NAME="Bern 2009" TYPE="JOURNAL_ARTICLE">
<AU>Bern C, Montgomery SP</AU>
<TI>An estimate of the burden of Chagas disease in the United States</TI>
<SO>Clinical Infectious Diseases</SO>
<YR>2009</YR>
<VL>49</VL>
<NO>5</NO>
<PG>e52-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chagas-1909" MODIFIED="2014-05-08 22:26:05 +0100" MODIFIED_BY="Anne Lawson" NAME="Chagas 1909" TYPE="JOURNAL_ARTICLE">
<AU>Chagas CA</AU>
<TO>Ajente etiolojico de nova entidade morbida do homem</TO>
<SO>Memorias do Instituto Oswaldo Cruz</SO>
<YR>1909</YR>
<VL>1</VL>
<NO>1</NO>
<PG>11-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coura-2005" MODIFIED="2014-05-08 22:27:09 +0100" MODIFIED_BY="Anne Lawson" NAME="Coura 2005" TYPE="JOURNAL_ARTICLE">
<AU>Coura JR</AU>
<TI>Chagas disease: clinical and therapeutic features</TI>
<SO>Enfermedades Emergentes</SO>
<YR>2005</YR>
<VL>7</VL>
<PG>18-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Coura-2010" MODIFIED="2014-05-08 22:27:25 +0100" MODIFIED_BY="Anne Lawson" NAME="Coura 2010" TYPE="JOURNAL_ARTICLE">
<AU>Coura JR, Vinas PA</AU>
<TI>Chagas disease: a new worldwide challenge</TI>
<SO>Nature</SO>
<YR>2010</YR>
<VL>465</VL>
<PG>S6-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dias-2009" MODIFIED="2012-02-21 16:27:48 +0000" MODIFIED_BY="[Empty name]" NAME="Dias 2009" TYPE="JOURNAL_ARTICLE">
<AU>Dias JCP</AU>
<TI>Elimination of Chagas disease transmission: perspectives</TI>
<SO>Memorias do Instituto Oswaldo Cruz</SO>
<YR>2009</YR>
<VL>104</VL>
<PG>41-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Escriba-2009" MODIFIED="2012-09-21 19:59:19 +0100" MODIFIED_BY="[Empty name]" NAME="Escriba 2009" TYPE="JOURNAL_ARTICLE">
<AU>Escriba JM, Ponce E, Romero Ade D, Vinas PA, Marchiol A, Bassets G, et al</AU>
<TI>Treatment and seroconversion in a cohort of children suffering from recent chronic Chagas infection in Yoro, Honduras</TI>
<SO>Memorias do Instituto Oswaldo Cruz</SO>
<YR>2009</YR>
<VL>104</VL>
<NO>7</NO>
<PG>986-91</PG>
<IDENTIFIERS MODIFIED="2012-09-21 19:59:15 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER TYPE="PUBMED" VALUE="20027465"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Follmann-1992" MODIFIED="2014-05-09 11:28:47 +0100" MODIFIED_BY="Anne Lawson" NAME="Follmann 1992" TYPE="JOURNAL_ARTICLE">
<AU>Follmann D, Elliott P, Suh I, Curter J</AU>
<TI>Variance imputation for overviews of clinical trials with continuous response</TI>
<SO>Journal of Clinical Epidemiology</SO>
<YR>1992</YR>
<VL>45</VL>
<PG>769-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Freitas-2005" MODIFIED="2014-05-08 22:29:06 +0100" MODIFIED_BY="Anne Lawson" NAME="Freitas 2005" TYPE="JOURNAL_ARTICLE">
<AU>Freitas HF, Chizzola PR, Paes AT, Lima AC, Mansur AJ</AU>
<TI>Risk stratification in a Brazilian hospital-based cohort of 1220 outpatients with heart failure: role of Chagas' heart disease</TI>
<SO>International Journal of Cardiology</SO>
<YR>2005</YR>
<VL>102</VL>
<NO>2</NO>
<PG>239-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gallerano-2001" MODIFIED="2014-05-08 22:33:10 +0100" MODIFIED_BY="Anne Lawson" NAME="Gallerano 2001" TYPE="JOURNAL_ARTICLE">
<AU>Gallerano R, Sr</AU>
<TO>Resultados de un estudio a largo plazo con drogas antiparasitarias en infectados chagásicos crónicos</TO>
<SO>Revista de la Federación Argentina de Cardiología</SO>
<YR>2001</YR>
<VL>30</VL>
<PG>289-96</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Galvao-2003" MODIFIED="2014-05-08 22:33:41 +0100" MODIFIED_BY="Anne Lawson" NAME="Galvao 2003" TYPE="JOURNAL_ARTICLE">
<AU>Galvao LM, Chiari E, Macedo AM, Luquetti AO, Silva SA, Andrade AL</AU>
<TI>PCR assay for monitoring <I>Trypanosoma cruzi</I> parasitemia in childhood after specific chemotherapy</TI>
<SO>Journal of Clinical Microbiology</SO>
<YR>2003</YR>
<VL>41</VL>
<PG>5066-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Garc_x00ed_a-2005" MODIFIED="2014-05-08 22:34:01 +0100" MODIFIED_BY="Anne Lawson" NAME="García 2005" TYPE="JOURNAL_ARTICLE">
<AU>García S, Ramos CO, Senra JF, Vilas-Boas F, Rodrigues MM, Campos de Carvalho AC, et al</AU>
<TI>Treatment with benznidazole during the chronic phase of experimental Chagas' disease decreases cardiac alterations</TI>
<SO>Antimicrobial Agents and Chemotherapy</SO>
<YR>2005</YR>
<VL>49</VL>
<NO>4</NO>
<PG>1521-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grupo-de-trabajo-cient_x00ed_fico-OMS-2007" MODIFIED="2014-03-17 13:12:04 +0000" MODIFIED_BY="Nicole Martin" NAME="Grupo de trabajo científico OMS 2007" TYPE="OTHER">
<AU>Grupo de trabajo científico OMS</AU>
<TO>Reporte sobre la enfermedad de Chagas</TO>
<YR>2007</YR>
<VL>17-20 de abril de 2005 (Actualizado en julio de 2007) - Buenos Aires Argentina</VL>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Guhl-2005" MODIFIED="2014-05-08 22:34:30 +0100" MODIFIED_BY="Anne Lawson" NAME="Guhl 2005" TYPE="JOURNAL_ARTICLE">
<AU>Guhl F, Restrepo M, Angulo VM, Antunes CM, Campbell-Lendrum D, Davies CR</AU>
<TI>Lessons from a national survey of Chagas disease transmission risk in Colombia</TI>
<SO>Trends in Parasitology</SO>
<YR>2005</YR>
<VL>21</VL>
<NO>6</NO>
<PG>259-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hagar-1991" MODIFIED="2014-03-17 13:12:53 +0000" MODIFIED_BY="Nicole Martin" NAME="Hagar 1991" TYPE="JOURNAL_ARTICLE">
<AU>Hagar JM, Rahimtoola SH</AU>
<TI>Chagas' heart disease in the United States</TI>
<SO>New England Journal of Medicine</SO>
<YR>1991</YR>
<VL>325</VL>
<NO>11</NO>
<PG>763-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2011" MODIFIED="2014-05-09 09:56:22 +0100" MODIFIED_BY="Anne Lawson" NAME="Higgins 2011" TYPE="OTHER">
<AU>Higgins JPT, Green S (editors)</AU>
<TI>Cochrane Handbook for Systematic Reviews of Intervention Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS MODIFIED="2014-05-09 09:56:22 +0100" MODIFIED_BY="Anne Lawson"/>
</REFERENCE>
<REFERENCE ID="REF-Higuchi-2003" MODIFIED="2014-03-17 13:14:18 +0000" MODIFIED_BY="Nicole Martin" NAME="Higuchi 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higuchi ML, Benvenuti LA, Martins RM, Metzger M</AU>
<TI>Pathophysiology of the heart in Chagas' disease: current status and new developments</TI>
<SO>Cardiovascular Research</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>96-107</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hotez-2008" MODIFIED="2014-03-17 13:16:42 +0000" MODIFIED_BY="Nicole Martin" NAME="Hotez 2008" TYPE="JOURNAL_ARTICLE">
<AU>Hotez PJ, Bottazzi ME, Franco-Paredes C, Ault SK, Periago MR</AU>
<TI>The neglected tropical diseases of Latin America and the Caribbean: a review of disease burden and distribution and a roadmap for control and elimination</TI>
<SO>PLoS Neglected Tropical Diseases</SO>
<YR>2008</YR>
<VL>2</VL>
<NO>9</NO>
<PG>e300</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jones-1993" MODIFIED="2014-05-08 22:36:45 +0100" MODIFIED_BY="Anne Lawson" NAME="Jones 1993" TYPE="JOURNAL_ARTICLE">
<AU>Jones EM, Colley DG, Tostes S, Lopes ER, Vnencak-Jones CL, McCurley TL</AU>
<TI>Amplification of a <I>Trypanosoma cruzi</I> DNA sequence from inflammatory lesions in human chagasic cardiomyopathy</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>1993</YR>
<VL>48</VL>
<PG>348-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuschnir-1985" MODIFIED="2014-05-08 22:37:03 +0100" MODIFIED_BY="Anne Lawson" NAME="Kuschnir 1985" TYPE="JOURNAL_ARTICLE">
<AU>Kuschnir E, Sgammini H, Castro R, Evequoz C, Ledesma R, Brunetto J</AU>
<TI>Evaluation of cardiac function by radioisotopic angiography, in patients with chronic Chagas cardiopathy</TI>
<SO>Arquivos Brasileiros de Cardiologia</SO>
<YR>1985</YR>
<VL>45</VL>
<NO>4</NO>
<PG>249-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Laranja-1956" MODIFIED="2014-05-08 22:37:13 +0100" MODIFIED_BY="Anne Lawson" NAME="Laranja 1956" TYPE="JOURNAL_ARTICLE">
<AU>Laranja FS, Dias E, Nobrega G, Miranda A</AU>
<TI>Chagas' disease: a clinical, epidemiologic, and pathologic study</TI>
<SO>Circulation</SO>
<YR>1956</YR>
<VL>14</VL>
<NO>6</NO>
<PG>1035-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lauria_x002d_Pires-2000" MODIFIED="2014-05-08 22:37:43 +0100" MODIFIED_BY="Anne Lawson" NAME="Lauria-Pires 2000" TYPE="JOURNAL_ARTICLE">
<AU>Lauria-Pires L, Braga MS, Vexenat AC, Nitz N, Simoes-Barbosa A, Tinoco DL, et al</AU>
<TI>Progressive chronic Chagas heart disease ten years after treatment with anti-<I>Trypanosoma cruzi</I> nitroderivatives</TI>
<SO>American Journal of Tropical Medicine and Hygiene</SO>
<YR>2000</YR>
<VL>63</VL>
<NO>3-4</NO>
<PG>111-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2011" MODIFIED="2014-05-08 22:39:14 +0100" MODIFIED_BY="Anne Lawson" NAME="Lefebvre 2011" TYPE="OTHER">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011</TI>
<SO>Available from www.cochrane-handbook.org</SO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-L_x00f3_pez-2009" MODIFIED="2014-05-09 09:57:01 +0100" MODIFIED_BY="Anne Lawson" NAME="López 2009" TYPE="JOURNAL_ARTICLE">
<AU>López S, Risech E, Riarte A</AU>
<TO>A nueve años de un estudio de tratamiento en adultos (TRAENA) con enfermedad de Chagas crónica: adherencia a los controles y expectativas de curación</TO>
<YR>2008</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Marinho-1999" MODIFIED="2014-05-09 08:36:55 +0100" MODIFIED_BY="Anne Lawson" NAME="Marinho 1999" TYPE="JOURNAL_ARTICLE">
<AU>Marinho CR, Imperio Lima MR, Grisotto MG, Alvarez JM</AU>
<TI>Influence of acute-phase parasite load on pathology, parasitism, and activation of the immune system at the late chronic phase of Chagas' disease</TI>
<SO>Infection and Immunity</SO>
<YR>1999</YR>
<VL>67</VL>
<NO>1</NO>
<PG>308-18</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moncayo-2003" MODIFIED="2014-05-09 08:37:10 +0100" MODIFIED_BY="Anne Lawson" NAME="Moncayo 2003" TYPE="JOURNAL_ARTICLE">
<AU>Moncayo A</AU>
<TI>Chagas disease: current epidemiological trends after the interruption of vectorial and transfusional transmission in the Southern Cone countries</TI>
<SO>Memorios do Instituto Oswaldo Cruz</SO>
<YR>2003</YR>
<VL>98</VL>
<NO>5</NO>
<PG>577-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Perez_x002d_Molina-2009" MODIFIED="2014-05-09 08:37:24 +0100" MODIFIED_BY="Anne Lawson" NAME="Perez-Molina 2009" TYPE="JOURNAL_ARTICLE">
<AU>Perez-Molina JA, Perez-Ayala A, Moreno S, Fernandez-Gonzalez MC, Zamora J, Lopez-Velez R</AU>
<TI>Use of benznidazole to treat chronic Chagas' disease: a systematic review with a meta-analysis</TI>
<SO>Journal of Antimicrobial Chemotherapy</SO>
<YR>2009</YR>
<VL>64</VL>
<PG>1139-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-RevMan-2012" MODIFIED="2014-05-09 09:59:10 +0100" MODIFIED_BY="Anne Lawson" NAME="RevMan 2012" TYPE="COMPUTER_PROGRAM">
<TI>Review Manager (RevMan)</TI>
<YR>2012</YR>
<EN>5.2</EN>
<PB>The Nordic Cochrane Centre, The Cochrane Collaboration</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reyes-2005" MODIFIED="2014-05-09 08:37:42 +0100" MODIFIED_BY="Anne Lawson" NAME="Reyes 2005" TYPE="COCHRANE_REVIEW">
<AU>Reyes PA, Vallejo M</AU>
<TI>Trypanocidal drugs for late stage, symptomatic Chagas disease (<I>Trypanosoma cruzi</I> infection)</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<NO>4</NO>
<IDENTIFIERS MODIFIED="2014-03-17 13:23:58 +0000" MODIFIED_BY="Nicole Martin">
<IDENTIFIER MODIFIED="2014-03-17 13:23:58 +0000" MODIFIED_BY="Nicole Martin" TYPE="DOI" VALUE="10.1002/14651858.CD004102.pub2"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Sosa-1999" MODIFIED="2014-05-09 09:57:29 +0100" MODIFIED_BY="Anne Lawson" NAME="Sosa 1999" TYPE="JOURNAL_ARTICLE">
<AU>Sosa ES, Segura EL</AU>
<TO>Tratamiento de la infeccion por <I>Trypanosoma cruzi</I> en fase indeterminada. Experiencia y normatizacion actual en la Argentina</TO>
<SO>Medicina</SO>
<YR>1999</YR>
<VL>59 Suppl 2</VL>
<PG>166-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Villar-2001" MODIFIED="2014-05-09 08:39:30 +0100" MODIFIED_BY="Anne Lawson" NAME="Villar 2001" TYPE="JOURNAL_ARTICLE">
<AU>Villar JC</AU>
<TI>Commentary: control of Chagas' disease: let's put people before vectors</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2001</YR>
<VL>30</VL>
<NO>4</NO>
<PG>894-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2002" MODIFIED="2014-05-09 08:41:01 +0100" MODIFIED_BY="Anne Lawson" NAME="WHO 2002" TYPE="BOOK">
<AU>WHO</AU>
<SO>Control of Chagas disease. Second Report of the WHO Expert Committee</SO>
<YR>2002</YR>
<PB>WHO</PB>
<CY>Geneva</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2009" MODIFIED="2014-05-09 08:44:12 +0100" MODIFIED_BY="Anne Lawson" NAME="WHO 2009" TYPE="OTHER">
<AU>WHO secretariat</AU>
<TI>Chagas disease: control and elimination: provisional agenda item 12.12 for the 62th World Health Assembly A62/17, 2009</TI>
<SO>apps.who.int/iris/bitstream/10665/2199/1/A62_17-en.pdf?ua=1</SO>
<YR>(accessed 8 May 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2010" MODIFIED="2014-05-09 11:45:01 +0100" MODIFIED_BY="Anne Lawson" NAME="WHO 2010" TYPE="OTHER">
<AU>WHO</AU>
<TI>Control and prevention of Chagas disease in Europe, 2010</TI>
<SO>www.fac.org.ar/1/comites/chagas/Chagas_WHO_Technical%20Report_16_06_10.pdf</SO>
<YR>(accessed 8 May 2014)</YR>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2014-05-09 08:49:51 +0100" MODIFIED_BY="Anne Lawson">
<REFERENCE ID="REF-Villar-2002" MODIFIED="2014-05-09 08:49:51 +0100" MODIFIED_BY="Anne Lawson" NAME="Villar 2002" TYPE="COCHRANE_REVIEW">
<AU>Villar JC, Villar LA, Marin-Neto JA, Ebrahim S, Yusuf S</AU>
<TI>Trypanocidal drugs for chronic asymptomatic <I>Trypanosoma cruzi</I> infection</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2002</YR>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2014-05-09 08:49:32 +0100" MODIFIED_BY="Anne Lawson">
<IDENTIFIER MODIFIED="2014-05-09 08:49:32 +0100" MODIFIED_BY="Anne Lawson" TYPE="OTHER" VALUE="10.1002/14651858.CD003463"/>
</IDENTIFIERS>
</REFERENCE>
</OTHER_VERSIONS_REFERENCES>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2014-05-09 10:19:52 +0100" MODIFIED_BY="Anne Lawson">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2014-05-09 10:19:52 +0100" MODIFIED_BY="Anne Lawson" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2014-05-09 08:30:31 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Andrade-1996">
<CHAR_METHODS MODIFIED="2014-05-08 20:02:41 +0100" MODIFIED_BY="Anne Lawson">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-08 20:02:45 +0100" MODIFIED_BY="Anne Lawson">
<P>School children</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 08:30:31 +0100" MODIFIED_BY="Anne Lawson">
<P>BZD (n = 64) 7.5 mg/kg/day (8 weeks)</P>
<P>Placebo (n = 65)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-01-13 19:18:54 +0000" MODIFIED_BY="Micah R Pepper">
<P>Serological status recorded</P>
<P>Antibody titres reported</P>
<P>Incidence of ECG abnormalities reported</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-02 20:07:32 +0000" MODIFIED_BY="Micah R Pepper">
<P>Brazil, 1996</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 08:30:33 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Andrade-2004">
<CHAR_METHODS MODIFIED="2014-05-08 20:03:52 +0100" MODIFIED_BY="Anne Lawson">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-08 20:03:56 +0100" MODIFIED_BY="Anne Lawson">
<P>School children</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 08:30:33 +0100" MODIFIED_BY="Anne Lawson">
<P>BZN (n = 64) 7.5 mg/kg/day (8 weeks)</P>
<P>Placebo (n = 65)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-02 20:09:11 +0000" MODIFIED_BY="Micah R Pepper">
<P>Incidence of ECG abnormalities</P>
<P>Serological status recorded</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-08 20:04:13 +0100" MODIFIED_BY="Anne Lawson">
<P>Brazil 2004</P>
<P>Same study as <LINK REF="REF-Galvao-2003" TYPE="REFERENCE">Galvao 2003</LINK> with different outcomes</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 10:06:00 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Apt-1998_x002a_">
<CHAR_METHODS MODIFIED="2014-05-09 10:06:00 +0100" MODIFIED_BY="Anne Lawson">
<P>Non-randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-28 17:09:49 +0000" MODIFIED_BY="Micah R Pepper">
<P>Adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 08:30:34 +0100" MODIFIED_BY="Anne Lawson">
<P>ALLOP (n = 104) 8.5 mg/kg/day (8 weeks)</P>
<P>ITRA (n = 135) 6 mg/kg/day (16 weeks)</P>
<P>Placebo (n = 165)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-28 17:11:58 +0000" MODIFIED_BY="Micah R Pepper">
<P>Xenodiagnosis recorded</P>
<P>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-02 20:11:38 +0000" MODIFIED_BY="Micah R Pepper">
<P>Chile 1998</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 10:18:07 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Britto-2001_x002a_">
<CHAR_METHODS MODIFIED="2014-05-09 10:06:05 +0100" MODIFIED_BY="Anne Lawson">
<P>Non-randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-28 17:16:33 +0000" MODIFIED_BY="Micah R Pepper">
<P>Adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 10:18:07 +0100" MODIFIED_BY="Anne Lawson">
<P>BZD 5-6 mg/kg/day (4-8 weeks)</P>
<P>NFTMX 7-8 mg/kg/day (8-12 weeks)</P>
<P>Untreated (n = 15)</P>
<P>BZD or NFTMX (n = 48)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-28 17:26:16 +0000" MODIFIED_BY="Micah R Pepper">
<P>PCR</P>
<P>Xenodiagnosis recorded</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-02 20:15:27 +0000" MODIFIED_BY="Micah R Pepper">
<P>Brazil 2001</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 10:18:07 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Catalioti-2001_x002a_">
<CHAR_METHODS MODIFIED="2014-05-09 10:06:09 +0100" MODIFIED_BY="Anne Lawson">
<P>Non-randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-29 21:44:14 +0100" MODIFIED_BY="Micah R Pepper">
<P>Adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 10:18:07 +0100" MODIFIED_BY="Anne Lawson">
<P>BZD (n = 74)</P>
<P>Untreated (n = 465)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-10-29 21:44:24 +0100" MODIFIED_BY="Micah R Pepper">
<P>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-29 14:48:13 +0000" MODIFIED_BY="Micah R Pepper">
<P>Venezuela 2001</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 10:06:13 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Coura-1997">
<CHAR_METHODS MODIFIED="2014-05-09 10:06:13 +0100" MODIFIED_BY="Anne Lawson">
<P>Non-randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-02 20:17:34 +0000" MODIFIED_BY="Micah R Pepper">
<P>Adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 08:30:38 +0100" MODIFIED_BY="Anne Lawson">
<P>BZD (n = 26) 5 mg/kg/day (4 weeks)</P>
<P>NFTMX (n = 27) 5 mg/kg/day (4 weeks)</P>
<P>Placebo (n = 24)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-08 20:08:36 +0100" MODIFIED_BY="Anne Lawson">
<P>Serological status recorded</P>
<P>Xenodiagnosis recorded</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-29 14:48:18 +0000" MODIFIED_BY="Micah R Pepper">
<P>Brazil 1997</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 10:18:08 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Fabbro-2000_x002a__x002a_">
<CHAR_METHODS MODIFIED="2012-07-17 20:47:47 +0100" MODIFIED_BY="Micah R Pepper">
<P>Observational study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-28 17:29:21 +0000" MODIFIED_BY="Micah R Pepper">
<P>Adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 10:18:08 +0100" MODIFIED_BY="Anne Lawson">
<P>BZD (n = 36) 5 mg/kg/day (4 weeks)</P>
<P>NFTMX (n = 34) 5 mg/kg/day (8 weeks)</P>
<P>Untreated (n = 130)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-08 20:09:22 +0100" MODIFIED_BY="Anne Lawson">
<P>Serology status recorded</P>
<P>Progression of cardiomyopathy</P>
<P>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-02 20:21:31 +0000" MODIFIED_BY="Micah R Pepper">
<P>Argentina 2000</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 10:19:50 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Gallerano-2000_x002a__x002a_">
<CHAR_METHODS MODIFIED="2012-02-28 17:29:55 +0000" MODIFIED_BY="Micah R Pepper">
<P>Observational study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-28 17:30:03 +0000" MODIFIED_BY="Micah R Pepper">
<P>Adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 10:19:50 +0100" MODIFIED_BY="Anne Lawson">
<P>BZD (n = 130) 4-8 mg/kg/day (6-8 weeks)</P>
<P>NFTMX (n = 96) 10 mg/kg/day (6-8weeks)</P>
<P>ALLOP (n = 309) 300, 600 or 900 mg/kg/day (8 weeks)</P>
<P>Untreated (n = 668)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-08 20:10:36 +0100" MODIFIED_BY="Anne Lawson">
<P>Serology status recorded</P>
<P>Side effects</P>
<P>Progression of cardiomyopathy</P>
<P>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-02 20:24:15 +0000" MODIFIED_BY="Micah R Pepper">
<P>Argentina 2000</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 10:18:09 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Galv_x00e3_o-_x0028_Andrade-substudy_x0029_">
<CHAR_METHODS MODIFIED="2014-05-08 20:10:48 +0100" MODIFIED_BY="Anne Lawson">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-08 20:10:52 +0100" MODIFIED_BY="Anne Lawson">
<P>School children</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 10:18:09 +0100" MODIFIED_BY="Anne Lawson">
<P>BZD (n = 64) 7.5 mg/kg/day (8 weeks)</P>
<P>Placebo (n = 65)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-11-02 20:27:25 +0000" MODIFIED_BY="Micah R Pepper">
<P>PCR recorded</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2014-05-08 20:11:26 +0100" MODIFIED_BY="Anne Lawson">
<P>Substudy of <LINK REF="STD-Andrade-2004" TYPE="STUDY">Andrade 2004</LINK>, different outcomes</P>
<P>Brazil 2003</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 10:19:51 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Gianella-1994">
<CHAR_METHODS MODIFIED="2014-05-08 20:11:39 +0100" MODIFIED_BY="Anne Lawson">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-11-02 20:26:38 +0000" MODIFIED_BY="Micah R Pepper">
<P>Adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 10:19:51 +0100" MODIFIED_BY="Anne Lawson">
<P>ALLOP (n = 18) 300 mg 3 times/day (8 weeks)</P>
<P>Placebo (n = 22)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-29 22:31:20 +0000" MODIFIED_BY="Micah R Pepper">
<P>Antibody titres recorded</P>
<P>Xenodiagnosis recorded</P>
<P>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-28 17:32:01 +0000" MODIFIED_BY="Micah R Pepper">
<P>Bolivia 1994</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 10:18:09 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Lauria_x002d_Pires-2000_x002a__x002a_">
<CHAR_METHODS MODIFIED="2014-05-08 20:12:53 +0100" MODIFIED_BY="Anne Lawson">
<P>Observational study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-29 22:01:35 +0100" MODIFIED_BY="Micah R Pepper">
<P>Adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 10:18:09 +0100" MODIFIED_BY="Anne Lawson">
<P>BZD (n = 17) 10 mg/kg/day (8 weeks)</P>
<P>NFTMX (n = 28) 10 mg/kg/day (8 weeks)</P>
<P>Untreated (n = 46)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-08 20:14:05 +0100" MODIFIED_BY="Anne Lawson">
<P>Serology status recorded</P>
<P>Mortality</P>
<P>Progression of cardiomyopathy</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2012-02-29 14:48:25 +0000" MODIFIED_BY="Micah R Pepper">
<P>Brazil 2000</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 10:18:10 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Prado-2008">
<CHAR_METHODS MODIFIED="2014-05-08 20:14:20 +0100" MODIFIED_BY="Anne Lawson">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-29 22:03:50 +0100" MODIFIED_BY="Micah R Pepper">
<P>Adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 10:18:10 +0100" MODIFIED_BY="Anne Lawson">
<P>BZD (n = 352)</P>
<P>Placebo (n = 357)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-29 20:32:49 +0000" MODIFIED_BY="Micah R Pepper">
<P>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-02 20:31:31 +0000" MODIFIED_BY="Micah R Pepper">
<P>Argentina 2008</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 10:19:52 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Rassi-2007">
<CHAR_METHODS MODIFIED="2014-05-08 20:14:48 +0100" MODIFIED_BY="Anne Lawson">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-29 22:05:55 +0100" MODIFIED_BY="Micah R Pepper">
<P>Adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 10:19:52 +0100" MODIFIED_BY="Anne Lawson">
<P>ALLOP (n = 23) 4.3 mg/kg/day (8 weeks)</P>
<P>Placebo (n = 12)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-29 20:32:43 +0000" MODIFIED_BY="Micah R Pepper">
<P>Xenodiagnosis recorded</P>
<P>Serology status recorded</P>
<P>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-02 20:34:17 +0000" MODIFIED_BY="Micah R Pepper">
<P>Brazil 2007</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 10:18:11 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Silveira-2000_x002a_">
<CHAR_METHODS MODIFIED="2014-05-09 10:06:27 +0100" MODIFIED_BY="Anne Lawson">
<P>Non-randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2012-02-29 14:33:25 +0000" MODIFIED_BY="[Empty name]">
<P>Adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 10:18:11 +0100" MODIFIED_BY="Anne Lawson">
<P>BZD (n = 34)</P>
<P>NFTMX (n = 25)</P>
<P>Untreated (n = 39)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-08 20:15:46 +0100" MODIFIED_BY="Anne Lawson">
<P>Serology status recorded</P>
<P>Progression of cardiomyopathy</P>
<P>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 10:18:11 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Sosa_x002d_Estani-1998">
<CHAR_METHODS MODIFIED="2014-05-08 20:16:01 +0100" MODIFIED_BY="Anne Lawson">
<P>RCT</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2014-05-08 20:16:04 +0100" MODIFIED_BY="Anne Lawson">
<P>School children</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 10:18:11 +0100" MODIFIED_BY="Anne Lawson">
<P>BZD (n = 55) 5 mg/kg/day (8 weeks)</P>
<P>Placebo (n = 51)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2012-02-29 14:39:16 +0000" MODIFIED_BY="Micah R Pepper">
<P>Serological status recorded</P>
<P>Antibody titres recorded</P>
<P>Xenodiagnosis recorded</P>
<P>Incidence of ECG abnormalities</P>
<P>Side effects</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-02 20:36:25 +0000" MODIFIED_BY="Micah R Pepper">
<P>Argentina 1998</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2014-05-09 10:18:12 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Viotti-2006_x002a_">
<CHAR_METHODS MODIFIED="2014-05-09 10:06:36 +0100" MODIFIED_BY="Anne Lawson">
<P>Non-randomised study</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-29 22:06:27 +0100" MODIFIED_BY="Micah R Pepper">
<P>Adults</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2014-05-09 10:18:12 +0100" MODIFIED_BY="Anne Lawson">
<P>BZD (n = 294) 5 mg/kg/day (4 weeks)</P>
<P>Untreated (n = 304)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2014-05-08 20:17:04 +0100" MODIFIED_BY="Anne Lawson">
<P>Serology status</P>
<P>Side effects</P>
<P>Progression of cardiomyopathy</P>
<P>Mortality</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2010-11-02 20:37:16 +0000" MODIFIED_BY="Micah R Pepper">
<P>Argentina 2006</P>
<P>Refer to study as subgroup of reported cohort</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>ALLOP: allopurinol; BZD: benznidazole; ECG: electrocardiogram; ITRA: itraconazole; NFTMX: nifurtimox; PCR: polymerase chain reaction; RCT: randomised controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2014-05-09 08:35:07 +0100" MODIFIED_BY="Anne Lawson" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:28:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Abitbol-1981">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:28:54 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:42:22 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Aguilera-1987">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:42:22 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:29:10 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amato-1980">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:29:10 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:29:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Amato-1998">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:29:46 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-09 08:35:02 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Andrade-1973">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-09 08:35:02 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate study population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-09 08:35:07 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Andrade-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-09 08:35:07 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate study population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:30:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Apt-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:30:11 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:30:15 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Apt-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:30:15 +0100" MODIFIED_BY="[Empty name]">
<P>Duplicated data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:49:49 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Apt-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:49:49 +0100" MODIFIED_BY="Anne Lawson">
<P>Observational study of previous RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:49:58 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Apt-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:49:58 +0100" MODIFIED_BY="Anne Lawson">
<P>Observational study of previous RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:30:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Bestetti-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:30:25 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:50:17 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Bocca-Tourres-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:50:17 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate study population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:50:26 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Braga-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:50:26 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:50:32 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Braga-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:50:32 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:46:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brener-1975">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:46:05 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:50:44 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Can_x00e7_ado-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:50:44 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:42:34 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Carpintero-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:42:34 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:50:52 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Chippaux-2010">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:50:52 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:46:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Coura-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:46:20 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:51:13 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Cutrullis-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:51:13 +0100" MODIFIED_BY="Anne Lawson">
<P>Not appropriate intervention, study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:46:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Araujo-Malta-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:46:28 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:51:23 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-De-Castro-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:51:23 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:51:30 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-De-Lana-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:51:30 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:52:06 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-De-Oliveira-1967">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:52:06 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate study population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:42:40 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-De-Oliveira-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:42:40 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:52:24 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Fabbro-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:52:24 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:52:44 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Fernandes-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:52:44 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:52:37 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Fernandez-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:52:37 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate study population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:47:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fragata-Filho-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:47:03 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-01-13 22:29:36 +0000" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Fragata_x002d_Filho-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-01-13 22:29:36 +0000" MODIFIED_BY="[Empty name]">
<P>Data from an abstract. Complete study not published</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:42:50 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Gallerano-1990a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:42:50 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:42:47 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Gallerano-1990b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:42:47 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:42:51 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Gonnert-1972">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:42:51 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:47:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gutteridge-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:47:28 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:47:32 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ivanovic-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:47:32 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:53:25 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Lacunza-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:53:25 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:42:55 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Levi-1971">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:42:55 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:48:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Levi-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:48:36 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:48:40 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-L_x00f3_pez_x002d_Antu_x00f1_a_x00f1_o-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:48:40 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:42:57 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Maldonado-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:42:57 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:48:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Marr-1986">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:48:55 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:54:15 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Martins_x002d_Filho-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:54:15 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:43:04 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Meirovich-1985">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:43:04 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:49:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mendoza-1992">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:49:07 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:43:07 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Prata-1978">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:43:07 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-29 22:13:51 +0100" MODIFIED_BY="Micah R Pepper" STUDY_ID="STD-P_x00e9_rez_x002d_Molina-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-29 22:13:51 +0100" MODIFIED_BY="Micah R Pepper">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:49:20 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rassi-1982">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:49:20 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:49:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Romeu-Can_x00e7_ado-1976">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:49:24 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:43:11 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Rubio-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:43:11 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2012-07-17 15:49:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Santana-1969">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2012-07-17 15:49:33 +0100" MODIFIED_BY="[Empty name]">
<P>Study not reporting original data</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:54:32 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Silveira-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:54:32 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:54:41 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Sosa_x002d_Estani-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:54:41 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate outcomes and treatment</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:54:47 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Streiger-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:54:47 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:43:24 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Viotti-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:43:24 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:55:01 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Wegner-1972a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:55:01 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate study population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:55:14 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Wegner-1972b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:55:14 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate study population</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2014-05-08 20:55:25 +0100" MODIFIED_BY="Anne Lawson" STUDY_ID="STD-Zulantay-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2014-05-08 20:55:25 +0100" MODIFIED_BY="Anne Lawson">
<P>Original studies, not RCT, not appropriate outcomes</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES>
<P>RCT: randomised controlled trial.</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2014-03-04 12:17:45 +0000" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Marin_x002d_Neto-2009">
<CHAR_STUDY_NAME/>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES/>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2014-05-09 08:34:06 +0100" MODIFIED_BY="Anne Lawson">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2014-05-09 08:34:00 +0100" MODIFIED_BY="Anne Lawson" NO="1">
<NAME>Random sequence generation (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate generation of a randomised sequence</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 16:42:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Andrade-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 17:06:35 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Andrade-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-09 08:31:52 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Apt-1998_x002a_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 18:04:17 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Britto-2001_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 18:09:29 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Catalioti-2001_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 18:19:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coura-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-09 08:28:13 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Fabbro-2000_x002a__x002a_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 21:01:57 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gallerano-2000_x002a__x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 21:05:42 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Galv_x00e3_o-_x0028_Andrade-substudy_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-23 15:18:05 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gianella-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 22:36:20 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lauria_x002d_Pires-2000_x002a__x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 22:41:13 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prado-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-09 08:33:18 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Rassi-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 22:52:13 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Silveira-2000_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-09 08:34:00 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Sosa_x002d_Estani-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-23 14:38:04 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Viotti-2006_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2014-05-09 08:34:03 +0100" MODIFIED_BY="Anne Lawson" NO="2">
<NAME>Allocation concealment (selection bias)</NAME>
<DESCRIPTION>
<P>Selection bias (biased allocation to interventions) due to inadequate concealment of allocations prior to assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 16:42:29 +0100" MODIFIED_BY="Micah R Pepper" RESULT="YES" STUDY_ID="STD-Andrade-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 17:06:37 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Andrade-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-09 08:31:57 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Apt-1998_x002a_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 18:04:19 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Britto-2001_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 18:09:31 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Catalioti-2001_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 18:18:51 +0100" MODIFIED_BY="Micah R Pepper" RESULT="YES" STUDY_ID="STD-Coura-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-09 08:28:13 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Fabbro-2000_x002a__x002a_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 21:02:02 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gallerano-2000_x002a__x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 21:06:46 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Galv_x00e3_o-_x0028_Andrade-substudy_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-23 15:18:08 +0100" MODIFIED_BY="Micah R Pepper" RESULT="UNKNOWN" STUDY_ID="STD-Gianella-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 22:36:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lauria_x002d_Pires-2000_x002a__x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-09 08:33:09 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Prado-2008">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-09 08:33:23 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Rassi-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-17 22:52:18 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Silveira-2000_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2014-05-09 08:34:03 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Sosa_x002d_Estani-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2012-07-23 14:38:25 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Viotti-2006_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2012-07-17 16:52:42 +0100" MODIFIED_BY="[Empty name]" NO="3">
<NAME>Blinding (performance bias and detection bias)</NAME>
<DESCRIPTION>
<P>Performance bias or detection bias due to knowledge of the allocated interventions after assignment</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="GROUP" MODIFIED="2014-05-09 08:33:03 +0100" MODIFIED_BY="Anne Lawson" NO="7">
<NAME>Blinding of participants and personnel (performance bias)</NAME>
<DESCRIPTION>
<P>Performance bias due to knowledge of the allocated interventions by participants and personnel during the study</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-07.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-17 16:44:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Andrade-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-17 17:06:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Andrade-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-17 17:39:23 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Apt-1998_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-17 18:04:22 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Britto-2001_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-17 18:09:34 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Catalioti-2001_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-17 18:15:04 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Coura-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-23 18:14:08 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Fabbro-2000_x002a__x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-17 21:02:03 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gallerano-2000_x002a__x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-17 21:05:28 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Galv_x00e3_o-_x0028_Andrade-substudy_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-23 15:17:14 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gianella-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2014-05-09 08:33:03 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Lauria_x002d_Pires-2000_x002a__x002a_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-17 22:41:19 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prado-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-17 22:45:39 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Rassi-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-17 22:59:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Silveira-2000_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-17 23:01:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sosa_x002d_Estani-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-07.01" MODIFIED="2012-07-23 14:44:51 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Viotti-2006_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-08" LEVEL="GROUP" MODIFIED="2014-05-09 08:34:06 +0100" MODIFIED_BY="Anne Lawson" NO="8">
<NAME>Blinding of outcome assessment (detection bias)</NAME>
<DESCRIPTION>
<P>Detection bias due to knowledge of the allocated interventions by outcome assessors</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-08.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-09 08:23:05 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Andrade-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-17 17:07:44 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Andrade-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-17 17:39:22 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Apt-1998_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-09 08:32:17 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Britto-2001_x002a_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-09 08:28:14 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Catalioti-2001_x002a_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-09 08:32:30 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Coura-1997">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-09 08:28:13 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Fabbro-2000_x002a__x002a_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-09 08:28:12 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Gallerano-2000_x002a__x002a_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-23 18:01:00 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Galv_x00e3_o-_x0028_Andrade-substudy_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-23 15:18:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gianella-1994">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-17 22:36:58 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lauria_x002d_Pires-2000_x002a__x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-17 22:42:31 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prado-2008">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-09 08:33:27 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Rassi-2007">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-09 08:33:36 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Silveira-2000_x002a_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2014-05-09 08:34:06 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Sosa_x002d_Estani-1998">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-08.01" MODIFIED="2012-07-17 23:22:30 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Viotti-2006_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2014-05-09 08:33:38 +0100" MODIFIED_BY="Anne Lawson" NO="4">
<NAME>Incomplete outcome data (attrition bias)</NAME>
<DESCRIPTION>
<P>Attrition bias due to amount, nature or handling of incomplete outcome data</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-17 21:16:37 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Andrade-1996">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-17 17:07:47 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Andrade-2004">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-23 17:40:53 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Apt-1998_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-09 08:32:19 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Britto-2001_x002a_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-09 08:28:15 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Catalioti-2001_x002a_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-17 18:25:39 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Coura-1997">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-09 08:28:12 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Fabbro-2000_x002a__x002a_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-23 17:20:25 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gallerano-2000_x002a__x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-23 18:02:00 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Galv_x00e3_o-_x0028_Andrade-substudy_x0029_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-17 21:20:54 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gianella-1994">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-17 22:37:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lauria_x002d_Pires-2000_x002a__x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-17 22:44:40 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Prado-2008">
<DESCRIPTION>
<P>For side effects outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-17 22:50:38 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Rassi-2007">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2014-05-09 08:33:38 +0100" MODIFIED_BY="Anne Lawson" RESULT="UNKNOWN" STUDY_ID="STD-Silveira-2000_x002a_">
<DESCRIPTION>
<P>Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-17 23:03:48 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Sosa_x002d_Estani-1998">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.01" MODIFIED="2012-07-17 23:22:46 +0100" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Viotti-2006_x002a_">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Selective reporting (reporting bias)</NAME>
<DESCRIPTION>
<P>Reporting bias due to selective outcome reporting</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Other bias</NAME>
<DESCRIPTION>
<P>Bias due to problems not covered elsewhere in the table</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2014-05-09 11:40:46 +0100" MODIFIED_BY="Anne Lawson">
<SOF_TABLE ID="SOF-01" MODIFIED="2014-05-09 11:40:46 +0100" MODIFIED_BY="Anne Lawson" NO="1" READONLY="YES">
<TITLE MODIFIED="2014-05-08 20:56:42 +0100" MODIFIED_BY="Anne Lawson">Nitroderivatives for chronic asymptomatic <I>Trypanosoma cruzi</I> infection</TITLE>
<TABLE COLS="7" ROWS="6">
<TR>
<TD COLSPAN="7">
<P>
<B>Nitroderivatives for chronic asymptomatic <I>Trypanosoma cruzi</I> infection</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>
<B>Patient or population:</B> people with chronic asymptomatic <I>Trypanosoma cruzi</I> infection<BR/>
<B>Intervention:</B> nitroderivatives<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Comments</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Nitroderivatives</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Positive serology: RCT data - nitroderivatives</B>
<BR/>Conventional serology, AT and F29 ELISA techniques</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 0.12 </B>
<BR/>(0.03 to 0.42)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>524<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>793 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>315 per 1000</B>
<BR/>(103 to 617)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>824 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>360 per 1000</B>
<BR/>(123 to 663)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Positive PCR: RCT data - </B>benznidazole<B> - Children</B>
<BR/>PCR</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 0.51 </B>
<BR/>(0.25 to 1.04)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>129<BR/>(1 study)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8861;<BR/>
<B>moderate</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>523 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>359 per 1000</B>
<BR/>(215 to 533)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>523 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>359 per 1000</B>
<BR/>(215 to 533)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Positive xenodiagnosis: all populations - RCT data - nitroderivatives</B>
<BR/>Xenodiagnosis</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 0.09 </B>
<BR/>(0.04 to 0.18)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>366<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8853;&#8853;<BR/>
<B>high</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>-</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>381 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>53 per 1000</B>
<BR/>(24 to 100)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>387 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>54 per 1000</B>
<BR/>(25 to 102)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>
<B>Mean reduction of antibodies titres: all populations, all tested drugs</B>
<BR/>Mean change of antibodies</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>The mean reduction of antibodies titres: all populations, all tested drugs in the intervention groups was<BR/>
<B>0.56 standard deviations lower</B>
<BR/>(0.89 to 0.23 lower)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>-</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>225<BR/>(3 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="1" VALIGN="TOP">
<P>SMD -0.56 (-0.89 to -0.23)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>AT:</B> antitrypsin; <B>CI:</B> confidence interval; <B>ELISA:</B> enzyme-linked immunosorbent assay; <B>OR:</B> odds ratio; <B>PCR:</B> polymerase chain reaction; <B>RCT:</B> randomised controlled trial; <B>SMD:</B> standardised mean difference.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="7">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
<SOF_TABLE ID="SOF-02" MODIFIED="2014-05-08 21:08:50 +0100" MODIFIED_BY="Anne Lawson" NO="2" READONLY="YES">
<TITLE MODIFIED="2014-05-08 21:05:29 +0100" MODIFIED_BY="Anne Lawson">Nitroderivatives for chronic asymptomatic <I>Trypanosoma cruzi</I> infection</TITLE>
<TABLE COLS="6" ROWS="19">
<TR>
<TD COLSPAN="6">
<P>
<B>Nitroderivatives for chronic asymptomatic <I>Trypanosoma cruzi</I> infection</B>
</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>
<B>Patient or population:</B> people with chronic asymptomatic <I>Trypanosoma cruzi</I> infection<BR/>
<B>Intervention:</B> nitroderivatives<BR/>
</P>
</TD>
</TR>
<TR>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Outcomes</P>
</TH>
<TH ALIGN="LEFT" COLSPAN="2" VALIGN="TOP">
<P>Illustrative comparative risks* (95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Relative effect<BR/>(95% CI)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>No of participants<BR/>(studies)</P>
</TH>
<TH ALIGN="LEFT" ROWSPAN="3" VALIGN="TOP">
<P>Quality of the evidence<BR/>(GRADE)</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Assumed risk</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>Corresponding risk</P>
</TH>
</TR>
<TR>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Control</B>
</P>
</TH>
<TH ALIGN="LEFT" VALIGN="TOP">
<P>
<B>Nitroderivatives</B>
</P>
</TH>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>ECG Abnormalities - RCT data - </B>benznidazole</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 0.41 </B>
<BR/>(0.07 to 2.31)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>235<BR/>(2 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8853;&#8861;&#8861;<BR/>
<B>low</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>43 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>18 per 1000</B>
<BR/>(3 to 94)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>41 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>17 per 1000</B>
<BR/>(3 to 90)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Progression of cardiomyopathy: non-RCT data - adults - nitroderivatives</B>
<BR/>Emergence of substantial changes in the diagnostic tests or clinical status, or both (see text)</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 0.74 </B>
<BR/>(0.32 to 1.73)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>986<BR/>(4 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>118 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>90 per 1000</B>
<BR/>(41 to 187)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>116 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>89 per 1000</B>
<BR/>(40 to 185)</P>
</TD>
</TR>
<TR>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>Mortality: non-RCT data - adults - nitroderivatives</B>
<BR/>All-cause mortality</P>
</TD>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Study population</B>
</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>
<B>OR 0.55 </B>
<BR/>(0.26 to 1.14)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>3396<BR/>(6 studies)</P>
</TD>
<TD ALIGN="LEFT" ROWSPAN="4" VALIGN="TOP">
<P>&#8853;&#8861;&#8861;&#8861;<BR/>
<B>very low</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>44 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>25 per 1000</B>
<BR/>(12 to 50)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="2" ROWSPAN="1">
<P>
<B>Moderate</B>
</P>
</TD>
</TR>
<TR>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>55 per 1000</B>
</P>
</TD>
<TD ROWSPAN="1" VALIGN="TOP">
<P>
<B>31 per 1000</B>
<BR/>(15 to 62)</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>*The basis for the <B>assumed risk</B> (e.g. the median control group risk across studies) is provided in footnotes. The <B>corresponding risk</B> (and its 95% confidence interval) is based on the assumed risk in the comparison group and the <B>relative effect</B> of the intervention (and its 95% CI).<BR/>
<B>CI:</B> confidence interval; <B>ECG:</B> electrocardiogram; <B>OR:</B> odds ratio; <B>RCT:</B> randomised controlled trial.</P>
</TD>
</TR>
<TR>
<TD COLSPAN="6">
<P>GRADE Working Group grades of evidence<BR/>
<B>High quality:</B> Further research is very unlikely to change our confidence in the estimate of effect.<BR/>
<B>Moderate quality:</B> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<BR/>
<B>Low quality:</B> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<BR/>
<B>Very low quality:</B> We are very uncertain about the estimate.<BR/>
</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</SOF_TABLE>
</SOF_TABLES>
<ADDITIONAL_TABLES MODIFIED="2012-02-28 16:08:04 +0000" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2014-05-16 08:57:58 +0100" MODIFIED_BY="Anne Lawson">
<COMPARISON ID="CMP-001" MODIFIED="2014-05-09 08:54:01 +0100" MODIFIED_BY="Anne Lawson" NO="1">
<NAME>Parasite-related outcomes</NAME>
<DICH_OUTCOME CHI2="38.341058066896046" CI_END="0.43659351925353024" CI_START="0.10103266286937573" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="0.21002429821736396" ESTIMABLE="YES" EVENTS_1="909" EVENTS_2="1830" I2="73.9182993266582" I2_Q="36.79552304038987" ID="CMP-001.01" LOG_CI_END="-0.3599227151988443" LOG_CI_START="-0.9955382003688324" LOG_EFFECT_SIZE="-0.6777304577838383" METHOD="MH" MODIFIED="2014-05-09 08:51:24 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="3.309801295570125E-5" P_Q="0.19132916370678754" P_Z="2.9194937788107903E-5" Q="4.746499210676333" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.8502572451916066" TOTALS="YES" TOTAL_1="1305" TOTAL_2="2109" WEIGHT="100.0" Z="4.179656787710012">
<NAME>Positive serology</NAME>
<GROUP_LABEL_1>Active TT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="15.172689080214099" CI_END="0.4224208111135758" CI_START="0.03190478661243754" DF="3" EFFECT_SIZE="0.11609154077378515" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="192" I2="80.22763147560876" ID="CMP-001.01.01" LOG_CI_END="-0.37425469386168164" LOG_CI_START="-1.4961441557070276" LOG_EFFECT_SIZE="-0.9351994247843546" MODIFIED="2012-09-07 16:50:53 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0016748706142718506" P_Z="0.0010845384949902082" STUDIES="3" TAU2="1.2714792073821648" TOTAL_1="282" TOTAL_2="242" WEIGHT="43.660871346838455" Z="3.2676252933599375">
<NAME>RCT data - nitroderivatives</NAME>
<DICH_DATA CI_END="0.2491299216846059" CI_START="0.03570969786744307" EFFECT_SIZE="0.09432048681541583" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="34" LOG_CI_END="-0.6035741085047923" LOG_CI_START="-1.4472138242697599" LOG_EFFECT_SIZE="-1.025393966387276" MODIFIED="2012-03-12 17:00:24 +0000" MODIFIED_BY="Micah R Pepper" ORDER="1" O_E="0.0" SE="0.495558145124286" STUDY_ID="STD-Andrade-2004" TOTAL_1="64" TOTAL_2="65" VAR="0.24557787519902288" WEIGHT="12.720931889643184"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="53" EVENTS_2="24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-09-07 16:50:13 +0100" MODIFIED_BY="[Empty name]" ORDER="72" O_E="0.0" SE="0.0" STUDY_ID="STD-Coura-1997" TOTAL_1="53" TOTAL_2="24" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="0.3370196170760782" CI_START="0.057636952306504265" EFFECT_SIZE="0.13937282229965156" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="41" LOG_CI_END="-0.4723448191882015" LOG_CI_START="-1.2392989916238586" LOG_EFFECT_SIZE="-0.85582190540603" MODIFIED="2012-09-07 16:50:53 +0100" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.4505126773730875" STUDY_ID="STD-Sosa_x002d_Estani-1998" TOTAL_1="55" TOTAL_2="51" VAR="0.2029616724738676" WEIGHT="13.235656609422778"/>
<DICH_DATA CI_END="0.06968273183553894" CI_START="2.3603373536307314E-4" EFFECT_SIZE="0.004055548728032444" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="51" LOG_CI_END="-1.1568748316249118" LOG_CI_START="-3.6270259206105404" LOG_EFFECT_SIZE="-2.3919503761177263" MODIFIED="2012-09-07 16:50:52 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Conventional serology&lt;/p&gt;" NOTES_MODIFIED="2012-09-07 16:50:52 +0100" NOTES_MODIFIED_BY="[Empty name]" ORDER="74" O_E="0.0" SE="1.4509789771152504" STUDY_ID="STD-Sosa_x002d_Estani-1998" TOTAL_1="55" TOTAL_2="51" VAR="2.1053399920304185" WEIGHT="4.716489700697659"/>
<DICH_DATA CI_END="1.318120940068753" CI_START="0.20697620867070643" EFFECT_SIZE="0.5223214285714286" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="42" LOG_CI_END="0.11995525941949114" LOG_CI_START="-0.6840795725954935" LOG_EFFECT_SIZE="-0.28206215658800116" MODIFIED="2012-03-12 17:00:23 +0000" MODIFIED_BY="Micah R Pepper" NOTES="&lt;p&gt;AT ELISA&lt;/p&gt;" NOTES_MODIFIED="2012-03-12 17:00:23 +0000" NOTES_MODIFIED_BY="Micah R Pepper" ORDER="94" O_E="0.0" SE="0.4722940403622097" STUDY_ID="STD-Sosa_x002d_Estani-1998" TOTAL_1="55" TOTAL_2="51" VAR="0.22306166056166055" WEIGHT="12.987793147074832">
<FOOTNOTE>The first row of data for Sosa-Estani refers to conventional serology. The second set refers to the AT ELISA technique (the same reported in Andrade's study). The third one refers to F29 ELISA technique.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="7.53564394607163" CI_END="0.729272233741593" CI_START="0.15879873210639464" DF="4" EFFECT_SIZE="0.34030501917921113" ESTIMABLE="YES" EVENTS_1="447" EVENTS_2="959" I2="46.918935811912654" ID="CMP-001.01.02" LOG_CI_END="-0.13711032141899554" LOG_CI_START="-0.7991529694240024" LOG_EFFECT_SIZE="-0.4681316454214989" MODIFIED="2014-05-09 08:51:13 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.11014788274081444" P_Z="0.005574921188949792" STUDIES="5" TAU2="0.3095088461820064" TOTAL_1="691" TOTAL_2="1187" WEIGHT="47.233159201632844" Z="2.7717886991554477">
<NAME>Non-RCT data - adults - nitroderivatives - conventional serology</NAME>
<DICH_DATA CI_END="0.656898273305487" CI_START="0.08993173751112413" EFFECT_SIZE="0.24305555555555555" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="32" LOG_CI_END="-0.18250187969851436" LOG_CI_START="-1.0460870157914337" LOG_EFFECT_SIZE="-0.614294447744974" MODIFIED="2011-01-11 16:33:29 +0000" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="0.5072741837563478" STUDY_ID="STD-Fabbro-2000_x002a__x002a_" TOTAL_1="68" TOTAL_2="130" VAR="0.25732709750566896" WEIGHT="12.585988616289265"/>
<DICH_DATA CI_END="0.546913052852288" CI_START="0.0016589793455719423" EFFECT_SIZE="0.030121710749983002" ESTIMABLE="YES" EVENTS_1="221" EVENTS_2="668" LOG_CI_END="-0.2620817114506045" LOG_CI_START="-2.780159020943675" LOG_EFFECT_SIZE="-1.5211203661971398" MODIFIED="2011-01-11 21:02:50 +0000" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="1.4791310762799394" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="226" TOTAL_2="668" VAR="2.1878287408170523" WEIGHT="4.588429686640347"/>
<DICH_DATA CI_END="16.124011537895342" CI_START="0.0592935188906992" EFFECT_SIZE="0.9777777777777777" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="45" LOG_CI_END="1.2074731002502077" LOG_CI_START="-1.2269927748285203" LOG_EFFECT_SIZE="-0.009759837289156262" MODIFIED="2012-02-12 00:34:48 +0000" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="1.4300173058216794" STUDY_ID="STD-Lauria_x002d_Pires-2000_x002a__x002a_" TOTAL_1="45" TOTAL_2="46" VAR="2.0449494949494946" WEIGHT="4.814869948834382">
<FOOTNOTE>This study includes 17 participants treated with BZD and 28 treated with NFTMX</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.1068167246920646" CI_START="0.04819380052483046" EFFECT_SIZE="0.23095823095823095" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="37" LOG_CI_END="0.04407571297939263" LOG_CI_START="-1.3170088242304354" LOG_EFFECT_SIZE="-0.6364665556255213" MODIFIED="2012-02-11 22:35:35 +0000" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.7995077946341729" STUDY_ID="STD-Silveira-2000_x002a_" TOTAL_1="58" TOTAL_2="39" VAR="0.6392127136807988" WEIGHT="9.359063501570295"/>
<DICH_DATA CI_END="0.7863331185488072" CI_START="0.41138963950900875" EFFECT_SIZE="0.5687611960865372" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="177" LOG_CI_END="-0.10439343246028222" LOG_CI_START="-0.38574664983313944" LOG_EFFECT_SIZE="-0.24507004114671083" MODIFIED="2011-01-11 17:29:56 +0000" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.16526827260570384" STUDY_ID="STD-Viotti-2006_x002a_" TOTAL_1="294" TOTAL_2="304" VAR="0.02731360193007324" WEIGHT="15.884807448298561"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="35.089090288793955" CI_START="0.11399554582574745" DF="0" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="11" I2="0.0" ID="CMP-001.01.03" LOG_CI_END="1.5451721089484278" LOG_CI_START="-0.9431121176204652" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-02-07 19:24:11 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.6353368007564364" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="4.667496974543702" Z="0.4742287424143797">
<NAME>RCT data - allopurinol</NAME>
<DICH_DATA CI_END="35.089090288793955" CI_START="0.11399554582574745" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="11" LOG_CI_END="1.5451721089484278" LOG_CI_START="-0.9431121176204652" LOG_EFFECT_SIZE="0.3010299956639812" MODIFIED="2013-02-07 19:24:11 +0000" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="1.4616304718921387" STUDY_ID="STD-Rassi-2007" TOTAL_1="23" TOTAL_2="12" VAR="2.1363636363636362" WEIGHT="4.667496974543702">
<FOOTNOTE>One case was deleted per each treatment arm in orther to generate an OR for this study.</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.2719371956991328" CI_START="0.003372845025044162" DF="0" EFFECT_SIZE="0.06549845068917619" ESTIMABLE="YES" EVENTS_1="306" EVENTS_2="668" I2="0.0" ID="CMP-001.01.04" LOG_CI_END="0.10446566773166667" LOG_CI_START="-2.472003613247319" LOG_EFFECT_SIZE="-1.1837689727578262" MODIFIED="2014-05-09 08:51:24 +0100" MODIFIED_BY="Anne Lawson" NO="4" P_CHI2="1.0" P_Z="0.07169872441030316" STUDIES="1" TAU2="0.0" TOTAL_1="309" TOTAL_2="668" WEIGHT="4.438472476984998" Z="1.801026365615915">
<NAME>Non-RCT data - adults - allopurinol - conventional serology</NAME>
<DICH_DATA CI_END="1.2719371956991328" CI_START="0.003372845025044162" EFFECT_SIZE="0.06549845068917619" ESTIMABLE="YES" EVENTS_1="306" EVENTS_2="668" LOG_CI_END="0.10446566773166667" LOG_CI_START="-2.472003613247319" LOG_EFFECT_SIZE="-1.1837689727578262" MODIFIED="2011-01-11 21:03:29 +0000" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="1.5134308093756865" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="309" TOTAL_2="668" VAR="2.2904728147675457" WEIGHT="4.438472476984998"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.008347867128281592" CI_END="0.9206355869323501" CI_START="0.27469935266780615" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.5028896496978859" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="42" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.03591224157583217" LOG_CI_START="-0.5611423639981894" LOG_EFFECT_SIZE="-0.2985273027870108" METHOD="MH" MODIFIED="2014-05-09 08:51:56 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.9272012503098503" P_Q="0.9272047921009581" P_Z="0.02588142775136455" Q="0.008347052606519951" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="112" TOTAL_2="80" WEIGHT="100.0" Z="2.2279863126125954">
<NAME>Positive PCR: nitroderivatives</NAME>
<GROUP_LABEL_1>Nitroderivatives</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.0355865467866054" CI_START="0.2526196402077476" DF="0" EFFECT_SIZE="0.5114777618364419" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="34" I2="0.0" ID="CMP-001.02.01" LOG_CI_END="0.015186399918211328" LOG_CI_START="-0.5975328877384614" LOG_EFFECT_SIZE="-0.29117324391012506" MODIFIED="2014-05-09 08:51:46 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="1.0" P_Z="0.06248934109844445" STUDIES="1" TAU2="0.0" TOTAL_1="64" TOTAL_2="65" WEIGHT="73.48118432920091" Z="1.86280759500203">
<NAME>RCT data - children</NAME>
<DICH_DATA CI_END="1.0355865467866054" CI_START="0.2526196402077476" EFFECT_SIZE="0.5114777618364419" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="34" LOG_CI_END="0.015186399918211328" LOG_CI_START="-0.5975328877384614" LOG_EFFECT_SIZE="-0.29117324391012506" MODIFIED="2010-11-02 18:41:06 +0000" MODIFIED_BY="Micah R Pepper" ORDER="96" O_E="0.0" SE="0.35991434257891924" STUDY_ID="STD-Galv_x00e3_o-_x0028_Andrade-substudy_x0029_" TOTAL_1="64" TOTAL_2="65" VAR="0.12953833399401563" WEIGHT="73.48118432920091"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.5526117199885237" CI_START="0.14829540724231594" DF="0" EFFECT_SIZE="0.4798387096774194" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" I2="0.0" ID="CMP-001.02.02" LOG_CI_END="0.19106286013934767" LOG_CI_START="-0.8288722990067188" LOG_EFFECT_SIZE="-0.3189047194336855" MODIFIED="2014-05-09 08:51:56 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Z="0.2203304360146704" STUDIES="1" TAU2="0.0" TOTAL_1="48" TOTAL_2="15" WEIGHT="26.51881567079908" Z="1.2256500013455487">
<NAME>Non-RCT data - adults</NAME>
<DICH_DATA CI_END="1.5526117199885237" CI_START="0.14829540724231594" EFFECT_SIZE="0.4798387096774194" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="8" LOG_CI_END="0.19106286013934767" LOG_CI_START="-0.8288722990067188" LOG_EFFECT_SIZE="-0.3189047194336855" MODIFIED="2012-02-15 14:22:28 +0000" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="0.5991149612428625" STUDY_ID="STD-Britto-2001_x002a_" TOTAL_1="48" TOTAL_2="15" VAR="0.35893873678503657" WEIGHT="26.51881567079908"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.53455606682149" CI_END="0.8641676271394454" CI_START="0.13892955404432095" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.3464944776731978" ESTIMABLE="YES" EVENTS_1="71" EVENTS_2="114" I2="78.97286368868205" I2_Q="88.42090544505294" ID="CMP-001.03" LOG_CI_END="-0.06340200696489513" LOG_CI_START="-0.8572053583438936" LOG_EFFECT_SIZE="-0.4603036826543943" METHOD="MH" MODIFIED="2014-05-09 08:52:28 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="7.449953995919412E-5" P_Q="1.775516239899133E-4" P_Z="0.023022971781994913" Q="17.272507712146794" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.1367736131561001" TOTALS="YES" TOTAL_1="576" TOTAL_2="497" WEIGHT="100.00000000000001" Z="2.2730532401670995">
<NAME>Positive xenodiagnosis: all populations, all tested drugs</NAME>
<GROUP_LABEL_1>TT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.7556937602565867" CI_END="0.18126897352140653" CI_START="0.04330035683515766" DF="1" EFFECT_SIZE="0.08859464564306158" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="45" I2="0.0" ID="CMP-001.03.01" LOG_CI_END="-0.7416765245396642" LOG_CI_START="-1.363508524641984" LOG_EFFECT_SIZE="-1.052592524590824" MODIFIED="2012-03-09 16:44:54 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.38467955274010057" P_Z="3.236843233950325E-11" STUDIES="2" TAU2="0.0" TOTAL_1="248" TOTAL_2="118" WEIGHT="29.144026333719495" Z="6.635372377924074">
<NAME>RCT data - nitroderivatives</NAME>
<DICH_DATA CI_END="0.23547931826274476" CI_START="0.04640820080897921" EFFECT_SIZE="0.10453789498693276" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="23" LOG_CI_END="-0.6280472301859967" LOG_CI_START="-1.3334052683376731" LOG_EFFECT_SIZE="-0.9807262492618349" MODIFIED="2012-03-09 16:44:54 +0000" MODIFIED_BY="Micah R Pepper" ORDER="102" O_E="0.0" SE="0.4143308031888951" STUDY_ID="STD-Coura-1997" TOTAL_1="193" TOTAL_2="67" VAR="0.1716700144711549" WEIGHT="16.6167483903879">
<FOOTNOTE>Based on the reporting of the numbers of tests, rather than participants.</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.22667860495543216" CI_START="0.010915618660065698" EFFECT_SIZE="0.04974271012006861" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="22" LOG_CI_END="-0.6445894687940061" LOG_CI_START="-1.9619516449261099" LOG_EFFECT_SIZE="-1.303270556860058" MODIFIED="2012-02-11 18:43:13 +0000" MODIFIED_BY="Micah R Pepper" ORDER="104" O_E="0.0" SE="0.7738250633079398" STUDY_ID="STD-Sosa_x002d_Estani-1998" TOTAL_1="55" TOTAL_2="51" VAR="0.5988052286035369" WEIGHT="12.527277943331594"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0010469846105007955" CI_END="1.7415703423411233" CI_START="0.19310252569258748" DF="1" EFFECT_SIZE="0.579915193607975" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="27" I2="0.0" ID="CMP-001.03.02" LOG_CI_END="0.2409410203811859" LOG_CI_START="-0.7142120458105573" LOG_EFFECT_SIZE="-0.2366355127146857" MODIFIED="2012-03-01 23:00:11 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9741872425354297" P_Z="0.3314750265548534" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="34" WEIGHT="24.292372556092353" Z="0.9711471360986003">
<NAME>RCT data - allopurinol</NAME>
<DICH_DATA CI_END="2.3808335506668317" CI_START="0.1453359732555685" EFFECT_SIZE="0.5882352941176471" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="17" LOG_CI_END="0.376729033979529" LOG_CI_START="-0.8376268767360767" LOG_EFFECT_SIZE="-0.2304489213782739" MODIFIED="2012-03-01 23:00:11 +0000" MODIFIED_BY="[Empty name]" ORDER="92" O_E="0.0" SE="0.7133186731130516" STUDY_ID="STD-Gianella-1994" TOTAL_1="18" TOTAL_2="22" VAR="0.5088235294117647" WEIGHT="13.212272907426884"/>
<DICH_DATA CI_END="3.362788242858336" CI_START="0.09548954258213116" EFFECT_SIZE="0.5666666666666667" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" LOG_CI_END="0.5266995203465664" LOG_CI_START="-1.0200441870293435" LOG_EFFECT_SIZE="-0.24667233334138852" MODIFIED="2012-02-15 14:03:33 +0000" MODIFIED_BY="[Empty name]" ORDER="93" O_E="0.0" SE="0.9085649102174436" STUDY_ID="STD-Rassi-2007" TOTAL_1="23" TOTAL_2="12" VAR="0.8254901960784313" WEIGHT="11.080099648665469"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="3.9473918894408664" CI_END="1.5663499315220417" CI_START="0.3308936474488159" DF="2" EFFECT_SIZE="0.7199272477289156" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="42" I2="49.33363456134342" ID="CMP-001.03.03" LOG_CI_END="0.1948887924294262" LOG_CI_START="-0.4803115704176864" LOG_EFFECT_SIZE="-0.1427113889941301" MODIFIED="2014-05-09 08:52:28 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="0.13894256153463214" P_Z="0.4073749404227376" STUDIES="2" TAU2="0.2316576196508325" TOTAL_1="287" TOTAL_2="345" WEIGHT="46.563601110188166" Z="0.828522015102993">
<NAME>Non-RCT data</NAME>
<DICH_DATA CI_END="2.677939509807692" CI_START="0.6263257277328633" EFFECT_SIZE="1.2950916617386161" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="19" LOG_CI_END="0.42780076279793544" LOG_CI_START="-0.20319974831318238" LOG_EFFECT_SIZE="0.11230050724237656" MODIFIED="2012-03-09 16:42:30 +0000" MODIFIED_BY="[Empty name]" ORDER="94" O_E="0.0" SE="0.37065282372957586" STUDY_ID="STD-Apt-1998_x002a_" TOTAL_1="104" TOTAL_2="165" VAR="0.13738351573870802" WEIGHT="17.06389114044935">
<FOOTNOTE>Participants treated with Allopurinol</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="1.0320403079271563" CI_START="0.1711110241696275" EFFECT_SIZE="0.42023026315789475" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="0.013696659663754681" LOG_CI_START="-0.7667220092677615" LOG_EFFECT_SIZE="-0.3765126748020034" MODIFIED="2012-03-09 16:42:49 +0000" MODIFIED_BY="[Empty name]" ORDER="91" O_E="0.0" SE="0.45842178926508764" STUDY_ID="STD-Apt-1998_x002a_" TOTAL_1="135" TOTAL_2="165" VAR="0.21015053687300442" WEIGHT="16.1420214663303">
<FOOTNOTE>Participants treated with Itraconazole</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="2.171482040802469" CI_START="0.13930578025329257" EFFECT_SIZE="0.55" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="4" LOG_CI_END="0.33675624188952574" LOG_CI_START="-0.856030862901038" LOG_EFFECT_SIZE="-0.2596373105057561" MODIFIED="2012-02-16 17:52:37 +0000" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="0.7006490497453707" STUDY_ID="STD-Britto-2001_x002a_" TOTAL_1="48" TOTAL_2="15" VAR="0.49090909090909096" WEIGHT="13.35768850340852">
<FOOTNOTE>Participants treated with BZD (n=34) and NFTMX (25)</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.7589050909899497" CI_END="-0.23338826159798065" CI_START="-0.8918099776339065" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="SMD" EFFECT_SIZE="-0.5625991196159436" ESTIMABLE="YES" I2="27.507473652079838" I2_Q="63.700307972573654" ID="CMP-001.04" MODIFIED="2014-05-09 08:54:01 +0100" MODIFIED_BY="Anne Lawson" NO="4" P_CHI2="0.2517165634975088" P_Q="0.09696033705363938" P_Z="8.097331949333414E-4" Q="2.7548443089942656" RANDOM="YES" SCALE="5.0" SORT_BY="EFFECT_SIZE" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" TAU2="0.024035509354409172" TOTALS="YES" TOTAL_1="115" TOTAL_2="110" UNITS="" WEIGHT="100.0" Z="3.349446062684316">
<NAME>Mean reduction of antibodies titres: all populations, all tested drugs</NAME>
<GROUP_LABEL_1>TT</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_SUBGROUP CHI2="0.004060781995683891" CI_END="-0.38587418820330016" CI_START="-0.956445414488019" DF="1" EFFECT_SIZE="-0.6711598013456596" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.01" MODIFIED="2014-05-09 08:53:49 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="0.9491897830803231" P_Z="4.0075629693675405E-6" STUDIES="2" TAU2="0.0" TOTAL_1="102" TOTAL_2="98" WEIGHT="84.69357636056495" Z="4.6109897517058895">
<NAME>Benznidazole children</NAME>
<CONT_DATA CI_END="-0.2978545925943291" CI_START="-1.060939400381773" EFFECT_SIZE="-0.6793969964880511" ESTIMABLE="YES" MEAN_1="-1409.0" MEAN_2="-566.0" MODIFIED="2010-11-04 16:11:31 +0000" MODIFIED_BY="Micah R Pepper" ORDER="108" SD_1="1052.12" SD_2="1400.49" SE="0.1946680688539584" STUDY_ID="STD-Andrade-1996" TOTAL_1="58" TOTAL_2="54" WEIGHT="45.555714219510826"/>
<CONT_DATA CI_END="-0.23107973562159234" CI_START="-1.0903505676209782" EFFECT_SIZE="-0.6607151516212852" ESTIMABLE="YES" MEAN_1="-1.4" MEAN_2="0.17" MODIFIED="2010-11-04 16:11:34 +0000" MODIFIED_BY="Micah R Pepper" ORDER="110" SD_1="2.31" SD_2="2.4" SE="0.21920577081446507" STUDY_ID="STD-Sosa_x002d_Estani-1998" TOTAL_1="44" TOTAL_2="44" WEIGHT="39.137862141054114"/>
</CONT_SUBGROUP>
<CONT_SUBGROUP CHI2="0.0" CI_END="0.8205872146285503" CI_START="-0.7487896499442476" DF="0" EFFECT_SIZE="0.035898782342151395" ESTIMABLE="YES" I2="0.0" ID="CMP-001.04.02" MODIFIED="2014-05-09 08:54:01 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Z="0.9285521819358369" STUDIES="1" TAU2="0.0" TOTAL_1="13" TOTAL_2="12" WEIGHT="15.30642363943505" Z="0.08966657030287249">
<NAME>Allopurinol adults</NAME>
<CONT_DATA CI_END="0.8205872146285503" CI_START="-0.7487896499442476" EFFECT_SIZE="0.035898782342151395" ESTIMABLE="YES" MEAN_1="-19.69" MEAN_2="-30.12" MODIFIED="2010-11-04 16:51:28 +0000" MODIFIED_BY="Micah R Pepper" ORDER="92" SD_1="317.52" SD_2="234.67" SE="0.4003585976456308" STUDY_ID="STD-Gianella-1994" TOTAL_1="13" TOTAL_2="12" WEIGHT="15.30642363943505"/>
</CONT_SUBGROUP>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2014-05-09 08:55:12 +0100" MODIFIED_BY="Anne Lawson" NO="2">
<NAME>Patient-related outcomes: efficacy</NAME>
<DICH_OUTCOME CHI2="0.5462555435786283" CI_END="2.312611938292451" CI_START="0.07140274105616293" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="OR" EFFECT_SIZE="0.406358008895219" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="0.36410276325157187" LOG_CI_START="-1.1462851159168728" LOG_EFFECT_SIZE="-0.3910911763326505" METHOD="MH" MODIFIED="2014-05-09 08:54:32 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="0.45985181775093087" P_Q="1.0" P_Z="0.3101040920066699" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="119" TOTAL_2="116" WEIGHT="100.0" Z="1.015003670057806">
<NAME>ECG abnormalities - RCT data - benznidazole</NAME>
<GROUP_LABEL_1>Benznidazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.227440594313952" CI_START="0.026305857197515686" EFFECT_SIZE="0.24206349206349206" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.34780613025967444" LOG_CI_START="-1.5799475418012285" LOG_EFFECT_SIZE="-0.616070705770777" MODIFIED="2010-10-26 21:43:17 +0100" MODIFIED_BY="Micah R Pepper" ORDER="4" O_E="0.0" SE="1.132372049503151" STUDY_ID="STD-Andrade-2004" TOTAL_1="64" TOTAL_2="65" VAR="1.2822664584959667" WEIGHT="61.38664600775284"/>
<DICH_DATA CI_END="15.201753711222798" CI_START="0.0563973628693147" EFFECT_SIZE="0.9259259259259259" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1818936921009335" LOG_CI_START="-1.2487412030748328" LOG_EFFECT_SIZE="-0.0334237554869497" MODIFIED="2012-02-11 18:49:36 +0000" MODIFIED_BY="Micah R Pepper" ORDER="135" O_E="0.0" SE="1.4277669692630233" STUDY_ID="STD-Sosa_x002d_Estani-1998" TOTAL_1="55" TOTAL_2="51" VAR="2.0385185185185186" WEIGHT="38.613353992247156"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.822809364992972" CI_END="1.7336921415058022" CI_START="0.3179308351847778" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="0.7424245352237664" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="61" I2="65.99722519333399" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.23897198061685754" LOG_CI_START="-0.49766734908688565" LOG_EFFECT_SIZE="-0.1293476842350141" METHOD="MH" MODIFIED="2014-05-09 08:54:52 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.03174200371486979" P_Q="1.0" P_Z="0.49125982276284563" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4896791605261636" TOTALS="YES" TOTAL_1="467" TOTAL_2="519" WEIGHT="99.99999999999999" Z="0.688306454357371">
<NAME>Progression of cardiomyopathy: non-RCT data - adults, nitroderivatives</NAME>
<GROUP_LABEL_1>TT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.409325977376102" CI_START="0.21953260986740444" EFFECT_SIZE="0.7272727272727273" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="10" LOG_CI_END="0.38189556321882584" LOG_CI_START="-0.6585009595513888" LOG_EFFECT_SIZE="-0.13830269816628143" MODIFIED="2012-02-20 21:47:45 +0000" MODIFIED_BY="[Empty name]" ORDER="65" O_E="0.0" SE="0.6111340675210706" STUDY_ID="STD-Fabbro-2000_x002a__x002a_" TOTAL_1="70" TOTAL_2="130" VAR="0.3734848484848485" WEIGHT="21.69160490129316"/>
<DICH_DATA CI_END="2.8358572327966707" CI_START="0.5462197198232687" EFFECT_SIZE="1.2445887445887447" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="21" LOG_CI_END="0.45268436312269916" LOG_CI_START="-0.26263262485568917" LOG_EFFECT_SIZE="0.09502586913350503" MODIFIED="2012-02-20 21:52:45 +0000" MODIFIED_BY="[Empty name]" ORDER="63" O_E="0.0" SE="0.4201807396147023" STUDY_ID="STD-Lauria_x002d_Pires-2000_x002a__x002a_" TOTAL_1="45" TOTAL_2="46" VAR="0.17655185394315828" WEIGHT="28.103483989554324"/>
<DICH_DATA CI_END="4.213010422136614" CI_START="0.4886294900669836" EFFECT_SIZE="1.434782608695652" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.6245925334849828" LOG_CI_START="-0.31102032576439353" LOG_EFFECT_SIZE="0.15678610386029457" MODIFIED="2012-02-22 19:47:51 +0000" MODIFIED_BY="[Empty name]" ORDER="64" O_E="0.0" SE="0.5495836248814304" STUDY_ID="STD-Silveira-2000_x002a_" TOTAL_1="58" TOTAL_2="39" VAR="0.30204216073781287" WEIGHT="23.64899383862917">
<FOOTNOTE>This study includes participants treated with Nifurtimox (25 out of the 58 participants treated)</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="0.6035834782849716" CI_START="0.09787544757566743" EFFECT_SIZE="0.24305555555555555" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="24" LOG_CI_END="-0.21926265655030971" LOG_CI_START="-1.0093262389396385" LOG_EFFECT_SIZE="-0.614294447744974" MODIFIED="2012-09-07 17:58:40 +0100" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.46408725917329824" STUDY_ID="STD-Viotti-2006_x002a_" TOTAL_1="294" TOTAL_2="304" VAR="0.21537698412698408" WEIGHT="26.555917270523334"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.565891199183298" CI_END="1.1433578364570904" CI_START="0.26304313120409656" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="OR" EFFECT_SIZE="0.548408994627563" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="103" I2="48.12332316921952" I2_Q="40.61288971880471" ID="CMP-002.03" LOG_CI_END="0.058182172720257344" LOG_CI_START="-0.5799730343690314" LOG_EFFECT_SIZE="-0.26089543082438704" METHOD="MH" MODIFIED="2014-05-09 08:55:12 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="0.07238423280014894" P_Q="0.19441148054765" P_Z="0.10902861543597223" Q="1.6838670803564022" RANDOM="YES" SCALE="431.01" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.4618304064112211" TOTALS="YES" TOTAL_1="1076" TOTAL_2="2320" WEIGHT="100.00000000000003" Z="1.602574553858694">
<NAME>Mortality: non-RCT data - adults, all tested drugs</NAME>
<GROUP_LABEL_1>TT</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="9.893969309829007" CI_END="1.5590360171054867" CI_START="0.2753847925746361" DF="5" EFFECT_SIZE="0.6552364536463011" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="66" I2="49.4641650542333" ID="CMP-002.03.01" LOG_CI_END="0.19285614844700924" LOG_CI_START="-0.5600600462260614" LOG_EFFECT_SIZE="-0.18360194888952608" MODIFIED="2012-02-11 23:40:49 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.07829607603619448" P_Z="0.33912691537546236" STUDIES="6" TAU2="0.5767336004652475" TOTAL_1="767" TOTAL_2="1652" WEIGHT="79.74481086462794" Z="0.9558917974160177">
<NAME>Nitroderivatives</NAME>
<DICH_DATA CI_END="7.6218028298312674" CI_START="0.330361717215626" EFFECT_SIZE="1.5868055555555556" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="8" LOG_CI_END="0.8820577097177206" LOG_CI_START="-0.4810102850964818" LOG_EFFECT_SIZE="0.20052371231061938" MODIFIED="2010-11-02 21:56:42 +0000" MODIFIED_BY="Micah R Pepper" ORDER="130" O_E="0.0" SE="0.8006728874492558" STUDY_ID="STD-Catalioti-2001_x002a_" TOTAL_1="74" TOTAL_2="465" VAR="0.6410770726963286" WEIGHT="12.740567020054156"/>
<DICH_DATA CI_END="7.633040792795962" CI_START="0.2030998090200023" EFFECT_SIZE="1.2450980392156863" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.8826975833614016" LOG_CI_START="-0.692290484973323" LOG_EFFECT_SIZE="0.09520354919403931" MODIFIED="2012-02-11 23:40:49 +0000" MODIFIED_BY="[Empty name]" ORDER="134" O_E="0.0" SE="0.925155787656493" STUDY_ID="STD-Fabbro-2000_x002a__x002a_" TOTAL_1="70" TOTAL_2="130" VAR="0.8559132314343059" WEIGHT="10.663429707361583"/>
<DICH_DATA CI_END="0.6369266176593" CI_START="0.03640238396852312" EFFECT_SIZE="0.15226833976833976" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="37" LOG_CI_END="-0.1959106012305216" LOG_CI_START="-1.4388701737555631" LOG_EFFECT_SIZE="-0.8173903874930424" MODIFIED="2011-01-11 21:06:54 +0000" MODIFIED_BY="[Empty name]" ORDER="129" O_E="0.0" SE="0.7301206056503237" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="226" TOTAL_2="668" VAR="0.5330760987951955" WEIGHT="14.123605163857453"/>
<DICH_DATA CI_END="6.633894601176644" CI_START="0.2947664857463349" EFFECT_SIZE="1.3983739837398375" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.8217685671998928" LOG_CI_START="-0.5305218962635907" LOG_EFFECT_SIZE="0.145623335468151" MODIFIED="2010-11-02 19:24:54 +0000" MODIFIED_BY="Micah R Pepper" ORDER="133" O_E="0.0" SE="0.7943421121842028" STUDY_ID="STD-Lauria_x002d_Pires-2000_x002a__x002a_" TOTAL_1="45" TOTAL_2="46" VAR="0.6309793911892607" WEIGHT="12.858291246420393"/>
<DICH_DATA CI_END="5.0363910904436775" CI_START="0.25446690906357006" EFFECT_SIZE="1.1320754716981132" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="3" LOG_CI_END="0.7021194469772927" LOG_CI_START="-0.5943686854115834" LOG_EFFECT_SIZE="0.05387538078285457" MODIFIED="2011-01-19 15:39:28 +0000" MODIFIED_BY="[Empty name]" ORDER="62" O_E="0.0" SE="0.7615635466849848" STUDY_ID="STD-Silveira-2000_x002a_" TOTAL_1="58" TOTAL_2="39" VAR="0.579979035639413" WEIGHT="13.48775129819353"/>
<DICH_DATA CI_END="0.8982214168168862" CI_START="0.07006100071811412" EFFECT_SIZE="0.2508591065292096" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="12" LOG_CI_END="-0.04661659401333332" LOG_CI_START="-1.1545236637175695" LOG_EFFECT_SIZE="-0.6005701288654514" MODIFIED="2011-01-11 18:01:00 +0000" MODIFIED_BY="[Empty name]" ORDER="127" O_E="0.0" SE="0.6507900969727118" STUDY_ID="STD-Viotti-2006_x002a_" TOTAL_1="294" TOTAL_2="304" VAR="0.4235277503177517" WEIGHT="15.87116642874081"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="0.720824897016797" CI_START="0.10914864112470052" DF="0" EFFECT_SIZE="0.28049431009957326" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="37" I2="0.0" ID="CMP-002.03.02" LOG_CI_END="-0.14217022140430358" LOG_CI_START="-0.9619816667868876" LOG_EFFECT_SIZE="-0.5520759440955956" MODIFIED="2011-01-11 21:07:14 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.00829670045677419" STUDIES="1" TAU2="0.0" TOTAL_1="309" TOTAL_2="668" WEIGHT="20.255189135372092" Z="2.6397508189297176">
<NAME>Allopurinol</NAME>
<DICH_DATA CI_END="0.720824897016797" CI_START="0.10914864112470052" EFFECT_SIZE="0.28049431009957326" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="37" LOG_CI_END="-0.14217022140430358" LOG_CI_START="-0.9619816667868876" LOG_EFFECT_SIZE="-0.5520759440955956" MODIFIED="2011-01-11 21:07:14 +0000" MODIFIED_BY="[Empty name]" ORDER="95" O_E="0.0" SE="0.48156130114983314" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="309" TOTAL_2="668" VAR="0.2319012867651203" WEIGHT="20.255189135372092"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2014-05-16 08:57:58 +0100" MODIFIED_BY="Anne Lawson" NO="3">
<NAME>Patient-related outcomes: safety</NAME>
<DICH_OUTCOME CHI2="51.96798669320529" CI_END="8.437712605094582" CI_START="1.743649412794058" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="OR" EFFECT_SIZE="3.83567629358868" ESTIMABLE="YES" EVENTS_1="392" EVENTS_2="144" I2="90.37869211767303" I2_Q="90.28974183253455" ID="CMP-003.01" LOG_CI_END="0.9262247288975858" LOG_CI_START="0.24145916787014834" LOG_EFFECT_SIZE="0.5838419483838672" METHOD="MH" MODIFIED="2014-05-09 08:56:02 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="5.477022169131374E-10" P_Q="6.857200363086235E-10" P_Z="8.311936798512504E-4" Q="51.49193681330398" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.7711257733955509" TOTALS="YES" TOTAL_1="1815" TOTAL_2="1836" WEIGHT="100.00000000000001" Z="3.342192588596675">
<NAME>BZD mild-to-moderate - RCT data only</NAME>
<GROUP_LABEL_1>Benznidazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="6.084034361808321" CI_START="2.4121131554444624" DF="0" EFFECT_SIZE="3.8308457711442787" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="27" I2="0.0" ID="CMP-003.01.01" LOG_CI_END="0.7841916582247478" LOG_CI_START="0.3823976772792383" LOG_EFFECT_SIZE="0.583294667751993" MODIFIED="2012-02-15 15:07:49 +0000" MODIFIED_BY="Micah R Pepper" NO="1" P_CHI2="1.0" P_Z="1.2654899751857957E-8" STUDIES="1" TAU2="0.0" TOTAL_1="352" TOTAL_2="357" WEIGHT="19.567854437081063" Z="5.69066036518455">
<NAME>Pruritus</NAME>
<DICH_DATA CI_END="6.084034361808321" CI_START="2.4121131554444624" EFFECT_SIZE="3.8308457711442787" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="27" LOG_CI_END="0.7841916582247478" LOG_CI_START="0.3823976772792383" LOG_EFFECT_SIZE="0.583294667751993" MODIFIED="2012-02-15 15:07:49 +0000" MODIFIED_BY="[Empty name]" ORDER="159" O_E="0.0" SE="0.23601577331967466" STUDY_ID="STD-Prado-2008" TOTAL_1="352" TOTAL_2="357" VAR="0.055703445255684055" WEIGHT="19.567854437081063"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="12.031172761975565" CI_START="4.786434162805146" DF="0" EFFECT_SIZE="7.588571428571427" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="25" I2="0.0" ID="CMP-003.01.02" LOG_CI_END="1.0803079631029446" LOG_CI_START="0.6800120895884638" LOG_EFFECT_SIZE="0.8801600263457041" MODIFIED="2014-05-09 08:55:53 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Z="6.752106931994315E-18" STUDIES="1" TAU2="0.0" TOTAL_1="352" TOTAL_2="357" WEIGHT="19.577671609292455" Z="8.619034401347633">
<NAME>Mild rash</NAME>
<DICH_DATA CI_END="12.031172761975565" CI_START="4.786434162805146" EFFECT_SIZE="7.588571428571429" ESTIMABLE="YES" EVENTS_1="128" EVENTS_2="25" LOG_CI_END="1.0803079631029446" LOG_CI_START="0.6800120895884638" LOG_EFFECT_SIZE="0.8801600263457042" MODIFIED="2010-11-04 19:12:59 +0000" MODIFIED_BY="Micah R Pepper" ORDER="161" O_E="0.0" SE="0.23513577759893708" STUDY_ID="STD-Prado-2008" TOTAL_1="352" TOTAL_2="357" VAR="0.0552888339070568" WEIGHT="19.577671609292455"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="14.609423466829204" CI_START="4.1476835005044785" DF="0" EFFECT_SIZE="7.784296028880867" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="12" I2="0.0" ID="CMP-003.01.03" LOG_CI_END="1.1646330776649516" LOG_CI_START="0.61780560904085" LOG_EFFECT_SIZE="0.8912193433529008" MODIFIED="2014-05-09 08:56:02 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="1.0" P_Z="1.6730394579474485E-10" STUDIES="1" TAU2="0.0" TOTAL_1="352" TOTAL_2="357" WEIGHT="18.50537968181763" Z="6.388698137978409">
<NAME>Moderate rash</NAME>
<DICH_DATA CI_END="14.609423466829204" CI_START="4.1476835005044785" EFFECT_SIZE="7.784296028880866" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="12" LOG_CI_END="1.1646330776649516" LOG_CI_START="0.61780560904085" LOG_EFFECT_SIZE="0.8912193433529008" MODIFIED="2010-11-04 19:13:27 +0000" MODIFIED_BY="Micah R Pepper" ORDER="162" O_E="0.0" SE="0.3212091619094223" STUDY_ID="STD-Prado-2008" TOTAL_1="352" TOTAL_2="357" VAR="0.10317532569455344" WEIGHT="18.50537968181763"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="246.49319901387864" CI_START="0.7421399722332711" DF="0" EFFECT_SIZE="13.525252525252535" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-003.01.04" LOG_CI_END="2.3918049411731257" LOG_CI_START="-0.12951417634420678" LOG_EFFECT_SIZE="1.1311453824144593" MODIFIED="2012-02-11 18:56:20 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.07864435248399726" STUDIES="1" TAU2="0.0" TOTAL_1="55" TOTAL_2="51" WEIGHT="5.45750543175433" Z="1.7586065924048087">
<NAME>Unspecified</NAME>
<DICH_DATA CI_END="246.4931990138784" CI_START="0.7421399722332708" EFFECT_SIZE="13.525252525252526" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="2.3918049411731253" LOG_CI_START="-0.12951417634420698" LOG_EFFECT_SIZE="1.131145382414459" MODIFIED="2012-02-11 18:56:20 +0000" MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="1.4810353303605992" STUDY_ID="STD-Sosa_x002d_Estani-1998" TOTAL_1="55" TOTAL_2="51" VAR="2.1934656497763294" WEIGHT="5.45750543175433"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1.7452144145042932" CI_START="0.8547272704568335" DF="0" EFFECT_SIZE="1.2213444857496902" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="72" I2="0.0" ID="CMP-003.01.05" LOG_CI_END="0.24184879136143686" LOG_CI_START="-0.06817243945962152" LOG_EFFECT_SIZE="0.08683817595090768" MODIFIED="2010-11-04 19:14:13 +0000" MODIFIED_BY="Micah R Pepper" NO="5" P_CHI2="1.0" P_Z="0.2722100232739343" STUDIES="1" TAU2="0.0" TOTAL_1="352" TOTAL_2="357" WEIGHT="20.11624155158984" Z="1.097987366195376">
<NAME>Headache</NAME>
<DICH_DATA CI_END="1.7452144145042932" CI_START="0.8547272704568335" EFFECT_SIZE="1.2213444857496902" ESTIMABLE="YES" EVENTS_1="83" EVENTS_2="72" LOG_CI_END="0.24184879136143686" LOG_CI_START="-0.06817243945962152" LOG_EFFECT_SIZE="0.08683817595090768" MODIFIED="2010-11-04 19:14:13 +0000" MODIFIED_BY="Micah R Pepper" ORDER="164" O_E="0.0" SE="0.18210800561413246" STUDY_ID="STD-Prado-2008" TOTAL_1="352" TOTAL_2="357" VAR="0.033163325708756894" WEIGHT="20.11624155158984"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.918070155860146" CI_START="0.8774806955880913" DF="0" EFFECT_SIZE="2.0773809523809526" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" I2="0.0" ID="CMP-003.01.06" LOG_CI_END="0.6917947196214091" LOG_CI_START="-0.05676242915477499" LOG_EFFECT_SIZE="0.31751614523331706" MODIFIED="2010-11-04 19:14:33 +0000" MODIFIED_BY="Micah R Pepper" NO="6" P_CHI2="1.0" P_Z="0.09636863704760272" STUDIES="1" TAU2="0.0" TOTAL_1="352" TOTAL_2="357" WEIGHT="16.775347288464705" Z="1.662719299881704">
<NAME>Insomnia</NAME>
<DICH_DATA CI_END="4.918070155860146" CI_START="0.8774806955880913" EFFECT_SIZE="2.0773809523809526" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.6917947196214091" LOG_CI_START="-0.05676242915477499" LOG_EFFECT_SIZE="0.31751614523331706" MODIFIED="2010-11-04 19:14:33 +0000" MODIFIED_BY="Micah R Pepper" ORDER="165" O_E="0.0" SE="0.4397061746087772" STUDY_ID="STD-Prado-2008" TOTAL_1="352" TOTAL_2="357" VAR="0.19334151998908444" WEIGHT="16.775347288464705"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.608842175452311" CI_END="23.799971841964833" CI_START="6.072877785566055" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="OR" EFFECT_SIZE="12.02224273154414" ESTIMABLE="YES" EVENTS_1="132" EVENTS_2="8" I2="11.822035664094539" I2_Q="34.39753333105883" ID="CMP-003.03" LOG_CI_END="1.3765764432377503" LOG_CI_START="0.783394541193641" LOG_EFFECT_SIZE="1.0799854922156957" METHOD="MH" MODIFIED="2014-05-09 08:56:35 +0100" MODIFIED_BY="Anne Lawson" NO="3" P_CHI2="0.3263809336722193" P_Q="0.15365958650589284" P_Z="9.547630181470707E-13" Q="10.670330485170735" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.18455767670586423" TOTALS="YES" TOTAL_1="3503" TOTAL_2="5705" WEIGHT="100.00000000000001" Z="7.136875421432281">
<NAME>BZD severe side effects</NAME>
<GROUP_LABEL_1>Benznidazole</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.24532630570238745" CI_END="125.09342848614286" CI_START="1.8435417171303266" DF="1" EFFECT_SIZE="15.186011785622435" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-003.03.01" LOG_CI_END="2.097234495567375" LOG_CI_START="0.265652969614775" LOG_EFFECT_SIZE="1.181443732591075" MODIFIED="2014-05-09 08:56:17 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="0.6203853978103973" P_Z="0.011454744427107675" STUDIES="2" TAU2="0.0" TOTAL_1="482" TOTAL_2="1025" WEIGHT="9.713285634141293" Z="2.5285111613415605">
<NAME>Toxic hepatitis</NAME>
<DICH_DATA CI_END="544.9924388764396" CI_START="1.2414982151833531" EFFECT_SIZE="26.011673151750973" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.73639047699771" LOG_CI_START="0.09394609953570746" LOG_EFFECT_SIZE="1.4151682882667087" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="1.552184907631805" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="130" TOTAL_2="668" VAR="2.4092779874799555" WEIGHT="4.680675474410259"/>
<DICH_DATA CI_END="172.11904247213766" CI_START="0.49522507327303494" EFFECT_SIZE="9.232424677187948" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2358289213622746" LOG_CI_START="-0.3051973750774827" LOG_EFFECT_SIZE="0.965315773142396" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="1.492611424811741" STUDY_ID="STD-Prado-2008" TOTAL_1="352" TOTAL_2="357" VAR="2.2278888654785356" WEIGHT="5.032610159731034"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="81.75135958535692" CI_START="1.3254178032135708" DF="0" EFFECT_SIZE="10.4093567251462" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" I2="0.0" ID="CMP-003.03.02" LOG_CI_END="1.9124949840296726" LOG_CI_START="0.12235279980380809" LOG_EFFECT_SIZE="1.0174238919167402" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.02588827970247088" STUDIES="1" TAU2="0.0" TOTAL_1="352" TOTAL_2="357" WEIGHT="9.409432713897315" Z="2.2278835756610316">
<NAME>Arthritis</NAME>
<DICH_DATA CI_END="81.75135958535692" CI_START="1.3254178032135708" EFFECT_SIZE="10.409356725146198" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.9124949840296726" LOG_CI_START="0.12235279980380809" LOG_EFFECT_SIZE="1.0174238919167402" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="96" O_E="0.0" SE="1.0515383803609986" STUDY_ID="STD-Prado-2008" TOTAL_1="352" TOTAL_2="357" VAR="1.105732965372232" WEIGHT="9.409432713897315"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.04472983546209026" CI_END="66.19070977948702" CI_START="2.0651167702108113" DF="1" EFFECT_SIZE="11.691515932409082" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="1" I2="0.0" ID="CMP-003.03.03" LOG_CI_END="1.8207970381612033" LOG_CI_START="0.31494461348608943" LOG_EFFECT_SIZE="1.0678708258236462" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.8325017273148148" P_Z="0.0054391480338406035" STUDIES="2" TAU2="0.0" TOTAL_1="482" TOTAL_2="1025" WEIGHT="13.653847377907528" Z="2.7798054104896135">
<NAME>Peripheral neuropathy</NAME>
<DICH_DATA CI_END="382.26061071324773" CI_START="0.6274025023102309" EFFECT_SIZE="15.486486486486486" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.582359549310664" LOG_CI_START="-0.20245375350987382" LOG_EFFECT_SIZE="1.189952897900395" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="97" O_E="0.0" SE="1.6358131191249552" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="130" TOTAL_2="668" VAR="2.6758845607013146" WEIGHT="4.244414664010213"/>
<DICH_DATA CI_END="81.75135958535692" CI_START="1.3254178032135708" EFFECT_SIZE="10.409356725146198" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="1" LOG_CI_END="1.9124949840296726" LOG_CI_START="0.12235279980380809" LOG_EFFECT_SIZE="1.0174238919167402" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="98" O_E="0.0" SE="1.0515383803609986" STUDY_ID="STD-Prado-2008" TOTAL_1="352" TOTAL_2="357" VAR="1.105732965372232" WEIGHT="9.409432713897315"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="341.0587528618677" CI_START="1.1465067388435193" DF="0" EFFECT_SIZE="19.77438136826783" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" ID="CMP-003.03.04" LOG_CI_END="2.5328291996546803" LOG_CI_START="0.05937661173403775" LOG_EFFECT_SIZE="1.2961029056943592" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.03996949332108816" STUDIES="1" TAU2="0.0" TOTAL_1="352" TOTAL_2="357" WEIGHT="5.288934132094057" Z="2.0540640462037114">
<NAME>Lymphadenopathy</NAME>
<DICH_DATA CI_END="341.0587528618677" CI_START="1.1465067388435193" EFFECT_SIZE="19.774381368267832" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="2.5328291996546803" LOG_CI_START="0.05937661173403775" LOG_EFFECT_SIZE="1.2961029056943592" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="99" O_E="0.0" SE="1.452918293932361" STUDY_ID="STD-Prado-2008" TOTAL_1="352" TOTAL_2="357" VAR="2.1109715688433224" WEIGHT="5.288934132094057"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="10.880203518795403" CI_START="1.482951795156195" DF="0" EFFECT_SIZE="4.016816816816817" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" I2="0.0" ID="CMP-003.03.05" LOG_CI_END="1.0366370190995824" LOG_CI_START="0.17112703407766047" LOG_EFFECT_SIZE="0.6038820265886213" MODIFIED="2014-05-09 08:56:35 +0100" MODIFIED_BY="Anne Lawson" NO="5" P_CHI2="1.0" P_Z="0.00623793483430307" STUDIES="1" TAU2="0.0" TOTAL_1="352" TOTAL_2="357" WEIGHT="27.404049768423814" Z="2.735004895396508">
<NAME>Oedema</NAME>
<DICH_DATA CI_END="10.880203518795403" CI_START="1.482951795156195" EFFECT_SIZE="4.016816816816817" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="5" LOG_CI_END="1.0366370190995824" LOG_CI_START="0.17112703407766047" LOG_EFFECT_SIZE="0.6038820265886213" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="100" O_E="0.0" SE="0.5084048495453998" STUDY_ID="STD-Prado-2008" TOTAL_1="352" TOTAL_2="357" VAR="0.25847549104128054" WEIGHT="27.404049768423814"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.8320207070805696" CI_END="57.36235991015312" CI_START="1.8675865349048815" DF="1" EFFECT_SIZE="10.35032226447899" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="1" I2="0.0" ID="CMP-003.03.06" LOG_CI_END="1.758627010073877" LOG_CI_START="0.2712807340542333" LOG_EFFECT_SIZE="1.014953872064055" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="0.36168893931340074" P_Z="0.007474502028757318" STUDIES="2" TAU2="0.0" TOTAL_1="635" TOTAL_2="640" WEIGHT="13.938291402469243" Z="2.6749292579514274">
<NAME>Fever</NAME>
<DICH_DATA CI_END="128.53298416312614" CI_START="2.235871374385267" EFFECT_SIZE="16.952380952380953" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="1" LOG_CI_END="2.1090145907167828" LOG_CI_START="0.3494468157611293" LOG_EFFECT_SIZE="1.229230703238956" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="53" O_E="0.0" SE="1.03357882100991" STUDY_ID="STD-Prado-2008" TOTAL_1="352" TOTAL_2="357" VAR="1.0682851792402355" WEIGHT="9.690683009751337"/>
<DICH_DATA CI_END="74.2169039726316" CI_START="0.1221262152167396" EFFECT_SIZE="3.010619469026549" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8705028333912757" LOG_CI_START="-0.9131911018050144" LOG_EFFECT_SIZE="0.4786558657931305" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="55" O_E="0.0" SE="1.6351555970415128" STUDY_ID="STD-Viotti-2006_x002a_" TOTAL_1="283" TOTAL_2="283" VAR="2.6737338265361865" WEIGHT="4.247608392717905"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.38329855761450904" CI_END="1036.380681231342" CI_START="19.643970695015437" DF="1" EFFECT_SIZE="142.68367717082643" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="0" I2="0.0" ID="CMP-003.03.07" LOG_CI_END="3.015519308874939" LOG_CI_START="1.29322927757713" LOG_EFFECT_SIZE="2.1543742932260344" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.5358435039654194" P_Z="9.421555273694402E-7" STUDIES="2" TAU2="0.0" TOTAL_1="424" TOTAL_2="972" WEIGHT="10.881083154302193" Z="4.903350710054514">
<NAME>Severe skin reactions</NAME>
<DICH_DATA CI_END="4365.272955283074" CI_START="15.787017529561524" EFFECT_SIZE="262.5159817351598" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="0" LOG_CI_END="3.6400114048037864" LOG_CI_START="1.1983000911991186" LOG_EFFECT_SIZE="2.4191557480014527" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="87" O_E="0.0" SE="1.4342733122773152" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="130" TOTAL_2="668" VAR="2.0571399343109413" WEIGHT="5.4159414357845765"/>
<DICH_DATA CI_END="1279.507582716104" CI_START="4.757052549573118" EFFECT_SIZE="78.01720841300191" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="0" LOG_CI_END="3.1070428639801437" LOG_CI_START="0.6773379489527118" LOG_EFFECT_SIZE="1.8921904064664274" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="78" O_E="0.0" SE="1.4272206943204155" STUDY_ID="STD-Viotti-2006_x002a_" TOTAL_1="294" TOTAL_2="304" VAR="2.036958910296449" WEIGHT="5.465141718517616"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.2351385402131258" CI_END="126.55143887222548" CI_START="1.8640574530224543" DF="1" EFFECT_SIZE="15.35900884889671" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-003.03.08" LOG_CI_END="2.1022670873900866" LOG_CI_START="0.2704592938259534" LOG_EFFECT_SIZE="1.18636319060802" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.6277396041270717" P_Z="0.011125688788514056" STUDIES="2" TAU2="0.0" TOTAL_1="424" TOTAL_2="972" WEIGHT="9.711075816764563" Z="2.5387260981694677">
<NAME>Severe gastrointestinal intolerance</NAME>
<DICH_DATA CI_END="544.9924388764396" CI_START="1.2414982151833531" EFFECT_SIZE="26.011673151750973" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.73639047699771" LOG_CI_START="0.09394609953570746" LOG_EFFECT_SIZE="1.4151682882667087" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="88" O_E="0.0" SE="1.552184907631805" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="130" TOTAL_2="668" VAR="2.4092779874799555" WEIGHT="4.680675474410259"/>
<DICH_DATA CI_END="175.99444614009082" CI_START="0.5056713826230091" EFFECT_SIZE="9.433734939759036" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2454989629915967" LOG_CI_START="-0.2961316236278576" LOG_EFFECT_SIZE="0.9746836696818695" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="79" O_E="0.0" SE="1.4929663878545794" STUDY_ID="STD-Viotti-2006_x002a_" TOTAL_1="294" TOTAL_2="304" VAR="2.22894863526355" WEIGHT="5.0304003423543024"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.776437304275996" CI_END="4.848825570915089" CI_START="0.7395717526277232" CI_STUDY="95" CI_TOTAL="95" DF="9" EFFECT_MEASURE="OR" EFFECT_SIZE="1.8936880486679406" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="0.6856365613166785" LOG_CI_START="-0.1310196847386384" LOG_EFFECT_SIZE="0.27730843828902" METHOD="MH" MODIFIED="2014-05-16 08:57:58 +0100" MODIFIED_BY="Anne Lawson" NO="5" P_CHI2="0.9255011396722226" P_Q="0.9446616898717036" P_Z="0.1831649824552527" Q="2.8283769726996093" RANDOM="YES" SCALE="569.74" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="225" TOTAL_2="130" WEIGHT="100.0" Z="1.3310730292723727">
<NAME>ALLOP - mild-to-moderate - RCT data only</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="89.72346186973661" CI_START="0.2030497045864843" DF="0" EFFECT_SIZE="4.2682926829268295" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-003.05.01" LOG_CI_END="1.9529060219541592" LOG_CI_START="-0.6923976380210414" LOG_EFFECT_SIZE="0.630254191966559" MODIFIED="2014-05-16 08:57:58 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.0" P_Z="0.3503356088526244" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="9.530759495624254" Z="0.9339385387395788">
<NAME>Pyrosis</NAME>
<DICH_DATA CI_END="89.72346186973661" CI_START="0.2030497045864843" EFFECT_SIZE="4.2682926829268295" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9529060219541592" LOG_CI_START="-0.6923976380210414" LOG_EFFECT_SIZE="0.630254191966559" MODIFIED="2012-02-15 14:34:35 +0000" MODIFIED_BY="[Empty name]" ORDER="105" O_E="0.0" SE="1.5538644643337345" STUDY_ID="STD-Rassi-2007" TOTAL_1="23" TOTAL_2="12" VAR="2.4144947735191638" WEIGHT="9.530759495624254"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="4.323828736089781" CI_START="0.006153879148574731" DF="0" EFFECT_SIZE="0.16312056737588654" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" I2="0.0" ID="CMP-003.05.02" LOG_CI_END="0.6358684835134216" LOG_CI_START="-2.2108510367889957" LOG_EFFECT_SIZE="-0.787491276637787" MODIFIED="2014-05-16 08:57:58 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.27819895388002147" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="8.229798790702798" Z="1.0843741572303298">
<NAME>Vertigo</NAME>
<DICH_DATA CI_END="4.323828736089781" CI_START="0.006153879148574731" EFFECT_SIZE="0.16312056737588654" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.6358684835134216" LOG_CI_START="-2.2108510367889957" LOG_EFFECT_SIZE="-0.787491276637787" MODIFIED="2012-02-15 14:34:35 +0000" MODIFIED_BY="[Empty name]" ORDER="70" O_E="0.0" SE="1.67217713771453" STUDY_ID="STD-Rassi-2007" TOTAL_1="23" TOTAL_2="12" VAR="2.7961763798951584" WEIGHT="8.229798790702798"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.9800752689088801" CI_END="12.191022911452439" CI_START="0.4076112974406248" DF="1" EFFECT_SIZE="2.2291699500185067" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" I2="0.0" ID="CMP-003.05.03" LOG_CI_END="1.0860401474691725" LOG_CI_START="-0.38975378750140927" LOG_EFFECT_SIZE="0.3481431799838816" MODIFIED="2014-05-16 08:57:58 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.3221804441405972" P_Z="0.3551115767248576" STUDIES="2" TAU2="0.0" TOTAL_1="41" TOTAL_2="34" WEIGHT="30.621547437691824" Z="0.924720014173599">
<NAME>Rash</NAME>
<DICH_DATA CI_END="9.87906457584872" CI_START="0.15816274790022455" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.9947158242657744" LOG_CI_START="-0.8008957982496616" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2012-03-02 16:50:45 +0000" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="1.0547511554864493" STUDY_ID="STD-Gianella-1994" TOTAL_1="18" TOTAL_2="22" VAR="1.1125" WEIGHT="20.68491594593519"/>
<DICH_DATA CI_END="146.71977018402723" CI_START="0.37650721367260803" EFFECT_SIZE="7.4324324324324325" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.166488638064993" LOG_CI_START="-0.42422669853845774" LOG_EFFECT_SIZE="0.8711309697632676" MODIFIED="2012-02-15 14:34:35 +0000" MODIFIED_BY="[Empty name]" ORDER="107" O_E="0.0" SE="1.52179901296861" STUDY_ID="STD-Rassi-2007" TOTAL_1="23" TOTAL_2="12" VAR="2.315872235872236" WEIGHT="9.936631491756632"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="65.52797984026658" CI_START="0.128960389315187" DF="0" EFFECT_SIZE="2.9069767441860463" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.05.04" LOG_CI_END="1.8164267793135558" LOG_CI_START="-0.8895436644566163" LOG_EFFECT_SIZE="0.4634415574284699" MODIFIED="2014-05-16 08:57:58 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.5019965896610469" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="9.108198329930733" Z="0.6713515763560202">
<NAME>Leukopenia</NAME>
<DICH_DATA CI_END="65.52797984026658" CI_START="0.128960389315187" EFFECT_SIZE="2.9069767441860463" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.8164267793135558" LOG_CI_START="-0.8895436644566163" LOG_EFFECT_SIZE="0.4634415574284699" MODIFIED="2012-02-15 14:34:35 +0000" MODIFIED_BY="[Empty name]" ORDER="108" O_E="0.0" SE="1.5895004334403238" STUDY_ID="STD-Rassi-2007" TOTAL_1="23" TOTAL_2="12" VAR="2.526511627906977" WEIGHT="9.108198329930733"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="44.04724180337426" CI_START="0.06306360316901809" DF="0" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.05.05" LOG_CI_END="1.6439187184897577" LOG_CI_START="-1.2002212192570447" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2014-05-16 08:57:58 +0100" MODIFIED_BY="Anne Lawson" NO="5" P_CHI2="1.0" P_Z="0.7597855416292139" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="8.244734112606533" Z="0.3057624229332219">
<NAME>Lymph node increase</NAME>
<DICH_DATA CI_END="44.04724180337426" CI_START="0.06306360316901809" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6439187184897577" LOG_CI_START="-1.2002212192570447" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-02-15 14:34:35 +0000" MODIFIED_BY="[Empty name]" ORDER="109" O_E="0.0" SE="1.6706618781522224" STUDY_ID="STD-Rassi-2007" TOTAL_1="23" TOTAL_2="12" VAR="2.7911111111111113" WEIGHT="8.244734112606533"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="44.04724180337426" CI_START="0.06306360316901809" DF="0" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.05.06" LOG_CI_END="1.6439187184897577" LOG_CI_START="-1.2002212192570447" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2014-05-16 08:57:58 +0100" MODIFIED_BY="[Empty name]" NO="6" P_CHI2="1.0" P_Z="0.7597855416292139" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="8.244734112606533" Z="0.3057624229332219">
<NAME>Vomit</NAME>
<DICH_DATA CI_END="44.04724180337426" CI_START="0.06306360316901809" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6439187184897577" LOG_CI_START="-1.2002212192570447" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-02-15 14:34:35 +0000" MODIFIED_BY="[Empty name]" ORDER="110" O_E="0.0" SE="1.6706618781522224" STUDY_ID="STD-Rassi-2007" TOTAL_1="23" TOTAL_2="12" VAR="2.7911111111111113" WEIGHT="8.244734112606533"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="44.04724180337426" CI_START="0.06306360316901809" DF="0" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.05.07" LOG_CI_END="1.6439187184897577" LOG_CI_START="-1.2002212192570447" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2014-05-16 08:57:58 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="1.0" P_Z="0.7597855416292139" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="8.244734112606533" Z="0.3057624229332219">
<NAME>Stomach ache</NAME>
<DICH_DATA CI_END="44.04724180337426" CI_START="0.06306360316901809" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6439187184897577" LOG_CI_START="-1.2002212192570447" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-02-15 14:34:35 +0000" MODIFIED_BY="[Empty name]" ORDER="111" O_E="0.0" SE="1.6706618781522224" STUDY_ID="STD-Rassi-2007" TOTAL_1="23" TOTAL_2="12" VAR="2.7911111111111113" WEIGHT="8.244734112606533"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="44.04724180337426" CI_START="0.06306360316901809" DF="0" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" ID="CMP-003.05.08" LOG_CI_END="1.6439187184897577" LOG_CI_START="-1.2002212192570447" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2014-05-16 08:57:58 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="1.0" P_Z="0.7597855416292139" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="8.244734112606533" Z="0.3057624229332219">
<NAME>Red Eye</NAME>
<DICH_DATA CI_END="44.04724180337426" CI_START="0.06306360316901809" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.6439187184897577" LOG_CI_START="-1.2002212192570447" LOG_EFFECT_SIZE="0.2218487496163564" MODIFIED="2012-02-15 14:34:35 +0000" MODIFIED_BY="[Empty name]" ORDER="112" O_E="0.0" SE="1.6706618781522224" STUDY_ID="STD-Rassi-2007" TOTAL_1="23" TOTAL_2="12" VAR="2.7911111111111113" WEIGHT="8.244734112606533"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="89.72346186973661" CI_START="0.2030497045864843" DF="0" EFFECT_SIZE="4.2682926829268295" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" I2="0.0" ID="CMP-003.05.09" LOG_CI_END="1.9529060219541592" LOG_CI_START="-0.6923976380210414" LOG_EFFECT_SIZE="0.630254191966559" MODIFIED="2014-05-16 08:57:58 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="1.0" P_Z="0.3503356088526244" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="9.530759495624254" Z="0.9339385387395788">
<NAME>Pruritus</NAME>
<DICH_DATA CI_END="89.72346186973661" CI_START="0.2030497045864843" EFFECT_SIZE="4.2682926829268295" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.9529060219541592" LOG_CI_START="-0.6923976380210414" LOG_EFFECT_SIZE="0.630254191966559" MODIFIED="2012-02-15 14:34:35 +0000" MODIFIED_BY="[Empty name]" ORDER="71" O_E="0.0" SE="1.5538644643337345" STUDY_ID="STD-Rassi-2007" TOTAL_1="23" TOTAL_2="12" VAR="2.4144947735191638" WEIGHT="9.530759495624254"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1770901126998239" CI_END="47.03664232779234" CI_START="3.234836687054246" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="OR" EFFECT_SIZE="12.335147191573812" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="1.6724363124184762" LOG_CI_START="0.5098523599037901" LOG_EFFECT_SIZE="1.0911443361611333" METHOD="MH" MODIFIED="2014-05-15 17:52:42 +0100" MODIFIED_BY="Anne Lawson" NO="6" P_CHI2="0.8818559993678069" P_Q="0.9006988343758647" P_Z="2.3410223190264645E-4" Q="0.2091688808767827" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="763" TOTAL_2="1535" WEIGHT="100.0" Z="3.679052331979735">
<NAME>ALLOP - severe side effects</NAME>
<GROUP_LABEL_1>Allopurinol</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.9824379502995804" CI_END="71.02451887308382" CI_START="2.1718904355206723" DF="2" EFFECT_SIZE="12.420043205557226" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" I2="0.0" ID="CMP-003.06.01" LOG_CI_END="1.8514083004523827" LOG_CI_START="0.3368379127911321" LOG_EFFECT_SIZE="1.0941231066217574" MODIFIED="2012-03-02 16:51:17 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.6118801271974974" P_Z="0.004629411701488253" STUDIES="3" TAU2="0.0" TOTAL_1="431" TOTAL_2="855" WEIGHT="58.92094791722545" Z="2.8317493872874384">
<NAME>Skin severe reactions</NAME>
<DICH_DATA CI_END="223.25050741587887" CI_START="0.5835358428352555" EFFECT_SIZE="11.413793103448276" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.3487924546497925" LOG_CI_START="-0.2339324628962675" LOG_EFFECT_SIZE="1.0574299958767626" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="61" O_E="0.0" SE="1.5171054012610865" STUDY_ID="STD-Apt-1998_x002a_" TOTAL_1="104" TOTAL_2="165" VAR="2.301608798535562" WEIGHT="20.262468041264306"/>
<DICH_DATA CI_END="582.2709040108493" CI_START="1.887163352805381" EFFECT_SIZE="33.14876033057851" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="2.7651250890205383" LOG_CI_START="0.27580949430985463" LOG_EFFECT_SIZE="1.5204672916651967" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="103" O_E="0.0" SE="1.4622363026439813" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="309" TOTAL_2="668" VAR="2.1381350047699406" WEIGHT="21.811660451645587">
<FOOTNOTE>Steven-John's</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="100.57750784441862" CI_START="0.1479212533623517" EFFECT_SIZE="3.857142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="2.0025008702705303" LOG_CI_START="-0.8299694219810692" LOG_EFFECT_SIZE="0.5862657241447304" MODIFIED="2012-03-02 16:51:17 +0000" MODIFIED_BY="[Empty name]" ORDER="90" O_E="0.0" SE="1.6638070706226633" STUDY_ID="STD-Gianella-1994" TOTAL_1="18" TOTAL_2="22" VAR="2.768253968253968" WEIGHT="16.846819424315555"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="146.71977018402723" CI_START="0.37650721367260803" DF="0" EFFECT_SIZE="7.4324324324324325" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" I2="0.0" ID="CMP-003.06.02" LOG_CI_END="2.166488638064993" LOG_CI_START="-0.42422669853845774" LOG_EFFECT_SIZE="0.8711309697632676" MODIFIED="2014-05-15 17:52:42 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.0" P_Z="0.18747679362286257" STUDIES="1" TAU2="0.0" TOTAL_1="23" TOTAL_2="12" WEIGHT="20.13767167352164" Z="1.318080224739718">
<NAME>Fever</NAME>
<DICH_DATA CI_END="146.71977018402723" CI_START="0.37650721367260803" EFFECT_SIZE="7.4324324324324325" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="2.166488638064993" LOG_CI_START="-0.42422669853845774" LOG_EFFECT_SIZE="0.8711309697632676" MODIFIED="2014-05-15 17:52:42 +0100" MODIFIED_BY="[Empty name]" ORDER="54" O_E="0.0" SE="1.52179901296861" STUDY_ID="STD-Rassi-2007" TOTAL_1="23" TOTAL_2="12" VAR="2.315872235872236" WEIGHT="20.13767167352164"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="366.9356734688405" CI_START="1.0570011918790216" DF="0" EFFECT_SIZE="19.693944353518823" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-003.06.03" LOG_CI_END="2.56458993589751" LOG_CI_START="0.024075477019999923" LOG_EFFECT_SIZE="1.294332706458755" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.045813057606357795" STUDIES="1" TAU2="0.0" TOTAL_1="309" TOTAL_2="668" WEIGHT="20.94138040925291" Z="1.997111632100124">
<NAME>Severe gastrointestinal effects</NAME>
<DICH_DATA CI_END="366.9356734688405" CI_START="1.0570011918790216" EFFECT_SIZE="19.693944353518823" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.56458993589751" LOG_CI_START="0.024075477019999923" LOG_EFFECT_SIZE="1.294332706458755" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="82" O_E="0.0" SE="1.49231076889404" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="309" TOTAL_2="668" VAR="2.226991430957121" WEIGHT="20.94138040925291"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6477441508006733" CI_END="352.34725323852047" CI_START="18.968095169047864" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="OR" EFFECT_SIZE="81.75179650613718" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="2.5469708902564365" LOG_CI_START="1.2780237199710094" LOG_EFFECT_SIZE="1.9124973051137228" METHOD="MH" MODIFIED="2014-05-09 11:04:21 +0100" MODIFIED_BY="Anne Lawson" NO="7" P_CHI2="0.8854206268057856" P_Q="0.8913158362976278" P_Z="3.4643212650080944E-9" Q="0.622269763493475" RANDOM="YES" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="384" TOTAL_2="2672" WEIGHT="100.0" Z="5.907930489666749">
<NAME>NFTMX - severe side effects</NAME>
<GROUP_LABEL_1>Nifurtimox</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="0.0" CI_END="742.3851795853918" CI_START="1.6851940670958303" DF="0" EFFECT_SIZE="35.370370370370374" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" ID="CMP-003.07.01" LOG_CI_END="2.8706292933717306" LOG_CI_START="0.22664992147778773" LOG_EFFECT_SIZE="1.548639607424759" MODIFIED="2014-05-09 11:04:21 +0100" MODIFIED_BY="Anne Lawson" NO="1" P_CHI2="1.0" P_Z="0.021676333929059984" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="668" WEIGHT="23.034084634079914" Z="2.2959920851504507">
<NAME>Polyneuritis</NAME>
<DICH_DATA CI_END="742.3851795853918" CI_START="1.6851940670958303" EFFECT_SIZE="35.370370370370374" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.8706292933717306" LOG_CI_START="0.22664992147778773" LOG_EFFECT_SIZE="1.548639607424759" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="101" O_E="0.0" SE="1.553086570959472" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="96" TOTAL_2="668" VAR="2.412077896894651" WEIGHT="23.034084634079914">
<FOOTNOTE>Polineuritis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="3079.037058040688" CI_START="10.502951253852673" DF="0" EFFECT_SIZE="179.8304093567251" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" I2="0.0" ID="CMP-003.07.02" LOG_CI_END="3.4884149159268194" LOG_CI_START="1.0213113498480269" LOG_EFFECT_SIZE="2.254863132887423" MODIFIED="2014-05-09 09:01:58 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="1.0" P_Z="3.4005626199313214E-4" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="668" WEIGHT="26.45527748581988" Z="3.5827036945601485">
<NAME>Toxic hepatitis</NAME>
<DICH_DATA CI_END="3079.037058040688" CI_START="10.502951253852673" EFFECT_SIZE="179.83040935672514" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="0" LOG_CI_END="3.4884149159268194" LOG_CI_START="1.0213113498480269" LOG_EFFECT_SIZE="2.2548631328874236" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="102" O_E="0.0" SE="1.4491888470742933" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="96" TOTAL_2="668" VAR="2.100148314484519" WEIGHT="26.45527748581988">
<FOOTNOTE>Toxic Hepatitis</FOOTNOTE>
</DICH_DATA>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1718.9032929852901" CI_START="5.364644228757485" DF="0" EFFECT_SIZE="96.02762430939221" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" ID="CMP-003.07.03" LOG_CI_END="3.2352514435839184" LOG_CI_START="0.7295409258153542" LOG_EFFECT_SIZE="1.9823961846996363" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="1.0" P_Z="0.001927014906552005" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="668" WEIGHT="25.64633384713461" Z="3.1012561886526524">
<NAME>Malaise</NAME>
<DICH_DATA CI_END="1718.9032929852917" CI_START="5.36464422875749" EFFECT_SIZE="96.02762430939227" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="3.235251443583919" LOG_CI_START="0.7295409258153546" LOG_EFFECT_SIZE="1.9823961846996365" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="83" O_E="0.0" SE="1.4718667616043581" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="96" TOTAL_2="668" VAR="2.1663917639157004" WEIGHT="25.64633384713461"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="0.0" CI_END="1217.8877493141424" CI_START="3.4737384409870304" DF="0" EFFECT_SIZE="65.04324324324327" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" I2="0.0" ID="CMP-003.07.04" LOG_CI_END="3.085607261942189" LOG_CI_START="0.5407971146544025" LOG_EFFECT_SIZE="1.8132021882982956" MODIFIED="2012-02-15 15:13:35 +0000" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="1.0" P_Z="0.005222377084873012" STUDIES="1" TAU2="0.0" TOTAL_1="96" TOTAL_2="668" WEIGHT="24.86430403296559" Z="2.792987122863733">
<NAME>Severe skin reactions</NAME>
<DICH_DATA CI_END="1217.8877493141424" CI_START="3.4737384409870304" EFFECT_SIZE="65.04324324324324" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="3.085607261942189" LOG_CI_START="0.5407971146544025" LOG_EFFECT_SIZE="1.8132021882982954" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" ORDER="84" O_E="0.0" SE="1.4948340775302367" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="96" TOTAL_2="668" VAR="2.2345289193456734" WEIGHT="24.86430403296559"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="91.35059128110146" CI_START="0.14917037250784482" CI_STUDY="95" CI_TOTAL="95" DF="0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.6914498141263934" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="1.960711362737145" LOG_CI_START="-0.8263174257511988" LOG_EFFECT_SIZE="0.5671969684929731" METHOD="MH" MODIFIED="2014-05-09 09:02:16 +0100" MODIFIED_BY="Anne Lawson" NO="8" P_CHI2="1.0" P_Q="1.0" P_Z="0.4250116229228442" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="135" TOTAL_2="165" WEIGHT="100.0" Z="0.7977568333547744">
<NAME>ITRA - severe side effects</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="91.35059128110146" CI_START="0.14917037250784482" EFFECT_SIZE="3.691449814126394" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.960711362737145" LOG_CI_START="-0.8263174257511988" LOG_EFFECT_SIZE="0.5671969684929732" MODIFIED="2012-02-15 15:04:00 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Gastrointestinal&lt;/p&gt;" NOTES_MODIFIED="2012-02-15 15:04:00 +0000" NOTES_MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="1.6371145063730554" STUDY_ID="STD-Apt-1998_x002a_" TOTAL_1="135" TOTAL_2="165" VAR="2.6801439069770927" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="53.585072397968545" CI_END="44.69515545195183" CI_START="3.13726112624969" CI_STUDY="95" CI_TOTAL="95" DF="10" EFFECT_MEASURE="OR" EFFECT_SIZE="11.841468394210889" ESTIMABLE="YES" EVENTS_1="237" EVENTS_2="22" I2="81.33808623839965" I2_Q="83.54902384937071" ID="CMP-003.09" LOG_CI_END="1.6502604521139141" LOG_CI_START="0.49655066819394994" LOG_EFFECT_SIZE="1.073405560153932" METHOD="MH" MODIFIED="2014-05-09 09:02:55 +0100" MODIFIED_BY="Anne Lawson" NO="9" P_CHI2="5.7967062483399445E-8" P_Q="0.01368246273410989" P_Z="2.652368275367978E-4" Q="6.0786666447252" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="10" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="3.6330189229749354" TOTALS="YES" TOTAL_1="1730" TOTAL_2="2655" WEIGHT="99.99999999999999" Z="3.6470805189127145">
<NAME>Drug discontinuation - all populations, all drugs</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="29.209510382260106" CI_END="17.657068370746742" CI_START="0.3966719751860567" DF="3" EFFECT_SIZE="2.646519258690433" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="22" I2="89.72937252032133" ID="CMP-003.09.01" LOG_CI_END="1.2469185986698244" LOG_CI_START="-0.4015684812802791" LOG_EFFECT_SIZE="0.4226750586947726" MODIFIED="2012-02-15 14:51:02 +0000" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="2.023547337803855E-6" P_Z="0.31485998177273833" STUDIES="5" TAU2="3.2848032136851923" TOTAL_1="547" TOTAL_2="509" WEIGHT="44.801645181966535" Z="1.0050765969366078">
<NAME>RCT data</NAME>
<DICH_DATA CI_END="1.46804406410561" CI_START="0.1756748420043705" EFFECT_SIZE="0.5078369905956113" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.16673909135029227" LOG_CI_START="-0.7552904283793926" LOG_EFFECT_SIZE="-0.29427566851455017" MODIFIED="2012-02-15 14:47:29 +0000" MODIFIED_BY="[Empty name]" ORDER="67" O_E="0.0" SE="0.5416047040089487" STUDY_ID="STD-Andrade-1996" TOTAL_1="64" TOTAL_2="65" VAR="0.2933356554046209" WEIGHT="11.697117117787645"/>
<DICH_DATA CI_END="14.162704425309425" CI_START="0.5860382573883911" EFFECT_SIZE="2.880952380952381" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.1511461915488135" LOG_CI_START="-0.23207403171171434" LOG_EFFECT_SIZE="0.4595360799185496" MODIFIED="2012-02-15 14:47:29 +0000" MODIFIED_BY="[Empty name]" ORDER="73" O_E="0.0" SE="0.812510406193767" STUDY_ID="STD-Coura-1997" TOTAL_1="53" TOTAL_2="24" VAR="0.6601731601731602" WEIGHT="10.697641395907494"/>
<DICH_DATA CI_END="37.12655268663169" CI_START="7.711234307360799" EFFECT_SIZE="16.920152091254753" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="7" LOG_CI_END="1.5696846255343053" LOG_CI_START="0.887123899448042" LOG_EFFECT_SIZE="1.2284042624911737" MODIFIED="2012-02-15 14:47:29 +0000" MODIFIED_BY="[Empty name]" ORDER="68" O_E="0.0" SE="0.40093954923315656" STUDY_ID="STD-Prado-2008" TOTAL_1="352" TOTAL_2="357" VAR="0.16075252213928679" WEIGHT="12.105903060769291"/>
<DICH_DATA CI_END="10.472350929316619" CI_START="0.2973722779374327" EFFECT_SIZE="1.7647058823529411" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="2" LOG_CI_END="1.0200441870293435" LOG_CI_START="-0.5266995203465664" LOG_EFFECT_SIZE="0.2466723333413885" MODIFIED="2012-02-15 14:47:29 +0000" MODIFIED_BY="[Empty name]" ORDER="66" O_E="0.0" SE="0.9085649102174436" STUDY_ID="STD-Rassi-2007" TOTAL_1="23" TOTAL_2="12" VAR="0.8254901960784313" WEIGHT="10.30098360750211"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2012-02-15 14:47:29 +0000" MODIFIED_BY="[Empty name]" ORDER="76" O_E="0.0" SE="0.0" STUDY_ID="STD-Sosa_x002d_Estani-1998" TOTAL_1="55" TOTAL_2="51" VAR="0.0" WEIGHT="0.0"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.3519885794202535" CI_END="130.9481670656821" CI_START="13.781181605427076" DF="6" EFFECT_SIZE="42.48082474752543" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="0" I2="5.541391880971857" ID="CMP-003.09.02" LOG_CI_END="2.1170994238087415" LOG_CI_START="1.1392864557948752" LOG_EFFECT_SIZE="1.6281929398018082" MODIFIED="2014-05-09 09:02:55 +0100" MODIFIED_BY="Anne Lawson" NO="2" P_CHI2="0.3849365781635925" P_Z="6.700220222251666E-11" STUDIES="5" TAU2="0.12806765711015058" TOTAL_1="1183" TOTAL_2="2146" WEIGHT="55.19835481803345" Z="6.527218652818446">
<NAME>Non-RCT data</NAME>
<DICH_DATA CI_END="223.25050741587887" CI_START="0.5835358428352555" EFFECT_SIZE="11.413793103448276" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.3487924546497925" LOG_CI_START="-0.2339324628962675" LOG_EFFECT_SIZE="1.0574299958767626" MODIFIED="2012-02-15 14:50:54 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ALLOP&lt;/p&gt;" NOTES_MODIFIED="2012-02-15 14:50:54 +0000" NOTES_MODIFIED_BY="[Empty name]" ORDER="75" O_E="0.0" SE="1.5171054012610865" STUDY_ID="STD-Apt-1998_x002a_" TOTAL_1="104" TOTAL_2="165" VAR="2.301608798535562" WEIGHT="7.738822299299665">
<FOOTNOTE>Refers to treatment with Allopurinol</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="91.35059128110146" CI_START="0.14917037250784482" EFFECT_SIZE="3.691449814126394" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.960711362737145" LOG_CI_START="-0.8263174257511988" LOG_EFFECT_SIZE="0.5671969684929732" MODIFIED="2012-02-15 14:50:54 +0000" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;ITRA&lt;/p&gt;" NOTES_MODIFIED="2012-02-15 14:50:54 +0000" NOTES_MODIFIED_BY="[Empty name]" ORDER="77" O_E="0.0" SE="1.6371145063730554" STUDY_ID="STD-Apt-1998_x002a_" TOTAL_1="135" TOTAL_2="165" VAR="2.6801439069770927" WEIGHT="7.274805131173273"/>
<DICH_DATA CI_END="624.8286840239291" CI_START="2.0164983590153915" EFFECT_SIZE="35.496" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="0" LOG_CI_END="2.795760958493072" LOG_CI_START="0.30459787292392493" LOG_EFFECT_SIZE="1.5501794157084985" MODIFIED="2012-02-15 14:51:02 +0000" MODIFIED_BY="[Empty name]" ORDER="81" O_E="0.0" SE="1.4633215279194698" STUDY_ID="STD-Fabbro-2000_x002a__x002a_" TOTAL_1="70" TOTAL_2="130" VAR="2.1413098940725717" WEIGHT="7.953656745988795"/>
<DICH_DATA CI_END="951.9350378341852" CI_START="3.315137821726617" EFFECT_SIZE="56.1764705882353" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="0" LOG_CI_END="2.9786073121735783" LOG_CI_START="0.5205015882373666" LOG_EFFECT_SIZE="1.7495544502054725" MODIFIED="2012-02-15 14:51:02 +0000" MODIFIED_BY="[Empty name]" ORDER="86" O_E="0.0" SE="1.4439034700597044" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="309" TOTAL_2="668" VAR="2.0848572308504556" WEIGHT="8.032183299133045">
<FOOTNOTE>Refers to treatment with allopurinol</FOOTNOTE>
</DICH_DATA>
<DICH_DATA CI_END="6230.834815655641" CI_START="23.48604633721576" EFFECT_SIZE="382.5410764872521" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="0" LOG_CI_END="3.794546237918192" LOG_CI_START="1.370809913395417" LOG_EFFECT_SIZE="2.5826780756568044" MODIFIED="2012-02-15 14:51:02 +0000" MODIFIED_BY="[Empty name]" ORDER="85" O_E="0.0" SE="1.4237147147129805" STUDY_ID="STD-Gallerano-2000_x002a__x002a_" TOTAL_1="226" TOTAL_2="668" VAR="2.0269635888902635" WEIGHT="8.114341210947053"/>
<DICH_DATA CI_END="743.9716695195583" CI_START="2.463340210228271" EFFECT_SIZE="42.80952380952381" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="0" LOG_CI_END="2.8715563979039613" LOG_CI_START="0.39152439609465794" LOG_EFFECT_SIZE="1.6315403969993094" MODIFIED="2012-02-15 14:51:02 +0000" MODIFIED_BY="[Empty name]" ORDER="89" O_E="0.0" SE="1.456783074219184" STUDY_ID="STD-Lauria_x002d_Pires-2000_x002a__x002a_" TOTAL_1="45" TOTAL_2="46" VAR="2.122216925331497" WEIGHT="7.980042966055361"/>
<DICH_DATA CI_END="1451.4151121115196" CI_START="5.419397583303466" EFFECT_SIZE="88.68932038834951" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="0" LOG_CI_END="3.161791640636439" LOG_CI_START="0.7339510133303291" LOG_EFFECT_SIZE="1.9478713269833845" MODIFIED="2012-02-15 14:50:33 +0000" MODIFIED_BY="[Empty name]" ORDER="80" O_E="0.0" SE="1.4261256024845383" STUDY_ID="STD-Viotti-2006_x002a_" TOTAL_1="294" TOTAL_2="304" VAR="2.0338342340618873" WEIGHT="8.104503165436261"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2014-05-09 11:52:24 +0100" MODIFIED_BY="Anne Lawson">
<FIGURE FILENAME="Tabla #3.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2014-05-09 11:51:23 +0100" MODIFIED_BY="Anne Lawson" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Quality assessment of the studies other than RCTs included.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQBAMAAACtWQSHAAAAMFBMVEUAAAAgICBAQEBfX19ra2t7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</FILE>
</FIGURE>
<FIGURE FILENAME="Flowchart.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2014-05-09 11:51:50 +0100" MODIFIED_BY="Anne Lawson" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Study flow diagram.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAZIAAAOrCAYAAAB9aAC2AABfhElEQVR42u2df4QV7f//3yRJ1ook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=
</FILE>
</FIGURE>
<FIGURE FILENAME="Tabla #1.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2014-05-09 11:51:50 +0100" MODIFIED_BY="Anne Lawson" NO="3" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Main characteristics of the included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAMAAABoqemGAAADAFBMVEUAAAASEhInTCdAQEBYWFhA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</FILE>
</FIGURE>
<FIGURE FILENAME="Tabla #2.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2014-05-09 11:51:50 +0100" MODIFIED_BY="Anne Lawson" NO="4" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Quality assessment of randomised controlled trials included.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQBAMAAACtWQSHAAAAMFBMVEUAAAAAMAAAUAAAgAB/f39g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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2014-05-09 11:52:19 +0100" MODIFIED_BY="Anne Lawson" NO="5" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
<P>*Non-randomised experiment</P>
<P>**Observational study</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAUMAAAM1CAIAAABltQSlAAApBElEQVR42u3dvW4exxXG8RcIEKRg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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2014-05-09 11:52:24 +0100" MODIFIED_BY="Anne Lawson" NO="6" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAl4AAADOCAMAAADYBvzeAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Gráfica #2.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2014-05-09 11:52:24 +0100" MODIFIED_BY="Anne Lawson" NO="7" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Meta-regression analysis. Relationship between effect of TT on progression of CCC and serology.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAMAAABoqemGAAADAFBMVEUAAAAAACkAACsAAFEAAFUA
KCkAK1UAKHoAK4AaR28AVYAAUaIAVaoAgP8nAAArAAArACsnACkrAFUnAFErKysrK4ArVVUnUVEn
eaInecorgNROAABVAABVACtOAClVAFVVKwBVVVVOUVFOUaJVgIBVgNROoaJOofNVqv91KAB1yqJ1
yvOAKwCAKyucUQCAgFWcoVGAqoCA1KqA1P+c8qKc8vOqVQCqgCuq1ICq/6qq///DeSnUgCvUgFXU
gIDDoVHU1IDU1NTD8srD8vPU///qoVH/qlXqynr/1IDq8qL//6rq8sr//9Tq8vP///8AAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAADPMa3gAAAhTElEQVR42u3di1Mb573G8RdZFqq4FCuqIyFiU4UDmMSk5lBPJ/Gp
zzBJeyZT88dCJmfGdpmm9S1O4raywYZxOLItGSUGFYtYleVlOe+7N60u3AxBu+j7mdarveiSFz16
39Xu/tQxLQD4VYAmAAgwAAIMgAADBBgAAQZAgAEQYIAAAyDAAAgwQIABEGAABBgAAQYIMAACDIAA
AyDAAAEGQIABEGCAAAMgwAAIMAACDBBgAAQYAAEGQIABAgyAAAMgwAABBkCAARBgAAQYIMAACDAA
AgwQYAAEGAABBkCAAQIMgAADIMAACDBAgAEQYAAEGCDAAAgwAAIMgAADBBgAAQZAgAEQYIAAAyDA
AAgwQIABEGAABBgAAQYIMAACDIAAAyDAAAEGQIABEGCAAAMgwAAIMAACDBBgAJ4RPNJn26LB0TY6
6IEBEGCAAAMgwAAIMAACDBBgAAQYAAEGCDAAAgyAAAMgwAABBkCAARBggAADIMAAjlqQJvCc2Wna
wHdaVS2KHhhgCA2AAAMgwAABBkCAsRvt3hyNAALsV7kcbQAC7FeFNG0AAuxXlfvDSVoBb4szsVq8
A/xg8/2GLpjfgAMB9skO8Oql6sws7QEC7Cfl+2MRzZm7YuW4g4bxHc6Fbssd4K/jKVoB9MA+9VOx
aAybvxgjx6AHBuiBcXSiaq9XS69P0RSgBwYIMACG0Nj7n2CCNgA9MECAARBgAAQYAAEGCDAAAgyA
AAMgwAABBkCAARBggAADIMAACDAAAgwQYAAEGAABBggwAAIMgAADIMAAAQZAgAEQYAAEGCDAAAgw
AAIMEGAABBgAAQZAgAECDIAAAyDAAAgwQIABEGAABBggwAAIMAACDIAAAwQYAAEGQIABEGCAAAMg
wAAIMECAARBgAAQYAAEGCDAAAgyAAAMEGAABBkCAARBggAADIMAACDAAAgwQYAAEGAABBggwAAIM
gAADIMAAAQZAgAEQYAAEGCDAAAgwAAIMEGAABBgAAQZAgAECDIAAAzgkQZqgpSq3i0KMDNMQIMA+
VL6m/l0sTtIUIMC+o2c7xlIyxT/m4zQG2Af2Gy0XTwkRHqclQA/sQ6HL1l+hl7YAAfZrP7wWjRg3
Zq0FW7QJCLBvdoQz61PmrSuiJscAAfZ+fpft/Do6aBXfadWoiS+xWqzyN51jSI02rP+DAHta+ep7
7XwWh748Z0wLV0va33OuxYvG/93LwBDag/m9PpZq6/6j/9FqTAgtMxgRF5q8Oy/wFiHAHqYtbM3P
y+mJiXY9kSMYL6gA5y8K7f7ppNAzD0T4Ulj+ez31QMz9Xi0DAfZsgNt+hBjsX5C7EOvhmDl0zmSm
Rf7GpUFRmNTl/zXeIgTYy8JX2r4JoqHVmLYyYn2gPR8XIhbLDvHW2PNOCE2A1nbBBaG9OGXO6KWI
fEv2FWkWAgyfvAH7smLdOhMNBBh+0x36cSlhvxsjJdkNr3NmOAGGX4SGftCSzng6LcTq6gCtQoDh
F33/5wQ2MDg4M5O+FAn0PZ9T/6dxdtUxfZTPxmU2ezE7TRv4TpO39pGc0k4PDDCEBkCAARBggAAD
IMAACDCAJrgaCd41Y044Lk4PDB/Gd6Y2x6AHhq+63x7z1sYMnTA9MPyW3x4rv3aOQYDhSz2Mogkw
/NYBk2ACDBBgAAQYeMsRNAgwfGWaX0YiwAABBlpvgzM5CDAYQxNg4Oi6XTpgAgzfdsF2gjfI7/a4
mAGeTfDMRjXMoAeG/zphY0J+6YHh4wSDHhggwAAIMAACDIAAAwQYAAEGQIABAgyAAAMgwAAIMECA
ARBgAAQYIMAACDAAAgyAAAMEGAABBkCAAbhRVtaX9MwDYzo6bC/R0t3D7ikIMDysf5I2AAH2vcrt
l1ZHrH31Mngx5kz1J4F/Bi4kZFcdvhShnQgwvEh7kLgs8veiMriZi7HCnYt91jQmthY/jeiZzLTI
3yDBBBje8nzGGEcHJ+Skz1gyFBO98UKfNZWJjkaE9nxciFgsy24xAYY394G1dNb4K3Z0CRHoKzhT
IXqF0EsRew4EGN4bQqez/dPlORqCAMOXAV791Nq/3XolO9z1XmdqCERkF+zM4fjhRA6/J7gkKl/r
r+Wtx6tidXWgOjU+n/vTojoHemB4S3jilgj+9pnsdTvOz78MX4po1tT6fB4UMxxGOs46jvQ3lLdo
8D2Y5Xet/afJW7uDITQAAgwQYAAEGAABBkCAAX/jOLAfqQsZONYEAuzX9BoTIgyG0L7Mb4/kJBkE
GH6iwmv8S4LBENp3HXCPE+SNGUbRh+raXjf8jAADR5o5emB4qwMmbofuMwKMn9f0zEZPO0TpOGeO
ADNW9GsMP+PvSIDbO7+/+LfTBW+IXxAlAgx/9V0zMrg9Rnw5kwMcB/bfXrAKr0R+QQ/s0wRzLjQI
sM97YcBrAX6Slv+MDO9hTojCTWPSMZY68NPqy8u71G3U5ntSe9jWeE2JSffrEycm4urVv+DHBHHM
94ErX6mMisW5XedctuaXjuCl5d7s4WNCu2dkduXLvHvp5j01mygv817Dse6BtQfFrin1WyG5peGd
59xdW/laZuCgVY8DQ0M7b1Cen9hDP57JdcrOWV9+mO6NOK9Pjhyychp67/sUbzYc5wAXc8bgM/jh
horkTnNu4fH5YkRffvqbm3IwLQPu5FqI+KmnU8JeJZx1MmHWWNy+ZQ6LXRss/+4rZyistsuG43Uf
Ns4TVZ9p/aFxj8BQ9OaCa7ycXNPVJPFsuWmCXY8E+DjAeuGE+QMgocu7zDUdft8XobjKktj8VqbV
2AHN57ucVcJZZ6RWLIphUb1lB9G8sxCvv1JDYaez13J1P03i2tZ5Juc1it7kaqn6KZPLJYx2jmea
Bbhyu6hG2SQYvg9w0d3N7TRXm6V0l1r1JnZZBlJ1p4Wbj+OhTIedVHOV7ETVusrtTEpTnbmWzg6L
6i1hb6DurLInx+uFm86P6v70qvbHwVzbas4zVV9j8J18UT7I5jfWUN/IdeBkOd/kv2GlKF+DOcoG
fD2E3i8rIB2Ddkq0XJeMXHT8fr4/l0iJwJncphMgGVa5LnT+Tj4qVuamguY+bfWW686yozwxpvrR
dfuZNoK1AXZtq7mfqSm176706KUmA+i1TvlU771ZLvHrRWizALu/yhJmxIy+7t37otQRVcuST51V
erE4a8S9FB9Mv5oV6uumkHNLuO9s3SXQawdYf2NMzGNEE7Xb1jxT4ysrX+v8nTUb2dKaDDs2ouoH
uKNLRQIMfwc40Ju3xpiFW2OpneZqo7tvZxNyv/P1X+S97VunD/f1a2tOjx3+7NqNnQ8xm1tavfOs
tZDfgIP/AhzdNPcEtUwgsuPc9oy91h9Ub1dIqZGuO14J5/iT+ibsSboYd26drrnzdqJXjKjVblt9
Juc1qq/MnRcZHk8vTO60459wz14RNTkGds+NZ15Jb3JFnaahpXOn4zvPbfdZlHy1JPvodCgeTOaX
hf606F63tCzz8vjLfHn2W7VH2hEU1Vs1d25sopPbPpFwPVPfuZWrJfUcN9V+rS2Z/NE8r6PUEWzW
bTf9L+mAp83OzjYsYx84+OGGuZ/aNbnL3HafRQMPFxflu38oIgZz8/P164wlibh+7qF6pM64CDm3
au/coKeST23zRMHqMwUGi7k/G2P7cddjyA0WjCfYaD52MD9kAuwC+8aM/a83Tkj30KmUof86pyYj
U7vObSP8R9mhnZiUYYuqq2eHk/XrxMikCKTUI3X9IeK6VXvnBt092nZP5H6m4MQnapL4vKYT7zun
umuhv2l2JCzQU1CddiHYSzB8El+rLLd9s+U6jvRz5Ei/ndHS+uFcQaAvP5066DNV7vY3+2x4kjaO
Aydq7j7LxUYe7n6dkmS1V2Q3eWsfybD6WF7QX/lK7THncofUrwUGSssHfaaVStMzKRO9K7Oz6RMD
RMMveprcaqUTI8ewkTs2ny8tLf3Q+eHJQ9o971zrP9gzVR6+d6pp8w/8e6PhgNjSCDnxagfsTm1n
ZXHHv1QHAX7bAPcFV+Xe7acnD+sBu9dKpw70TNnKB9v07omRkf/oFgTYf/ndNcFHEuDjWZFj1wsE
99tKHx3wmc6e5e0P9oEBEGDguKConU/2vhQOL4Ee2I/xnXHHGCDAPut+ewwkGATYh/ntsY5ekODW
mlZnX7lseGCnhgD7IL/ObRLsJV7ILwEG9tMFb7jyyxAa8FmC7Qh75dflOIwE7CfBM3bX642DegQY
2G+EhXeOyRNgz79hZjZ6aAWPjaO9g31gP9ngZCwQYN994Fe/NyG/IMA+HLJtKJwMDfaB/ZlgT31v
AgKMfXfCeFt6prBDzUHt/ulk7YJ0Vk1GhxtXEWDAawm40LBIZleUr3clm6wiwEDLVG6/VPHU0t3D
ojx3Mfok8M/Ab17IbtZa4do0NLaSVD2wrra5kMg8EOFLEVG4IQIXkgQYaAHtQeKyyN+L9tkLthY/
jWgvqiti7q17q9vIQfi0DO+lwJ2PY+W5zhgBBlrwZlc/DtvnXhKNbLNCVBYuVLepPLoo1w9lz8jZ
8OcMoYEW9cHpbM1bvrfpikePhGukLLcpabfUrf7Q6K3agTYBBo4yvv3T5bntV8hdXNH9+yYZDVu/
8pxK5e8ueWonmACjfQK8+mlkxxVRdbhOa1wf0Ur2HeN/yqx4KcCcieUX+ZmZGeNHkv+ek/9reAs2
LkJjUEui8rX+OtCXFfrzJiu2u19o9F5JlL/Ilb9cFVo2wRAa+8/vwrTQM3NT6rhlkz7CD4csW+e5
OpOteyo8cUsEf/vsVeDM+kzgI9cP0tkrtu3mBsV1Y69YbidGPXUY6Rj/vKhvNft5UfOkoPLcxZi8
9e790ycWplSop2SojSOUcmnCOGL5q4YjmmjRW5vfRkK1D/jlYtJ9CKOvvBrTng8I+whlSFhHNdNN
jmji+CLAPgmwHPU534Wqv1u8ENPyF50jlMavD0cjzY5oggCj9X+oiQktfb17yp7tXxheD8ecI5TG
QmOvrv5QJwgwPJLhD+/kks4Y+oUcQTtHKO3vtbY91IljOjSjCXxBHcCQf63uV9Ux9ItS1DhCWbOd
tvrpJK1FgOExxpFIUcxHnQAPPq7Eqkcoqwne+YgmGEKjFR+0qch1OV7+7+qZRN2/VCcU2Eco7SH0
bkc0ccxwHNh7Zqm/4T+tOg7MEBpgHxgAAQZAgAECDIAAAyDAAAgwQIABEGAABBggwAAIMAACDIAA
AwQYAAEGQIABEGCAAAMgwAAIMECAARBgAAQYAAEGCDAAAgyAAAMgwAABBkCAARBggAADIMAACDAA
AgwQYAAEGAABBggwAAIMgAADIMAAAQZAgAEQYAAEGCDAAAgwAAIMtK0gTdBSldtFIUaGaQgQYB8q
X1P/LhYnaQoQYN/Rsx1jKZniH/NxGgPsA/uNlounhAiP0xKgB/ah0GXrr9BLW4AA+7UfXotGahZs
0SYgwL7ZEc6sT5m3ZmkMEGBfKNyU/yTUl8/6sp1fccXKcQft4zutGjXxJVaLVf6mcwwJ9MA+E7V6
2/L1sRStAXpgfyK/oAf2L21ha35eTk9McCIH6IH9F+AcbQB6YN8KX6ENQA8MEGAABBgAAQZAgAEC
DIAAAyDAAAgwQIABEGAABBhoO1zMcHzpmQeif9I1q6lfgMjfFYELSaGls6J7ylmZLw4793Etrtx5
P9mwsGa+fNWYjJ6xpsPa/dNJ2p4A4+D5zUxr6W8nq6kbVUnNTovyXGf06fq0nnFWFhasPP6YcS/W
s8XGhbXz4Wn1oOkBeyqCH3x3KkLrE2DsXeXO2X+K7o+v1vSTWnZEBMf+WjLTVLgRGlRbLr0vQ/e5
0NYHRKAvY2/6zKotX1kakYsfW/cR6z/2Ni5smBflexcj1Wno1wtU+SLA2I+t76fLV29NV+7kkuaY
Vo6S9fIpOY1YOQt8HM1osk9VC9VsX2ZYX7fryRfXPjJvhH4vN1m3y1RXFj/4R8PCxnn9+emYe9qX
LtEFE2Dshxy6DnSLQPcrc0yrlMx0vTbn+oRuLty4LoIXY4FUZEaMWj1lNcnGSDt8ybqZOxNuWNhk
vvLoYs00+Kt/EWACjH3o6DL/v7vyM7UPfLEvrU+L/NxUQ4ADqZRcbfSk62uTlYaFjfP1HbAI/PIV
fxECjLfjDKGtoXNn7erwmBwDjxa6V2UPGg3mkk7+CzeEtQstV8eMAfRHrvtZC5vMa9n3a6ZqSM6f
gQDj7ThDaGP3V6/bHW0+tt2SXWZU3c/oV/X1brXwpxfX5b/fvRp2LxR1G4nqbrU9lfittiPDiRzH
97O5Py20hbrfTQsNZdXOajQYW5CdrvONVrHar8qudHVA3Y5OT0//T99/DtcsrN9IjbSDkZqp0F92
0fr0wDjoZ/OgmDFP5MhnJ6sLMzPqSywxnp4R4UvWMNs5nmSsVotdd2lY6MxbC3rr+l3txQitf2Tf
fkwf5bPxu5l7MTt91M+4x7OnKt+f28ujucPfNpq8tY/kN+oYQkOOw84u7mWzV3vat6383xgtyj4w
jlLf4NIetjq1l25amz/DUWD2gXG0n+OH9xNrwQs0Jz0wAAIMEGAABBgAAQZAgIFjgcNIx4GW7h6u
XVJXD8ssbuWqZWUWuzI1q4elSmYFjQsGrRpaou6xnOdRhbase1IOiwDjUNTVw7KKW1VrWVnFrgzN
6mFp6nLhwh2ZYKuGlutSQvd9rUJb1j0ph8UQGm/ZB3818+Wqa9aoh1Uo2fNGcSuzlpWx0Cx2ZW5a
Ww/LvI+WHxSiN/FaLkyoGlruS4Fd9y18sTTovmfo1wv8KeiBsX+ZizHZYXY3r4dlFbeq1rKyil0Z
mtbDCn+uuteN0+6LfIX7sayPf7PQVvWelMMiwHgbQzHRGy/EmtfDcopbWbWsqsWutq2HZQyVtaRT
Q6u61HVfu9BW9Z6UwyLAeAuqJo4cxG6z1iluZdWyqha72rYelrEbrfaNrRpasYbHqt0Ts+5JOSwC
jLfXvB5WTXGr0Giht6bYVdN6WPJOt7uMBVYNrZgzgP5om+e2NqIcFgHGvqmiVrIvbV4Pyy5udcaq
ZeUUu3Lu2lAPS5Svm4eO6gfEtfe1Pzdc96QcFgHG/j2OxlZXR6t/1v70lFMPS8VTHbvVVR+prY5G
pl3HcqsD75C12uho71qHfkND2WGn4LPrsRo7X+Oe+svT/C0IMPa9D3x+/qVd4cqIpV0Pq2ltq5q9
16b1sH5a/+47oX6qzKmh1VAnp77QlvHAlMM68r88NbE852hrYh1qPay2LIe13Vubmlg4ijHYIdbD
ohzWkSPAbe/w6mFRDot9YBz9Z/ih1cOiHBY9MAACDBBgAAQYwM+FL7FQz12ZAwQYPrOu6mssDdMQ
DKHhLRt72io65frFYNAD4wgUbow6fWZ57mJfkxMk9Uyh9kRH+zpfNWaWXKdJa88GXeNpuzqeebWi
GB2uL5kHAowD0TKxzIDrNKh9nlMxapSWXLAzqd0/Xb2sv1odz7haMZ8eqC+ZBwKMAwY4P/nIqGaj
pbOB8+YlCkaxWdXLFm4YdbJktzk3pf5VXa21nXtvqv+xdQGx63pBszreX6uVrsr3LkYq9QtBgHEg
66djAysydfpTXXaOtevKdz6Oqcqwg6IwKYfR03K4fSncZDtb5e5YzK7t8U5tdTyhP5d9c13JPBBg
HExl6f1A36PVmHHtfXAs37CBUWZSbaiuze8byp5p3M4pAFAo3BL2Lq55tb9dHc+6f6luIQgwDuQn
2SeqqpSiFJQhDNRe+hcavSXsb7hK2i016a/b7tEjIZxjv/Htr0c2OmAQYBzuHnCmrEpVhQeaDmoD
qVT+7pJVI8f6qrmugKXMd/7euHvYbQ+hzUfodHaJ3xd2oSxnIQgwDhbg/McxVYjuX5GIpqrZNRzE
jf8ps2IWqdPMPdfG7eITd13ln+3yeBV3dTxh1XkP1C5EC3Eix3GwHlbRC42tyOFyWu7MWn/bvqwc
88pgf7kqu86ENZy+VxLlL3Lu7SyxeJMvtYL96erOsXwiNfKuXwh6YByE+m0iI7CPVmODYiZw3vxy
KnBmfSbwUa8IT8j93tGkXP9gbmpQXDd+bdC1nf1WGLs613AGtFMdzyp31Vu7EK1GUTvvOYyidvzS
5xGjqB0Ok75BGzCEhl8VbnTTARNg+FV0mjZoDwyhAQIMgCE0DoBKOAQYPkYlHIbQ8DEq4RBg+Fu1
Eg4IMHyX3/sxLvZjHxh+U7k7qoLrqoSjuCrP2dXozthV6WgzAgzPxXgsVpPfauU5uxqdPaWxCDC8
xl0JRzSWo1PV6NxTEGB4iVkJxy6lkayrPGcXw6EoDgGGh9mlNOorzxnV6FxTHA98C90e6IDpgeEH
zhC6tvKcWY2uOgUBhqeH0LWV58xqdNUpGELD2x/NNZXnzGp01SnogeHtj2a78pyrGp1riuOBonbe
M0s5Df+hqB0AAgwQYBwh7d4cjQAC7Fe5HG0AAuxXhTRtAALsV5X7w5RgBwH26w7wg03ObcTb40SO
Fu8Ar15qXMjhchBgXyjfH4toztwsDQIC7AuFm/KfxPjX8ZRr4RUrxx20j+9sEeA29FOxaPS6X4yl
aAwQYP+IGr1tgYYAAfZ5jLX0Or9ohLfEYSSAAANgCN2ef4IJ2gD0wAABBkCAAbAP3K5maALfuUKA
0eS9MHvFIy/KMy+EJmEIDbAPDIAAAyDAAAEGQIBxeK7QBDTJTvhtJOBnyhY9MAACDBBgAAQYAAEG
QIABf+NqJM968r2rWOUT4zcME5PeeUWtfB1eaAwtnRMnJuL0wGiu5mdH9Tdee0Ut5InGqNzMCbF5
L08PjB16GefjPjcy7K1X1Mq+zwONIVaKcgTwJJ2NE2A0HZ8Nv1p3dTob73nsFbWyB255Y8jmWOsc
E+K9N8ulCAFGo/AVzd3hlQInZ0VHS39Bqe4VtZAHGkN+iERlcgPRpWKLA8w+sCcFx2rnNzb/IcTW
/JJ3XlELtb4xlF4zyCWG0Nj98/6N6nD05eWBCI3hicbQiwmPfNTzhvAS82eDG46PBIaG1L/RR/mU
R15RC19GCxvD9Rfp9cg7hiE08DaKZn5aPSSiB/aUaPOr1Su3uyZb9HaJXvFaw7SwMVwdX89qKSL0
QrDVPTE9sB8Ekz/mhdAy4Tht4Y3GCL7zekGIZw+j9MDYUfnayLAIDDz8Rt7uGKM1Roa90RiJzMqs
ECcG2AfGHoT/KIdqJyZTtIRXGiP0SVJ44VxoamIBP1O26IEBEGDguOJLrDZnnCEhtj+1WF9evhSp
fJuKGzd2eiTjaqVdT/nY9WGqtPmewR23dp9kYv13WLulT15Mtsnfjx4Yys6nFv+0+2VI2j3jUoeV
q4d3cnDuTWrnZzQyu/JlzTW55iW6ifIyPTDagtllla9lmp9abJ646L7RXDFndIVP0guH1feV5yd2
7MozuU7ZO+vLD9O9Eee/w7pEN/Te9ykCjPYRHp9XF8Y5dWJkLoRQ183LIe8nKw/FN4kJNZp9Mq9W
aun1qfqaMhvmIdHkmtFZux7n6W9uyvF5XQEa12z5mhDxU0+nCrfUKF5ub5Xt0bPhJpvbWwux/tD4
xAgMRW+6PzOSa7qaJJ4tt0eCGULD1en9r6oT8+2ymV+x2DCsfndTnQKs5QZc25p6NrNGhzAxJWrX
Ve6LULxuY9dsQSZS5OWzdfcU1NYP7VMjjCep39zZWugF+ySK3mTBNWzP5cyOKZ6hB0YbRTfdFZed
nup0Czcfx4NqQKyls0bpmo6h6J2JuNGxBZNq0Q8neq1tK7czKTtGuVn7G6WadW9il+Xngf3Akep6
Y1bLyO7Z+LgIJlV1C/XQ1n73K/tWdfOQs7XQi3YHHXwnrwYPm99YuwRGrgMny/m2OO+UHrjdbX4z
K13rGFSdXpeMZ3S8khdiZc7qTWs/7wfLeaGtnY7LbRNy29D5svUVUnBiXH2jNKu+xKpZpwLlfmBR
M6vl4ikRONOrrg9Us2vOuHnDuU6gunl16211fW4+QE/LL7WnB8ZRf5UljN7rXTnoHUy/mhWdjYdw
uruKce35mOoBi7NG9+zk5OxZ2ekWX9+Zql1n5tB+YIszW+qIGh37U9mH9xdSWm7E7nbdpSftzV1b
N/0vKF/r/J01G9nSCDDaJ7p1ziZuF8XrvzSsk+EZ/iG03eA0dFlfXnrboWvwncXSixN7vTwv0Ju3
nkhbc/rq8GfXblxqr6IlBBguxk7vD2YW1SGZYn0YA9GllTWjnltvwl3btXJ7c8rc9xQN62ofuHY2
slVIqUGy2cWuvDwd3+llubYORDetkq7FXMLJbHj88A5jsQ8Mv32aJ18tqfrtoXh59lu1H9lhf75X
dyi7uwrPzXHs0rJc/tg6jULedU5Ny2nZHdatcz9w/WwwmV8W+lOjvEWwf60Udd6YJ5u8LPfWfeeM
k0b0xzc7XRcWJo2LhYUam7dH30QPjOqn+cDDxUX1rXNEP/dQ7cV22v3h1nxhwk7TQ2Op3HZ+Xk4T
5iaBMzlrv3coUr/O/cD1s8HBnLGpOYZOd1Y74J6KXfPKtblr68BgMfdnYx9g3DVolo+3YDzGRqA9
htL0wKhyrrQNpM7J2a4/WCHoTYrCv+0xtDCrUBjbipFJZ/dXfQstOqdSjesaLuF1zUY/k/8MJ43F
iV5XgYvuHq3x3u6tgxOfGHf6vGbU3XdOdddCf9Mm1Uu4Hhitp6V1FXbzZCx71O6ck7XN1juq3O1v
+ZlYXA+MY6/yldp1zuVUj61l3F9vBwZKyzttvbOVCudCAz//+y9p7mwPGOc7j7j3W8PnX6S23Xq3
z4Vng23SgCdGeBOhhcPMvuCq3Nn+9KQQpdXE+Zp13WulU9tuvbNs5QMP/LexDwz4+MOJfWAABBgg
wAAIMAACDIAAAwQYAAEGQIABAgyAAAMgwAAIMECAARBgAAQYIMAACDAAAgyAAAMEGAABBvDzONrC
7h00OEAPDIAAAwQYAAEGQIABAgyAAAMgwAAIMECAARBgAAQYIMAACDAAAgyAAAMEGAABBkCAARBg
gAADIMAACDBAgAEQYAAEGAABBggwAAIMgAADIMAAAQZAgAEQYIAAAyDAAAgwAAIMEGAABBgAAQZA
gAECDIAAAyDAAAEGQIABEGAABBggwAAIMAACDBBgAAQYAAEGQIABAgyAAAMgwAAIMECAARBgAAQY
IMAACDAAAgyAAAMEGAABBkCAARBggAADIMAACDBAgAEQYAAEGAABBggwAAIMgAADIMAAAQZAgAEQ
YIAAAyDAAAgwAAIMEGAABBgAAQYIMAACDIAAAyDAAAEGQIABEGAABBggwAAIMAACDBBgAAQYAAEG
QIABAgyAAAMgwAAIMECAARBgAAQYIMAACDAAAgyAAAMEGAABBkCAAQJMEwAEGEAL/D8oEMG/Z3fk
QAAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Gráfica #3.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2014-05-09 11:52:22 +0100" MODIFIED_BY="Anne Lawson" NO="8" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION>
<P>Meta-regression analysis. Relationship between effect of TT on mortality and serology.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAA8AAAALQCAMAAABoqemGAAADAFBMVEUAAAAJAAAAACsAACkAACUA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2014-05-09 09:17:49 +0100" MODIFIED_BY="Anne Lawson">
<APPENDIX ID="APP-01" MODIFIED="2014-05-09 09:16:16 +0100" MODIFIED_BY="Anne Lawson" NO="1">
<TITLE MODIFIED="2014-03-17 09:18:59 +0000" MODIFIED_BY="Nicole Martin">Search strategies 2010</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-09 09:16:16 +0100" MODIFIED_BY="Anne Lawson">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>#1 MeSH descriptor Chagas Disease explode all trees<BR/>#2 chaga*<BR/>#3 MeSH descriptor Trypanosoma cruzi, this term only<BR/>#4 cruzi<BR/>#5 trypanosomiasis<BR/>#6 (#1 OR #2 OR #3 OR #4 OR #5)<BR/>#7 MeSH descriptor Trypanocidal Agents explode all trees<BR/>#8 trypanocid*<BR/>#9 MeSH descriptor Nitrofurans explode all trees<BR/>#10 MeSH descriptor Allopurinol, this term only<BR/>#11 MeSH descriptor Itraconazole, this term only<BR/>#12 nifurtimox<BR/>#13 allopurinol<BR/>#14 Zyloprim<BR/>#15 Zyloric<BR/>#16 benznidazol*<BR/>#17 itraconazol*<BR/>#18 Sporanox<BR/>#19 antitrypanosom*<BR/>#20 anti-trypanosom*<BR/>#21 nitrofuran*<BR/>#22 Macrobid<BR/>#23 Macrodantin<BR/>#24 bzd<BR/>#25 MeSH descriptor Amiodarone, this term only<BR/>#26 MeSH descriptor Amitriptyline, this term only<BR/>#27 MeSH descriptor Pravastatin, this term only<BR/>#28 MeSH descriptor Alendronate, this term only<BR/>#29 amitriptilin*<BR/>#30 amitriptylin*<BR/>#31 Triptafen<BR/>#32 Elavil<BR/>#33 pravastatin*<BR/>#34 Pravachol<BR/>#35 Lipostat<BR/>#36 alendronat*<BR/>#37 alendronic<BR/>#38 Fosamax<BR/>#39 amiodaron*<BR/>#40 Cordarone<BR/>#41 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40)<BR/>#42 (#6 AND #41)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE</HEADING>
<P>1. exp Chagas Disease/<BR/>2. Trypanosomiasis/<BR/>3. chaga$.tw.<BR/>4. trypanosomiasis.tw.<BR/>5. Trypanosoma cruzi/<BR/>6. cruzi$.tw.<BR/>7. or/1-6<BR/>8. exp Trypanocidal Agents/<BR/>9. trypanocid$.tw.<BR/>10. exp Nitrofurans/<BR/>11. Allopurinol/<BR/>12. Itraconazole/<BR/>13. nifurtimox.tw.<BR/>14. allopurinol.tw.<BR/>15. Zyloprim.tw.<BR/>16. Zyloric.tw.<BR/>17. benznidazol$.tw.<BR/>18. itraconazol$.tw.<BR/>19. Sporanox.tw.<BR/>20. antitrypanosom$.tw.<BR/>21. anti-trypanosom$.tw.<BR/>22. nitrofuran$.tw.<BR/>23. Macrobid.tw.<BR/>24. Macrodantin.tw.<BR/>25. bzd.tw.<BR/>26. Amiodarone/<BR/>27. Amitriptyline/<BR/>28. Pravastatin/<BR/>29. Alendronate/<BR/>30. amitriptilin$.tw.<BR/>31. amitriptylin$.tw.<BR/>32. Triptafen.tw.<BR/>33. Elavil.tw.<BR/>34. pravastatin$.tw.<BR/>35. Pravachol.tw.<BR/>36. Lipostat.tw.<BR/>37. alendronat$.tw.<BR/>38. alendronic.tw.<BR/>39. Fosamax.tw.<BR/>40. amiodaron$.tw.<BR/>41. Cordarone.tw.<BR/>42. Pacerone.tw.<BR/>43. or/8-42<BR/>44. 7 and 43<BR/>45. exp animals/ not humans.sh.<BR/>46. 44 not 45<BR/>47. (199911$ or 199912$ or 20$).ed.<BR/>48. 46 and 47<BR/>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE</HEADING>
<P>1. Chagas disease/<BR/>2. trypanosomiasis/<BR/>3. chaga$.tw.<BR/>4. trypanosomiasis.tw.<BR/>5. trypanosoma cruzi/<BR/>6. cruzi$.tw.<BR/>7. or/1-6<BR/>8. exp antitrypanosomal agent/<BR/>9. trypanocid$.tw.<BR/>10. exp nitrofuran derivative/<BR/>11. allopurinol/<BR/>12. nifurtimox/<BR/>13. benznidazole/<BR/>14. itraconazole/<BR/>15. nifurtimox.tw.<BR/>16. allopurinol.tw.<BR/>17. Zyloprim.tw.<BR/>18. Zyloric.tw.<BR/>19. benznidazol$.tw.<BR/>20. itraconazol$.tw.<BR/>21. Sporanox.tw.<BR/>22. antitrypanosom$.tw.<BR/>23. anti-trypanosom$.tw.<BR/>24. nitrofuran$.tw.<BR/>25. Macrobid.tw.<BR/>26. Macrodantin.tw.<BR/>27. bzd.tw.<BR/>28. amiodarone/<BR/>29. amitriptyline/<BR/>30. pravastatin/<BR/>31. alendronic acid/<BR/>32. amitriptilin$.tw.<BR/>33. amitriptylin$.tw.<BR/>34. Triptafen.tw.<BR/>35. Elavil.tw.<BR/>36. pravastatin$.tw.<BR/>37. Pravachol.tw.<BR/>38. Lipostat.tw.<BR/>39. alendronat$.tw.<BR/>40. alendronic.tw.<BR/>41. Fosamax.tw.<BR/>42. amiodaron$.tw.<BR/>43. Cordarone.tw.<BR/>44. Pacerone.tw.<BR/>45. or/8-44<BR/>46. 7 and 45<BR/>47. (animal/ or nonhuman/) not human/<BR/>48. 46 not 47<BR/>49. (20$ not "200001").em.<BR/>50. 48 and 49</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">LILACS</HEADING>
<P>(chaga$ or trypanosom$ or cruzi) [Words] and (antitrypanocidal$ or anti-trypanocidal$ or trypanocid$ or nitrofuran$ or Macrobid or Macrodantin or bzd or nifurtimox or allopurinol or Zyloprim or Zyloric or benznidazol$ or itraconazol$ or Sporanox or antitrypanosom$ or anti-trypanosom$ or amiodaron$ or Cordarone or Pacerone or amitriptilin$ or amitriptylin$ or Triptafen or Elavil or pravastatin$ or Pravachol or Lipostat or alendronat$ or alendronic or Fosamax) [Words] and 20$ [Country, year publication]<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2014-05-09 09:17:49 +0100" MODIFIED_BY="Anne Lawson" NO="2">
<TITLE MODIFIED="2014-03-17 09:19:23 +0000" MODIFIED_BY="Nicole Martin">Search strategies 2014</TITLE>
<APPENDIX_BODY MODIFIED="2014-05-09 09:17:49 +0100" MODIFIED_BY="Anne Lawson">
<SUBSECTION>
<HEADING LEVEL="3">CENTRAL</HEADING>
<P>#1 MeSH descriptor Chagas Disease explode all trees<BR/>#2 chaga*<BR/>#3 MeSH descriptor Trypanosoma cruzi, this term only<BR/>#4 cruzi<BR/>#5 trypanosomiasis<BR/>#6 (#1 OR #2 OR #3 OR #4 OR #5)<BR/>#7 MeSH descriptor Trypanocidal Agents explode all trees<BR/>#8 trypanocid*<BR/>#9 MeSH descriptor Nitrofurans explode all trees<BR/>#10 MeSH descriptor Allopurinol, this term only<BR/>#11 MeSH descriptor Itraconazole, this term only<BR/>#12 nifurtimox<BR/>#13 allopurinol<BR/>#14 Zyloprim<BR/>#15 Zyloric<BR/>#16 benznidazol*<BR/>#17 itraconazol*<BR/>#18 Sporanox<BR/>#19 antitrypanosom*<BR/>#20 anti-trypanosom*<BR/>#21 nitrofuran*<BR/>#22 Macrobid<BR/>#23 Macrodantin<BR/>#24 bzd<BR/>#25 MeSH descriptor Amiodarone, this term only<BR/>#26 MeSH descriptor Amitriptyline, this term only<BR/>#27 MeSH descriptor Pravastatin, this term only<BR/>#28 MeSH descriptor Alendronate, this term only<BR/>#29 amitriptilin*<BR/>#30 amitriptylin*<BR/>#31 Triptafen<BR/>#32 Elavil<BR/>#33 pravastatin*<BR/>#34 Pravachol<BR/>#35 Lipostat<BR/>#36 alendronat*<BR/>#37 alendronic<BR/>#38 Fosamax<BR/>#39 amiodaron*<BR/>#40 Cordarone<BR/>#41 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36 OR #37 OR #38 OR #39 OR #40)<BR/>#42 (#6 AND #41)</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">MEDLINE</HEADING>
<P>1. exp Chagas Disease/<BR/>2. Trypanosomiasis/<BR/>3. chaga$.tw.<BR/>4. trypanosomiasis.tw.<BR/>5. Trypanosoma cruzi/<BR/>6. cruzi$.tw.<BR/>7. or/1-6<BR/>8. exp Trypanocidal Agents/<BR/>9. trypanocid$.tw.<BR/>10. exp Nitrofurans/<BR/>11. Allopurinol/<BR/>12. Itraconazole/<BR/>13. nifurtimox.tw.<BR/>14. allopurinol.tw.<BR/>15. Zyloprim.tw.<BR/>16. Zyloric.tw.<BR/>17. benznidazol$.tw.<BR/>18. itraconazol$.tw.<BR/>19. Sporanox.tw.<BR/>20. antitrypanosom$.tw.<BR/>21. anti-trypanosom$.tw.<BR/>22. nitrofuran$.tw.<BR/>23. Macrobid.tw.<BR/>24. Macrodantin.tw.<BR/>25. bzd.tw.<BR/>26. Amiodarone/<BR/>27. Amitriptyline/<BR/>28. Pravastatin/<BR/>29. Alendronate/<BR/>30. amitriptilin$.tw.<BR/>31. amitriptylin$.tw.<BR/>32. Triptafen.tw.<BR/>33. Elavil.tw.<BR/>34. pravastatin$.tw.<BR/>35. Pravachol.tw.<BR/>36. Lipostat.tw.<BR/>37. alendronat$.tw.<BR/>38. alendronic.tw.<BR/>39. Fosamax.tw.<BR/>40. amiodaron$.tw.<BR/>41. Cordarone.tw.<BR/>42. Pacerone.tw.<BR/>43. or/8-42<BR/>44. 7 and 43<BR/>45. exp animals/ not humans.sh.<BR/>46. 44 not 45<BR/>47. randomized controlled trial.pt.<BR/>48. controlled clinical trial.pt.<BR/>49. randomized.ab.<BR/>50. placebo.ab.<BR/>51. drug therapy.fs.<BR/>52. randomly.ab.<BR/>53. trial.ab.<BR/>54. groups.ab.<BR/>55. 47 or 48 or 49 or 50 or 51 or 52 or 53 or 54<BR/>56. exp animals/ not humans.sh.<BR/>57. 55 not 56<BR/>58. 46 and 57<BR/>59. (201004* or 201005* or 201006* or 201007* or 201008* or 201009* or 20101* or 2011* or 2012* or 2013* or 2014*).ed.<BR/>60. 58 and 59</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">EMBASE</HEADING>
<P>1. Chagas disease/<BR/>2. trypanosomiasis/<BR/>3. chaga$.tw.<BR/>4. trypanosomiasis.tw.<BR/>5. trypanosoma cruzi/<BR/>6. cruzi$.tw.<BR/>7. or/1-6<BR/>8. exp antitrypanosomal agent/<BR/>9. trypanocid$.tw.<BR/>10. exp nitrofuran derivative/<BR/>11. allopurinol/<BR/>12. nifurtimox/<BR/>13. benznidazole/<BR/>14. itraconazole/<BR/>15. nifurtimox.tw.<BR/>16. allopurinol.tw.<BR/>17. Zyloprim.tw.<BR/>18. Zyloric.tw.<BR/>19. benznidazol$.tw.<BR/>20. itraconazol$.tw.<BR/>21. Sporanox.tw.<BR/>22. antitrypanosom$.tw.<BR/>23. anti-trypanosom$.tw.<BR/>24. nitrofuran$.tw.<BR/>25. Macrobid.tw.<BR/>26. Macrodantin.tw.<BR/>27. bzd.tw.<BR/>28. amiodarone/<BR/>29. amitriptyline/<BR/>30. pravastatin/<BR/>31. alendronic acid/<BR/>32. amitriptilin$.tw.<BR/>33. amitriptylin$.tw.<BR/>34. Triptafen.tw.<BR/>35. Elavil.tw.<BR/>36. pravastatin$.tw.<BR/>37. Pravachol.tw.<BR/>38. Lipostat.tw.<BR/>39. alendronat$.tw.<BR/>40. alendronic.tw.<BR/>41. Fosamax.tw.<BR/>42. amiodaron$.tw.<BR/>43. Cordarone.tw.<BR/>44. Pacerone.tw.<BR/>45. or/8-44<BR/>46. 7 and 45<BR/>47. (animal/ or nonhuman/) not human/<BR/>48. 46 not 47<BR/>49. random$.tw.<BR/>50. factorial$.tw.<BR/>51. crossover$.tw.<BR/>52. cross over$.tw.<BR/>53. cross-over$.tw.<BR/>54. placebo$.tw.<BR/>55. (doubl$ adj blind$).tw.<BR/>56. (singl$ adj blind$).tw.<BR/>57. assign$.tw.<BR/>58. allocat$.tw.<BR/>59. volunteer$.tw.<BR/>60. crossover procedure/<BR/>61. double blind procedure/<BR/>62. randomized controlled trial/<BR/>63. single blind procedure/<BR/>64. 49 or 50 or 51 or 52 or 53 or 54 or 55 or 56 or 57 or 58 or 59 or 60 or 61 or 62 or 63<BR/>65. (animal/ or nonhuman/) not human/<BR/>66. 64 not 65<BR/>67. 48 and 66<BR/>68. (2010* or 2011* or 2012* or 2013* or 2014*).em.<BR/>69. (2010* or 2011* or 2012* or 2013* or 2014*).dd.<BR/>70. 68 or 69<BR/>71. 67 and 70<BR/>
</P>
</SUBSECTION>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS>
<EXTENSION ID="FLOW_2" NAME="FIGURE" REVMAN_VERSION="5.1.0" TYPE="FLOWCHART">
<ALIAS ALIAS_ID="2">
<FLOWCHARTBOX TEXT="&lt;p&gt;Included:&lt;/p&gt;&lt;p&gt;8 studies (10 references) from 2010 and 2014 search&lt;/p&gt;&lt;p&gt;+&lt;/p&gt;&lt;p&gt;5 studies (5 articles) from 2000 search&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" WIDTH="270">
<FLOWCHARTBOX TEXT="&lt;p&gt;30 full-text articles assessed for eligibility&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1565 records screened&lt;/p&gt;" WIDTH="120">
<FLOWCHARTBOX TEXT="&lt;p&gt;1283 (in 2010) and 282 (in 2014) records after duplicates removed&lt;/p&gt;" WIDTH="270">
<FLOWCHARTBOX TEXT="&lt;p&gt;1714 (in 2010) and 347 (in 2014) of records identified through database searching&lt;/p&gt;" WIDTH="120"/>
<FLOWCHARTBOX TEXT="&lt;p&gt;4 additional records identified through other sources in 2010&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;1535 records excluded&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
<OUT TEXT="&lt;p&gt;19 of full-text articles excluded:&lt;/p&gt;&lt;p&gt;- 15 not appropriate outcome&lt;/p&gt;&lt;p&gt;- 4 not the population of interest&lt;/p&gt;&lt;p&gt;- 2 not appropriate intervention&lt;/p&gt;&lt;p&gt;- 2 not reporting original date&lt;/p&gt;&lt;p&gt;&lt;/p&gt;&lt;p&gt;1 full-text article of ongoing study&lt;/p&gt;" WIDTH="120"/>
</FLOWCHARTBOX>
</FLOWCHARTBOX>
</ALIAS>
</EXTENSION>
</EXTENSIONS>
</COCHRANE_REVIEW>